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Characterisation of human Haematopoietic Stem Cell differentiation and exit from quiescence 
at single cell resolution 
Blood formation is coordinated by a set of functionally heterogeneous haematopoietic stem cell (HSC) 
compartments both in mouse and in human. However, how this diversity is regulated at the cellular and 
molecular level and when HSC multipotency is lost is still not known, in particular in humans. 
Quiescence is an important property of HSCs and fine regulation of the balance between quiescence and 
cell cycle entry is of vital importance for maintaining a healthy HSC pool and avoid haematological 
malignancies. Very little is known about how molecular networks change during exit from quiescence 
and no studies have formally examined if cell fate decisions occur during this process or later on during 
the cell cycle.  
Here, I combine index sorting, in-vitro single cell functional assays and single cell RNA-sequencing 
with xenotransplantation assays to profile single human HSC properties in the purest HSC compartment 
reported to date (CD49+ HSCs) and to understand when the first steps of lineage restriction occur during 
HSC differentiation. Moreover, I use an in-vitro model system to comprehensively study HSC activation 
and to investigate whether HSC self-renewal is lost during quiescence exit or during cell cycle 
progression.  
First, I unveil an unexpected degree of intrinsic functional and molecular heterogeneity within the 
human CD49f+ HSC pool. I demonstrate that the first restriction step towards the lymphoid lineage 
occurs already within the CD49f+ HSC compartment and generates erythroid-deficient myeloid-
lymphoid committed cells. Within this compartment, transcriptional programmes and lineage potential 
progressively change along a gradient of opposing cell surface expression of CLEC9A and CD34. Two 
functionally distinct populations can be identified and purified. CLEC9Ahi CD34lo cells contain long-
term repopulating multipotent HSCs with slow quiescence exit kinetics, whereas CLEC9Alo CD34hi cells 
are restricted to myelo-lymphoid differentiation and display infrequent but durable repopulation 
capacity. 
Second, I demonstrate that a drastic transcriptional remodelling reflective of the fast metabolic activation 
seen in ex-vivo cultured HSCs occurs during quiescence exit, and independently of cell cycle 
progression. In-vivo data show that the reduction in repopulation capacity that accompanies HSC culture 
also occurs independently of cell cycle progression. Recent work highlighted the active role of 
mitochondria and metabolism in HSC fate decision and self-renewal. My data is consistent with a model 
in which the metabolic remodelling seen during exit from quiescence represents the first step towards 
loss of self-renewal and differentiation. This has important implications for improving ex-vivo protocols 
for HSC culture and HSC transplants. 
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1.1 Haematopoiesis and haematopoietic stem cells 
The production of all mature blood cell types during an individual lifetime is constantly maintained by 
a process called haematopoiesis. Haematopoiesis in adults occurs primarily in the bone marrow (BM) 
and it produces approximately one trillion cells every day (Doulatov et al. 2012). Haematopoiesis is one 
of the best-described models for the study of stem cells due to the ease of blood collection and cell 
isolation. 
The advent of flow cytometry and the development of clonal in-vivo and in-vitro functional assays 
contributed to a better understanding of haematopoiesis, which is generally described as a hierarchical 
organisation of multipotent and unipotent cells with a common identified precursor residing at the root 
of the hierarchy, the haematopoietic stem cell (HSC) (Doulatov et al. 2012; Eaves 2015). HSCs are 
defined as multipotent cells with the ability to self-renew. They can generate more committed daughter 
cells but also equally potent cells with the same properties of the parental HSC. The ability to self-renew 
is better defined by the capacity of serial long-term reconstitution of all blood lineages upon 
transplantation into a myeloablated recipient. The ability to generate daughter stem cells is at the basis 
of the differentiation process that leads to a gradual cell fate restriction through the production of 
progenitors cells and differentiated mature blood cells (Eaves 2015). Another important property of HSC 
is the ability to reside outside of the cell cycle in a state called quiescence. Quiescent HSCs divide only 
once every 145 days in homeostatic conditions in mice whereas it has been estimated that they divide 
every 280 days in the human BM (A. Wilson et al. 2008; Catlin et al. 2011). Human HSCs do not only 
reside in the BM but can also be isolated from cord blood (CB) or peripheral blood (PB). They are very 
rare cells and their frequency varies between tissues in human, with CB having the highest frequency (1 
in 9.3x105 cells), followed by BM (1 in 3x106 cells) and PB (1 in 6x106) (J. C. Wang, Doedens, and Dick 
1997). In mice, HSC frequency has been confirmed by functional studies and is estimated to be of 1 in 
105 BM cells (Szilvassy et al. 1990).  
It is of vital importance for HSCs to finely regulate the balance between proliferation and quiescence in 
order to avoid the exhaustion of their pool and the development of haematological malignancies.  
Due to the ability of HSCs to reconstitute the entire blood system upon transplantation, HSC transplants 
(HSCTs) are nowadays routinely used to treat leukaemia and other haematological malignancies. 
Despite their use in clinical transplantation, most of our understanding of HSCs is still derived from 
mouse models and the mouse HSC is probably the best characterised adult stem cell. However, after the 
first engraftment of primary human HSCs in immune-deficient mice over 20 years ago, 
xenotransplantation has been routinely used for the study of human HSCs. Xenotransplantation assays 
have improved over the years thanks to the development of different new humanised mouse models 
(Kamel-Reid and Dick 1988; Doulatov et al. 2012). Although the use of mouse models has been 
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indispensable for the study of haematopoiesis, these models are still far from modelling what really 
happens in humans. The discovery of species-specific differences in HSC biology highlighted the 
necessity to study human HSCs directly. 
The extreme rarity of human HSCs has put some obstacles in the study of these cells. However, the 
availability of CB tissues, highly enriched HSC sources, and the advances in HSC isolation and 
purification facilitated the study of this rare population. This makes CB the most studied source of HSCs 
in human. Other than differences in HSC frequency, differences in composition and properties also 
exists in HSCs isolated from CB, BM and PB. CB derived cells seems to have greater proliferative 
response when cultured in-vitro in the presence of cytokines and they are less dependent on stromal 
cells, often used to sustain HSC proliferation and differentiation. A higher number of colony forming 
cells with high proliferative potential and more primitive HSCs are present in CB compared to BM and 
PB (Hordyjewska, Popiołek, and Horecka 2015). These studies could reveal even more important 
difference in their properties than what is already known. 
1.1.1 Early evidence and isolation of adult mouse and human HSCs 
In the early 1950s, research on the consequences of myeloablation showed that intravenous transplant 
of mouse BM cells could protect the syngeneic recipient from a lethal dose of radiation regenerating the 
previously ablated haematopoietic system in the host. This was the first evidence of the existence of 
HSCs in mouse (Jacobson et al. 1951; Ford et al. 1956). However, the confirmation of the presence of 
single multipotent cells capable of regenerating any mature blood cells only came later thanks to the 
seminal work of Till and McCulloch that confirmed the presence of macroscopic colonies of multiple 
lineages in the spleen of mice transplanted with donor-derived BM cells. These colonies, named colony 
forming unit-spleen (CFU-S), were derived from a few or even a single progenitor cell capable of 
forming multiple lineages and they also contained daughter cells with similar characteristics as the 
parental cell (A. J. Becker, McCulloch, and Till 1963; Till, McCulloch, and Siminovitch 1964). These 
results introduced for the first time the concept of multipotentiality and self-renewal that will later be 
definitive characteristics of HSCs. To complement these studies, new short-term in-vitro clonogenic 
assays were developed to assess haematopoietic cells for their function and differentiation capacity. 
These studies provided first evidence for intermediate differentiation stages between HSCs (measured 
as CFU-S) and mature blood cell (Pluznik and Sachs 2005; Eaves 2015).  
HSC isolation and characterisation were only possible thanks to the availability of new strategies 
allowing for better separation of these cells from other BM cellular components and the emergence of 
in-vivo competitive repopulating unit assays (CRU) designed to detect single cells capable of 
reconstituting blood cell production for long-term (Miller, Dykstra, and Eaves 2008). Resistance to 
irradiation and 5-florouracil, together with Hoechst 33342 dye exclusion were the properties used to 
isolate HSCs for the first time (Goodell et al. 1996). A better understanding of surface antigen markers 
and the advent of flow cytometry later allowed for prospective isolation of multipotent cells capable of 
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reconstituting multiple lineages. These populations, enriched in HSCs, were further characterised based 
on their lineages reconstitution upon transplantation and assessed for self-renewing properties through 
serial transplantation (Spangrude, Heimfeld, and Weissman 1988; Ng and Alexander 2017).  
Over the past few decades continuous reporting of new surface markers for mouse HSC isolation has 
made even more difficult to know which isolation strategy can yield the purest fraction of true long-
term repopulating HSCs (Challen et al. 2009). It is important to note that despite the type of strategy 
used for HSC isolation, identification of true HSCs should be proved as gold-standard by in-vivo long-
term (>16 weeks) repopulating and serial transplantation assays. 
Investigation of human HSCs was firstly conducted using an in-vitro colony forming unit-cell (CFU-C) 
assay (Moore, Williams, and Metcalf 1973). Improved culturing conditions and the use of feeder layers 
cells allowed for the development of long-term initiating culture (LT-IC) assays that were aimed at 
detecting primitive hematopoietic stem cells based on their capacity to produce myeloid progeny for at 
least 4 weeks (Sutherland et al. 1991; Miller, Dykstra, and Eaves 2008). The study and isolation of 
human HSCs, as compared to mouse HSCs, was challenged by the extreme rarity of these cells and the 
lack of efficient in-vivo model systems. Over the past 20 years, improved xenograft models (NSG mice) 
which supported higher levels of human engraftment allowed to better characterise and isolate human 
HSCs (M. Ito et al. 2002; Doulatov et al. 2012). Xenograft models are now extensively used to track the 
lineage output and the self-renewal properties of single HSCs over more than 8 months (Notta et al. 
2011).  
It is now known that human HSCs diverge in terms of cell surface markers expression when compared 
to mouse HSCs. While CD34 expression was first identified to enrich for human HSCs and progenitors 
(Civin et al. 1984), the expression of this marker is minimal in mouse long-term repopulating cells. 
Further studies confirmed the lack of congruence for most of the expressed cell surface markers between 
mice and humans (Sitnicka et al. 2003; Larochelle et al. 2011; Doulatov et al. 2012).  
All human HSCs are negative (Lin-) for the expression of mature lineage markers (CD2, CD3, CD14, 
CD19, CD56, GlyA), similarly to the mouse model. However, most of the markers used for HSCs 
isolation in mouse are not useful in human. Human HSCs have been initially defined by being CD34+, 
CD38- and CD45RA-. Although the CD34+ haematopoietic stem and progenitor cell compartment 
(HSPC) compartment is the most studied and characterised to date, several studies questioned whether 
the CD34- compartment would also have a role in haematopoiesis. A CD34- population with severe 
combined immunodeficiency repopulation capacity was identified by Dick et al. in 1998 and confirmed 
by other studies (Bhatia et al. 1997; Danet et al. 2003; J. Wang et al. 2003). More recent studies identified 
and characterised an immature ad highly quiescent Lin- CD34- CD38- CD93hi population, with self-
renewal capacity and similar to previously identified CD34+ HSCs but placed above those in the 
haematopoietic hierarchy (Anjos-Afonso et al. 2013). CD90 and CD49f expression has also been 
associated with HSC enrichment, even though heterogeneity in their expression has been identified in 
the HSC pool (Laurenti and Dick 2012). The more differentiated progenitor populations are instead 
 14 
identified by the expression of CD34 and gradual acquisition of CD38 and CD45RA expression during 
the differentiation process (Lansdorp, Sutherland, and Eaves 1990; Bhatia et al. 1997; Doulatov et al. 
2012). Therefore, the combined expression of Lin- CD34+ CD38- CD45RA- CD90+ CD49f+ (CD49f+ 
HSCs) is the best purification strategy to date for the isolation of human HSCs. However, only 10% of 
this population is capable of long-term engraftment in xenograft mouse models (Notta et al. 2011), 
underlying the fact that the HSC pool is still a heterogeneous compartment.  
A very recent publication identified and characterised a prospectively separable CD33+ CD90+ subset 
of cells within the most primitive human CB cell phenotype thanks to a single cell multiparameter 
analysis of CD49f+ HSCs. This subset showed durable repopulation potential but diverse differentiation 
profiles and a deeper quiescence state than CD33- HSCs (Knapp et al. 2018). More and more studies are 
now looking for other surface markers that may be able to isolate even purer HSCs populations and new 
strategies for the isolation of these cells may become soon available. 
1.1.2 The haematopoietic niche  
In the adult, the bone marrow is considered the primary tissue for haematopoiesis. In order to maintain 
the HSC pool for the lifetime of an individual, HSCs reside in a protected and highly regulated 
microenvironment called the BM niche. The BM niche has long been studied in mouse and a better 
understanding of the niche environment and molecular regulation is necessary to understand HSC 
maintenance and development of ex-vivo protocols for HSC expansion which would be extremely 
beneficial for HSCTs. The concept of “niche” was first proposed in 1978 by Ray Scofield and its location 
was later demonstrated to be in the endosteal region of the trabecular bone (Calvi et al. 2003; J. Zhang 
et al. 2003). However, more recent studies reported that most HSCs reside in the central marrow in 
proximity of sinusoids that constitute the venous circulation of the bone. These studies identified a 
second niche referred to as the “vascular niche”.  
The real location of the niche in the BM has long been debated but recent evidence shows that several 
niche compartments coexist to regulate HSCs in different states (Itkin et al. 2016). The BM vasculature 
has emerged as a key player for HSC maintenance and the presence of distinct cells surrounding BM 
blood vessels (perivascular microenvironment) is vital for HSC maintenance and differentiation. 
Therefore, the study of the niche microenvironment is important to better understand HSC regulation 
(Birbrair and Frenette 2016). Quiescent HSCs, characterised by low reactive oxygen species (ROSlow) 
are found to localise near the endosteal region by perivascular, endothelial, Schwann, and sympathetic 
neuronal cells that promote their maintenance through secretion of CXCL12 and SCF. On the other 
hand, activated HSCs (ROShigh) are found close to sinusoids in the central marrow (Itkin et al. 2016; 
Zhao and Li 2016). The endosteal niche is thought to provide a hypoxic environment which allows 
quiescence maintenance while the vascular niche regulates HSC maintenance and differentiation. 
Several studies investigated the specific role of different cellular components of the BM niche and 
identified a key role for perivascular and endothelial cells in HSC regulation within the vascular niche 
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(Figure 1) (Méndez-Ferrer et al. 2010; Omatsu et al. 2010; Ding et al. 2012; Pinho et al. 2013; Itkin et 
al. 2016). Osteoblasts were the first cells to be tested for their role in HSC regulation and, despite these 
cells can produce growth factors that would support haematopoietic progenitor cells like G-SCF, their 
role as direct regulators of HSC function has been confuted by the fact that conditional deletion of 
CXCL12 and SCF produced from osteoblasts doesn’t affect HSCs numbers in the BM (Ding and 
Morrison 2013). On the contrary, perivascular cells have a central role in HSC regulation within the 
vascular niche. Stromal Nestin-GFP+ cells physically associate with HSCs and are involved in their 
maintenance through SCF and CXCL12 secretion (Méndez-Ferrer et al. 2010). Nestin-GFP+ also 
overlap with other perivascular cells like CAR cells (CXCL12-abundantt reticular cell) and LepR+ cells 
(leptin receptor-expressing cells) which have been demonstrated to promote HSC maintenance through 
cytokine production (Omatsu et al. 2010; Ding et al. 2012; Pinho et al. 2013) (Figure 1). Endothelial 
cells also have a role in promoting HSC proliferation through expression of Notch ligands like Jag-1  
and endothelial cell permeability may also be involved in the regulation of HSC quiescence and 
activation, however, to date, the function of single endothelial cells in the vascular niche is still poorly 
understood (Itkin et al. 2016). Other cells like megakaryocytes (MEGs), macrophages and non-
myelinating Schwann cells were also confirmed to be involved in maintaining quiescence in HSCs and 
facilitate their retention within the niche (Figure 1) (Bruns et al. 2014; Zhao et al. 2014; Nakamura-
Ishizu et al. 2014). Despite advances in the understanding of the niche microenvironment, none of the 
niche cellular components identified has appeared to be sufficient for HSC maintenance. Additional 
work still needs to be done in order to better understand the complexity of the niche microenvironment 
and how this influences haematopoiesis and maybe reveal the “secret” of HSC ex-vivo expansion. 
Figure 1: Schematic representation of the regulatory microenvironment of the adult BM niche and its cellular components.   
Cell types identified in the BM niche and their action on HSC maintenance are shown (Gao et al. 2018). 
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1.2 Levels of heterogeneity in the human HSC pool 
To secure their maintenance over the lifetime of an individual, HSCs are quiescent and thus reside in 
the G0 phase of the cell cycle. HSCs do however divide, although very infrequently. They can commit 
to different fate choices. They can exit and re-enter quiescence, they can self-renew to produce identical 
cells or proliferate and differentiate into mature blood cell lineages (Seita and Weissman 2010). 
Alternatively, they can also undergo apoptosis (Figure 2).  
With the extensive study of molecular and functional properties of HSCs in the mouse and later in the 
human, it has become clear that this compartment comprises distinct subsets of cells with differences in 
their capacity of self-renewal, cycling properties or differentiation potential. This introduced the concept 
of heterogeneity in the HSC compartment, which is now identified as a heterogeneous population 
composed by sub-populations with different properties. Moreover, findings demonstrating the existence 
of lineage-biased HSCs and lineage-restricted progenitors, challenged the classical model of 
haematopoiesis suggesting that lineage specification occurs much earlier than previously thought. Both 
cell intrinsic and extrinsic mechanisms are thought to be responsible for this functional heterogeneity 
(Copley and Eaves 2013; Wilkinson and Göttgens 2013). This brought the field to reconsider the 
classical model of haematopoiesis.  
Figure 2: Summary of HSC fate choices. 
HSCs can self-renew to maintain themselves, they can enter and exit quiescence, differentiate or undergo apoptosis. 
1.2.1 Heterogeneity in self-renewal  
In the past decade, knowing that the HSC pool is not a homogeneous stem cell compartment , different 
studies tried to identify possible HSC subsets based on their blood reconstitution properties and 
durability of engraftment following in-vivo transplantation, as a readout of different self-renewal 
properties. Single cell transplants of HSCs showed a variety in the kinetics of blood reconstitution and 
different self-renewal potential (Müller-Sieburg et al. 2002; Morita, Ema, and Nakauchi 2010). 
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Two main different sub-populations have been defined in the mouse HSC pool based on their self-
renewal properties: Long-Term HSCs (LT-HSCs) and Short-Term HSCs (ST-HSCs). LT-HSCs are 
capable of long-term lympho-myeloid blood reconstitution for a minimum of 16 week in primary 
transplants (with at least 1% graft size) and they also retain the ability to engraft in secondary transplants. 
In contrast, ST-HSCs are defined as HSCs with more limited self-renewal and therefore only capable of 
short-term (more than 4 weeks but less than 16 weeks) transient engraftment after transplant (Uchida et 
al. 2003; Dykstra et al. 2007; Copley, Beer, and Eaves 2012). A third intermediate HSC population was 
identified as a subset of LT-HSCs by Benveniste et al. and defined as HSCs with intermediate 
reconstitution potential (IT-HSCs). The self-renewing ability of these cells is longer than ST-HSCs but 
shorter than LT-HSCs (Benveniste et al. 2010). Evidence in the literature reported that  HSC self-
renewal is affected by cell cycle regulators, transcription factors (TFs) and epigenetic regulators, 
however it is still not clear how this intrinsic regulation is integrated with other extrinsic factors. 
On the other hand, studies on human HSCs discovered that the loss of CD90 expression was associated 
with loss of long-term self-renewal, demarcating a population with transient engraftment abilities 
(Majeti, Park, and Weissman 2007). In the attempt to identify new markers to separate HSCs from their 
nearest progeny, the CD49f marker was found to be expressed on ~50% of CD90+ human HSCs and on 
~25% of CD90- HSCs. This allowed to define in the human HSC pool the presence of a LT-HSCs sub-
population identified as Lin- CD34+ CD38- CD45RA- CD90+ CD49f+ (hereby referred as CD49f+ HSCs), 
which provides robust multilineage repopulation beyond 30 weeks while retaining serial transplantation 
ability, and a ST-HSCs sub-population defined as CD34+ CD38- CD45RA- CD90- CD49f- (hereby 
referred as CD49f- HSCs), which can generate multilineage engraftments over intermediate periods but 
lacks serial transplantation ability (Notta et al. 2011). The transcriptional analysis of these two cell types 
confirmed a high degree of transcriptional similarity (Laurenti et al. 2013) but further studies are needed 
to better define the mechanisms underlying these differences in self-renewal properties.  
1.2.2 Heterogeneity in division and cell cycle properties  
A defining feature of adult HSCs is the ability to reside outside the cell cycle in a dormant state called 
quiescence or G0 state. Studies in adult mice indicate a level of heterogeneity in the division properties 
of HSCs, suggesting that they are not uniformly quiescent. Indeed, two different populations have been 
defined according to their division kinetics and they have been named “active” and “dormant” HSCs 
(A. Wilson et al. 2008). In-vivo label incorporation-based assays using DNA analogues such as BrdU 
(5’-bromo-2’-deoxyuridine) or histone 2B-GFP retention analysis identified a more dormant sub-
population in the HSC pool, based on their degree of quiescence. This sub-population differs in the 
frequency of division and it accounts for the 5-10% of the HSC pool. When compared to the other 90-
95% of less quiescent HSCs, the highly dormant HSC pool shows a turnover of 145 days in-vivo while 
the more active counterpart divides approximately every 30-50 days and it is thought to contribute more 
actively to the continuous blood formation. Nonetheless, it has been shown that despite being in a deep 
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quiescent state the most dormant cells display the longest repopulation capacity upon transplantation 
and they contribute as a reservoir in case of injury, but they are not involved in everyday blood cells 
production (A. Wilson et al. 2008; Foudi et al. 2009). In human, the rate of division of the most dormant 
human HSCs was calculated, thanks to the use of X-chromosome inactivation ratios to track HSC 
replications, to be around once every 40 weeks (Catlin et al. 2011). These findings support the idea that 
infrequent cycling of HSCs is a protective mechanism adapted to preserve genome integrity avoiding 
the accumulation of DNA damage due to replicative and oxidative stress. 
Studies by Elisa Laurenti confirmed that there is heterogeneity in the division properties also in the 
human HSC pool, and they highlighted differences in stem cell quiescence states between LT-HSCs and 
ST-HSCs. The division frequency of human LT- and ST-HSCs was assessed by BrdU incorporation in 
xenograft transplantation assays and, similarly to mouse models, LT-HSCs were found to divide less 
frequently than ST-HSCs. Moreover, the transcriptional analysis of these populations conducted at 
different times after xenotransplantation identified 241 genes differentially expressed, indicating that 
LT- and ST-HSCs have distinct transcriptional profiles with most of the differences in genes involved 
in the regulation of the cell cycle (Laurenti et al. 2015). Table 1 summarises the main differences in 
surface markers expression, repopulation capacity self-renewal and division frequency between LT- and 
ST-HSCs.  









Lin- CD34+ CD38- CD45RA- 
CD90+ CD49f+ 
Long term YES Rare 
ST-HSC 
(CD49f- HSCs) 
Lin- CD34+ CD38-CD45RA- 
CD90+ CD49f- 
Short term NO Often 
Table 1: Summary of the differences between LT-HSCs and ST-HSCs. 
The analysis of the cell cycle status on freshly isolated LT- and ST-HSCs showed that 90% of cells from 
both subsets are quiescent as defined by Ki67 staining. However, the differences found in the expression 
of cell cycle genes suggested a possible difference in cell cycle regulation between LT- and ST-HSCs. 
Molecular analysis of these two HSC subsets revealed that ST-HSCs have higher CDK6 mRNA and 
protein expression than LT-HSC. CDK6 is an important regulator of the entrance and progression in the 
G1 phase of the cell cycle. On the other hand, LT-HSCs lack CDK6 protein, showing that ST-HSCs, 
despite being equally quiescent are in a CDK6-primed quiescent state that confers them a competitive 
advantage in shortening the duration of exit from quiescence (Laurenti et al. 2015). CDK6 expression 
levels were then found to regulate the duration of the quiescence exit upon mitogenic stimulation in the 
human HSC pool underlying a new level of heterogeneity in HSC quiescence states (Figure 3). More 
recently, also retinoic acid (RA) signalling was identified as important in the regulation of HSC 
dormancy and prolonged self-renewal together with low Myc expression in mouse (Cabezas-Wallscheid 
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et al. 2017). However, what other molecular mechanisms, beside RA and CDK6 levels, underlie the 
regulation of quiescence exit in this compartment is still unknown. 
Figure 3: The haematopoietic stem cell compartment is heterogeneous in term of cell cycle properties.  
Summarising scheme of the differences in the division kinetics, expression of CDK6 and duration of quiescence exit between human LT- and 
ST-HSCs (from Laurenti et al., 2015). 
1.2.3 Heterogeneity in repopulation potential and lineage commitment  
Single cell transcriptomic analyses, in-vitro differentiation assays and single HSC transplants have 
revealed another level of heterogeneity related to HSC repopulation potential and lineage commitment.  
Initially, limiting dilutions transplants in mouse showed that different HSC behaviours can be inherited 
by daughter cells and are due to intrinsic differences in self-renewal and differentiation properties 
(Muller-Sieburg et al. 2004, 2012). Subsets of HSCs with different repopulation potential have thus been 
identified and characterised as “myeloid-biased” (My-bi), “lymphoid-biased” (Ly-bi) and “balanced” 
(Bala) based on the ratio of lymphoid to myeloid lineage detected in donor derived blood cells after 20 
weeks from transplantation (Morita, Ema, and Nakauchi 2010; Muller-Sieburg et al. 2012). Another 
study from Eaves et al. provided a similar categorisation using a different method that measured single 
HSC relative contribution to the total myeloid and lymphoid circulating cells (Dykstra et al. 2007). In 
this case, the classification included “lymphoid-deficient” α-HSCs primarily giving rise to myeloid cells 
and “balanced” β-HSCs with balanced lymphoid and myeloid lineage output and both able to repopulate 
secondary recipients. On the other hand, single HSCs unable to be serially transplanted were categorised 
as “myeloid-deficient” γ- or δ-HSCs, where γ-HSCs are lymphoid-biased but can produce myeloid cells, 
whereas δ-HSCs only produce lymphoid cells (Dykstra et al. 2007). According to Benveniste et al. γ- or 
δ-HSCs coincides with IT-HSCs (see chapter 1.2.1) since they show prolonged repopulation capacity in 
between of ST- and LT-HSCs (Benveniste et al. 2010). Prospective isolation of these functionally 
heterogeneous populations has been possible thanks to the identification of new markers including 
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CD150, whose expression correlates with myeloid bias and higher self-renewal potential. In fact, a 
higher expression of CD150 (CD150high) correlates with α- and β-HSCs enrichment while lower levels 
of CD150 (CD150low) correlate with γ- or δ-HSCs (Kent et al. 2009; Morita, Ema, and Nakauchi 2010). 
Despite the differences in the nomenclature of two classifications proposed above, lots of similarities 
are shared and HSC differentiation potential seems to be linked to their reconstitution time. In a more 
recent review, a new classification was proposed which divided HSCs into ST- IT- and LT- based on 
the length of blood reconstitution in transplanted mice and lineage balance. In this classification My-bi 
HSCs and α- HSCs overlap with LT-HSCs, while Ly-bi HSCs and γ- or δ-HSCs overlap with ST-HSCs. 
IT-HSCs instead correlate with Bala HSCs and β-HSCs (Ema, Morita, and Suda 2014). For this purpose, 
the consideration of long-term lineage reconstitution has been reconsidered and in this new classification 
LT-HSCs reconstitution time is more than 12 months after transplantation, while for IT-HSCs and ST-
HSCs is more than 6 and less than 6 months respectively (Ema, Morita, and Suda 2014).  
Other than myeloid and lymphoid biased HSCs, recent studies have also identified platelet-biased HSCs 
which precede lymphoid-biased HSCs in the haematopoietic hierarchy. Evidence of this population has 
also been reported in unperturbed haematopoiesis thanks to lineage tracing and transposon tagging 
experiments (Sanjuan-Pla et al. 2013; Yamamoto et al. 2013; Rodriguez-Fraticelli et al. 2018). Overall, 
in mouse, it seems that heterogeneity in differentiation potential is controlled by cell-autonomous 
mechanisms in individual HSCs. These differences are in fact maintained by daughter cells and probably 
involve epigenetic mechanism (Challen et al. 2010; Copley, Beer, and Eaves 2012). However, the 
molecular basis of this heterogeneity is still unclear. Although most of the identified heterogeneity seems 
to be intrinsically determined in HSCs, there is also a possibility that HSC differentiation and self-
renewal could be influenced by external signals and modulated by the surrounding niche 
microenvironment. Some examples include is the responsiveness to TGF-β or IL-7 signalling which 
were found to be different in My-Bi and Ly-bi HSCs (Muller-Sieburg et al. 2004; Crisan and Dzierzak 
2016). Moreover, niche changes during ageing and differences in the niche microenvironment 
(endosteal or central niches) have recently been associated with differences in HSC function. Mouse 
My- and Ly biased HSCs were demonstrated to be regulated by and to reside in distinct bone marrow 
niches respectively occupied by megakaryocytes (MK) and arterioles (Pinho et al. 2018). Moreover, 
age-related niche remodelling was found to be associated with My expansion (Y. H. Ho et al. 2019). 
Despite the extensive evidence obtained with single cells transplantation experiments in support of HSC 
heterogeneity, evidence has emerged from lineage tracking studies showing that these behaviours are 
probably not reflective of steady-state haematopoiesis in native conditions prompting for a major role 
of multipotent progenitors (MPPs) in homeostatic blood production (Sun et al. 2014; Busch et al. 2015). 
Investigation of the MPP progenitor compartment in mouse revealed the presence of lineage-biased 
MPPs (MPP2, MPP3 and MPP4) which were found to work together to guarantee adequate blood 
production (Cabezas-Wallscheid et al. 2014). Similarly, in human, Notta et al. re-classified the MPPs 
compartment (CD34+ CD38- CD90- CD45- CD49f-) into three different subpopulations based on 
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expression of CD71 and CD110 (or BAH1) (F1 (CD71– BAH1–), F2 (CD71+ BAH1–), and F3 (CD71+ 
BAH1+)). This uncovered heterogeneity within human MPPs and demonstrated how the hierarchy of 
blood cell progenitors changes across all developmental stages (fetal liver (FL), CB and BM). This 
showed that a higher number of cells with unilineage potential and with megakaryocytic and erythroid 
fates directly branches from the HSC compartment in CB and BM and it originates from the F3 CD71+ 
BAH1+ MPPs fraction (Notta et al. 2016). A summary of the HSC subsets identified to date in mouse 
or human, including their self-renewal potential, differentiation bias and cell cycle properties is shown 
in Table 2. 
Table 2: Summary of phenotypic or functionally defined HSC subsets in mouse and human. 
Mouse and human HSC subtypes identified in the literature to date are summarised here. Cell surface phenotype, self-renewal potential, cell 
cycle properties and differentiation potential are shown (Laurenti and Göttgens 2018). 
Single cell transcriptional profiling of previously identified mouse HSC subset populations, supported 
the results obtained from single cell transplants revealing the expression of lineage priming modules 
reflective of the functional lineage biased seen in-vivo (Månsson et al. 2007; Pina et al. 2012; Guo et al. 
2013; Moignard and Göttgens 2014; Grover et al. 2016). More recent papers, comprehensively analysed 
the whole transcriptional landscape of the full haematopoietic hierarchy in mouse (Nestorowa et al. 
2016) or the human HSC and progenitor compartment (Perié et al. 2015; Paul et al. 2015; Velten et al. 
2017; Karamitros et al. 2018). Together, these data show that lineage commitment is more of a 
continuous process where single cells with unilineage transcriptional profiles directly branch from a 
continuum of low-primed HSPCs without transitioning through multi, oligo or bipotent progenitors, thus 
suggesting that steps of lineage commitment may already occur in the phenotypic HSC/MPP 
compartments. This was demonstrated to be the case for dendritic cells (DCs) specification from human 
progenitor cells (CD34+) which was proven to happen in parallel to myeloid and lymphoid specification 
thanks to specific transcriptional programs which involved expression of IRF8 in HSCs (J. Lee et al. 
2017). Overall, some questions remain unanswered and when the first lineage restriction events occur 
or what exactly drives this heterogeneity is still not known.  
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1.2.4 Refining the haematopoietic hierarchy 
In the past two decades, the emergence of the concept of heterogeneity in the HSC and progenitor 
compartments has challenged the classical view of the haematopoietic tree. Different aspects of HSC 
heterogeneity have been discussed above and here I will give a general overview of how the 
haematopoietic tree has changed from the classic model to the current one.  
The classical model, also called bifurcation model, derived from the studies of Akashi and Kondo in the 
murine system, proposed that HSCs pass through defined steps of oligopotent, bipotent and unipotent 
progenitors and progressively restrict their differentiation potential in a stepwise manner to finally 
produce mature blood cells of different lineages. According to this model, HSCs reside at the top of the 
tree and are characterised by long-term repopulation potential, thus the name LT-HSCs. ST-HSCs then 
originate following a loss of self-renewal potential after which the first lineage restriction separates 
myeloid and lymphoid fates in a binary branching point that sees a separation between common myeloid 
progenitors (CMPs) and common lymphoid progenitors (CLPs). Megakaryocyte-erythrocyte 
progenitors (MEPs) and granulocyte-monocyte progenitors (GMPs) then originate from CMPs (Kondo, 
Weissman, and Akashi 1997; Akashi et al. 2000) while CLPs give rise to all lymphoid lineages. In this 
model each population is considered discrete and homogeneous (Figure 4, left).  
A few years later, the identification of lymphoid-primed multipotent progenitor (LMPPs) both in mouse 
and human, challenged the classical model. For the first time a new multipotent progenitor population 
with both myeloid and lymphoid but no megakaryocyte-erythroid potential was identified (Adolfsson et 
al. 2005; Månsson et al. 2007; Doulatov et al. 2010). An alternative model was thus proposed where 
myeloid and lymphoid lineages would remain associated within LMPPs whereas progenitors of the 
megakaryocytic and erythroid lineage (CMPs and MEPs) would branch out closer to HSCs/MPPs, 
CMPs and LMPPs would then both give rise to GMPs (Figure 4, right). However, after evidence in the 
field suggesting that differentiation does not always occur through maturation into intermediate 
progenitors, another interpretation of this model was proposed. Following the discovery of cells with 
self-renewal capacity but megakaryocyte-restricted lineage potential in the phenotypic HSC 
compartment (Sanjuan-Pla et al. 2013; Yamamoto et al. 2013; Haas et al. 2015; Notta et al. 2016; 
Rodriguez-Fraticelli et al. 2018; Carrelha et al. 2018) this new model would include a direct shortcut 
from HSCs to the megakaryocytic-erythroid lineage (Figure 4, right). A major pitfall of the models 
discussed above is that LMPPs and other progenitor populations rely on the analysis of defined 
populations purified through specific cell surface markers combinations using fluorescence-activated 
cell sorting (FACS). This is indeed a biased method which derives information that is representative of 
the average of the studied population.  
 23 
 
Figure 4: Graphical representations of the haematopoietic hierarchy. 
The classical model, also called bifurcation model is shown on the left. The revised model which includes LMPPs is shown on the right (Based 
on Ema, Morita, and Suda 2014; Haas, Trumpp, and Milsom 2018; Laurenti and Göttgens 2018). 
LT-HSC: long-term HSC; ST-HSC: short-term HSC; MPP: multipotent progenitor; CMP: common myeloid progenitor; MEP: megakaryocyte 
and erythrocyte progenitor; CLP: common lymphoid progenitor; LMPP: lymphoid-primed multipotent progenitor; GMP: granulocyte and 
macrophage progenitor; DC: Dendritic cell; NK: natural-killer cell.  
According to recent advances in the field and thanks to extensive single cell transcriptomic analyses of 
HSCs, MPPs and downstream progenitors, it is now known that the frequency of unipotent progenitors 
is higher than previously thought and such progenitors can branch out directly from the HSC 
compartment (Yamamoto et al. 2013; J. Lee et al. 2017; Haas, Trumpp, and Milsom 2018). However, 
the unilineage potential readout doesn’t necessarily mean that these cells may not have multi, oligo, or 
bipotential readouts in a different context (Carrelha et al. 2018). This put into discussion all the previous 
models and suggested that lineage choices may occur earlier than previously thought and probably 
already within the phenotypic HSC/MPP compartment.  
In the first experiment of its kind, Velten et al. analysed human HSC lineage commitment integrating 
flow cytometry, transcriptomics and single cell functional data. This revealed a high degree of 
connection between single CD34+ CD38- cells and identified a continuum of low-primed 
undifferentiated HSPCs (CLOUD-HSPCs) characterised by gradual differences between cells within 
this compartment (Velten et al. 2017). In this representation, the main route of lineage commitment is 
represented by direct transition from primed multilineage states towards a unilineage transcriptomic 
state. Distinct lineages thus emerge directly from this cloud by-passing discrete progenitors’ 
populations. Since then, many other studies, both transcriptomic (Moignard et al. 2013; Nestorowa et 
al. 2016; Pellin et al. 2019; Hay et al. 2018) and functional (Perié et al. 2015; Paul et al. 2015; Velten et 
al. 2017; Karamitros et al. 2018; Zheng et al. 2018) supported this idea and a new haematopoietic model 
was suggested. In this model (Figure 5 left) HSCs do not pass through discrete intermediate states but 
gradually acquire intrinsic differences in lineage bias and self-renewal potential within a continuum of 
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transitional stages. An alternative visualisation of this model was recently proposed by Laurenti and 
Göttgens (Laurenti and Göttgens 2018). In this representation single HSCs move along newly identified 
differentiation trajectories and they transition though phenotypically defined compartments. The lineage 
potential of the cells in each compartment is shown and it highlights the prevalence of unilineage cells 
over tri and bilineage ones (Figure 5, right).  
 
Figure 5: New hierarchical models of haematopoiesis. 
The model of continuum of differentiation is shown on the left. Red dots represent single cells and their position is indicative of their 
differentiation trajectory. The trajectory-based visualisation suggested by Laurenti and Göttgens is shown on the right. Trajectories are shown 
as single lines and shaded areas represent phenotypic HSC compartments. Snapshot of lineage potential are represented by horizontal lines. 
The number of colors is inficative of the lineage potential (single colour= unilineage; two colours=bilineage; three colours= trilineage; black= 
multipotent) (Laurenti and Göttgens 2018). 
1.3 Cellular and molecular properties of HSCs 
The study of the cellular and molecular properties of HSCs started a few decades ago in mouse. 
Molecular and biochemical pathways involved in the regulation of HSC function and important for the 
regulation of the balance between self-renewal and differentiation were initially investigated. Gene 
knock-outs and enforced expression, together with transplantation experiments were predominantly 
used to identify TFs involved in HSC function, formation and differentiation (Rossi et al. 2012). Most 
of these studies were based on the classic model of haematopoiesis and thus relied on the prospective 
purification of defined HSC and progenitor populations. Several studies defined and categorised TFs 
involved in HSC maintenance and lineage specification (Orkin and Zon 2008). However, it must be 
considered that the mechanisms regulating cell fate choices are not driven by single TFs but are the 
result of a complex crosstalk between different factors. In mouse, most of the regulatory maps involved 
in HSC lineage commitment have been identified and are being gradually refined. Because of the 
heterogeneity and complexity that characterise the HSC pool it has become now necessary to study these 
regulatory networks at the single cell level.  
 25 
Single cell transcriptomics further enhanced the level of resolution in the study of HSC and progenitors 
molecular properties and transcriptional states but also confirmed the heterogeneity in TF expression 
within these populations (Moignard et al. 2013; Moignard and Göttgens 2014; N. K. Wilson et al. 2015; 
Paul et al. 2015; Nestorowa et al. 2016; Hamey et al. 2017). Bioinformatical integration of single cell 
expression data allows to derive regulatory connections between TFs with the possibility of 
reconstructing network hierarchies involved in stem cell fate choices (Hamey and Göttgens 2019). An 
example of this comes from the study of Moignard et al. where the expression analysis of a network of 
TFs in more than 500 single HSPCs identified a new regulatory connection between Gata2 and 
Gfi1/Gfi1b during myelo-lymphoid specification where the antagonism between Gfi1 and Gfi1b is 
modulated by Gata2. In this case, the downregulation of Gata2 and Gfi1b by Gfi1 represent a key event 
in lymphoid lineage specification (Moignard et al. 2013). In another study by Cabezas et al., a genome 
wide molecular characterisation of highly purified HSCs and MPPs from mouse BM is obtained through 
quantitative proteomics, transcriptomics and methylome analysis and then validated through in-vitro 
and in-vivo functional assays. Here, they identify progressively changing landscape in cell type-specific 
methylation, gene and protein expression but also a high number of alternatively spliced transcripts 
isoforms which were not previously identified in these populations (Cabezas-Wallscheid et al. 2014).  
Looking instead at the human counterpart, initial gene expression profiling experiments conducted on 
human HSCs identified some degree of conservation but also specific differences between mouse and 
human transcriptional profiles (Ivanova et al. 2002; Georgantas et al. 2004). Thus, due to these species-
specific differences, it is important to understand how molecular programmes are associated with HSC 
differentiation directly into human samples, as this is crucial for the development of new clinical 
therapies. The molecular characterisation of human HSCs, similarly to what happened in mouse, was 
initially based on the prospective purification of HSCs and progenitor populations accordingly to the 
classical model of the haematopoietic hierarchy. MLL, RUNX1, SCL/TAL1 and LMO2 were just some 
of the TFs identified as involved in HSC formation and maintenance and they were also commonly 
found in translocations of leukaemic patients (Orkin and Zon 2008). A genome-wide expression analysis 
was conducted in 38 human hematopoietic cell subtypes and it identified the main TF circuits active in 
stem, progenitor and differentiated cells. The expression of several gene modules was found restricted 
to specific lineages while others were expressed over multiple lineages (Novershtern et al. 2011). The 
identification of a population of early-lymphoid biased progenitors that retains myeloid potential called 
“multi-lymphoid progenitors” (MLPs) challenged the view of a unique binary divergence between 
myeloid and lymphoid fates (Doulatov et al. 2010). The transcriptional dynamics of early-stage human 
haematopoiesis were thus investigated with a focus on the understanding of the transcriptional programs 
underlying lymphoid-versus-myeloid lineage choices in primary human HSCs. The gene-expression 
profiles of 10 prospectively isolated populations of CB HSCs and progenitors were analysed. In this 
study, the gene expression of MLPs clustered closely with the HSCs and not with more lymphoid-
committed fractions. Differences in gene expression between multipotent and myeloid-committed 
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progenitors were instead clearly demarcated underlying a transcriptional dichotomy between the HSC 
pool and haematopoietic progenitor cells. Moreover, gene expression changes along the lymphoid 
lineage resulted to be more gradual with a persistent association with myeloid-associated genes 
(Laurenti et al. 2013). Early step of lymphoid development will be discussed more in detail in section 
1.3.1.  
Interestingly, as previously reported in mouse (see above), a recent study identified another level of 
regulation mediated by non-coding RNA and splicing variants during early stages of lineage 
commitment in human HSCs and progenitors. Here, the authors stress the importance of looking at cell-
specific transcripts variations and not only at the gene expression level as the former ones are responsible 
of exerting the biological function and they do not result in noticeable gene expression changes. Novel 
transcript isoforms, splicing junctions and alternative splicing events were characterised at the genome-
wide level and recorded providing evidence of another level of regulation during lineage specification 
in HSCs and progenitors (Chen et al. 2014). 
More recently, the integration of flow cytometry, transcriptional and functional data at the single cell 
level in human BM samples demonstrated how unilineage restricted cells can originate from a 
continuum of low primed undifferentiated HSC and progenitor cells (CLOUD-HSCPs). In this model 
co-expressed gene modules associated with lineage priming were identified and used to demonstrate 
how distinct lineages can derive directly from lineage-primed HSCs without passing through discrete 
progenitor populations (Velten et al. 2017). The expression of HOXA3, PRDM16 and HOXB6 was 
associated with typical HSC properties such as quiescence and low RNA content, representing the least-
primed state. Common HSC specific genes like HLF, MECOM and GATA3 were also found highly 
expressed in immature HSCs but their expression was also present in the entire ‘CLOUD’. Moreover, 
genes modules associated with lympho-myeloid or megakaryocyte-erythrocyte priming including genes 
such as FLT3 or GATA2 were already expressed in HSCs demonstrating how these cells can express 
stem cell modules together with early lineage priming modules.  
Other than TF regulation for HSC differentiation and maintenance, HSC metabolism and mitochondria 
function play a very important role. Cell cycle and quiescence are also strictly regulated and because of 
the importance of this in my research, these mechanisms will be discussed more in detail in the next 
sections.  
1.3.1 Steps of lymphoid development  
A brief overview of the molecular properties of HSCs was given in the previous paragraph. The aim of 
this paragraph is to dig a little bit deeper into the steps of lineage commitment with a specific focus on 
the steps of lymphoid lineage development. As discussed before, the haematopoiesis field has recently 
seen a revolution in the analysis of transcriptional networks and differentiation maps, thanks to the 
advent of single cells transcriptomics. In 2001 a new “myeloid-based” model was proposed by 
Kawamoto et al. in which lymphoid and myeloid fates would not separate early on in the haematopoietic 
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hierarchy but they would rather remain coupled (H Kawamoto et al. 1999; Hiroshi Kawamoto et al. 
2010). A new population defined as lymphoid-primed multipotent progenitors (LMPPs) was thus 
identified in mouse BM and defined as Lin− Sca-1+ c-kit+ CD34+ CD135+ (Adolfsson et al. 2005).  
Similarly, in human, two lympho-myeloid populations were identified, both lacking erythroid and 
megakaryocytic potential. Human LMPPs retaining B cell, T cell, granulocytic and monocytic potential 
were identified as Lin- CD34+ CD38- CD90- CD45RA+ CD10- (Goardon et al. 2011). On the other hand, 
multi-lymphoid progenitors (MLPs) defined as Lin- CD34+ CD38- CD90- CD45RA+ CD10+, retained 
lymphoid, monocytic and dendritic potential but were unable to produce granulocytes (Doulatov et al. 
2010; Laurenti et al. 2013). MLPs are largely lymphoid restricted and express the early B cell marker 
CD10. The identification of these two populations facilitated the study of the molecular mechanisms 
driving myeloid versus lymphoid lineage choices in human HSCs.  
In one study, MLPs transcriptomic landscapes were compared to HSC and other progenitor populations 
(MEPs, CMPs, GMPs, ETPs, ProB and NK cells). This showed that the transcriptional architecture of 
MLPs is more similar to the one of HSCs suggesting that, similarly to the mouse, lymphoid specification 
happens more gradually and it is not a binary decision (Laurenti et al. 2013). When looking at specific 
transcriptional programs, MLPs showed enrichment for gene signature specific for both myeloid and 
lymphoid lineages and in part of HSCs, demonstrating that HSC programmes are not totally switched 
off in MLPs. Among the TFs identified in MLPs specification, TFs like C/EBP-α, IKFZ1 and EBF1, 
important for both lymphoid and myeloid commitment were included. Moreover, other factors like 
BCL11A, SOX4 and TEAD1 emerged as important for the specification of the lymphoid lineage 
upstream of other important regulators involved in B cell commitment (Laurenti and Dick 2012; 
Laurenti et al. 2013). Similarities between LMPPs and MLPs have been reported and the progressive 
acquisition of CD10 expression has been linked with loss of myeloid potential (Ichii et al. 2010), 
however, MLPs population negative for CD10 have also been identified and they resulted to have similar 
differentiation potential although with lower myeloid differentiation capacity (Farlik et al. 2016). 
Moreover, other lympho-myeloid populations have been identified in the more mature Lin– CD34+ 
CD38+ CD45RA+ compartment. One is the CD62Lhi CD10– population (Kohn et al. 2012) which retains 
lymphoid, monocytic and DC potential and the other is the granulocyte-monocyte progenitor population 
(GMPs, CD19− CD34+ CD38+ CD10− CD7− CD45RA+) which still has residual lymphoid potential 
(Goardon et al. 2011). 
Recent studies reported a better in-vivo and in-vitro characterisation of the lympho-myeloid populations 
in CB and demonstrated that LMPPs, MLPs and GMPs are heterogenous populations which differ 
functionally and transcriptionally. While erythroid and megakaryocytic fates seem to originate directly 
from HSCs or MPPs (Pietras et al. 2015; Grover et al. 2016) lymphoid progenitor populations appear to 
be part of a continuum of lympho-myeloid progenitors. MLPs and LMPPs showed similar expression 
of several lymphoid-specific genes like IL-7R, LCK, SYK, ADA, HLX, LST1 and ITGAL and they 
only had a few differentially expressed genes, supporting the idea that these populations are very similar. 
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GMPs, despite being more like other myeloid progenitors such as CMPs, still retained similarities with 
LMPPs with less than 200 differentially expressed genes (Karamitros et al. 2018). Moreover, genes 
signatures enrichment analysis showed that a balance between myeloid and lymphoid signature was 
enriched in LMPPs including myeloid-associated genes such as TRPM2, S100A8, PADI4 and 
ALOX15B and lymphoid associated genes like ETS1, EBF1 and CYTIP. On the contrary MLPs showed 
higher enrichment for lymphoid genes signature and GMPs for myeloid associated genes. Overall, 
heterogeneity was found in these progenitors populations suggesting the presence of intermediate 
populations as part of a continuum of lympho-myeloid progenitors (Karamitros et al. 2018). To date, 
LMPPs/MLPs are believed to be the cells where the first lineage commitment choice towards the 
lymphoid branch is made, and myeloid differentiation is believed to be the default commitment program 
that is progressively shut down for other lineages specification. 
1.3.2 Role of mitochondria and metabolism in HSCs 
Emerging evidence in the field has suggested that mitochondria and metabolism in HSCs have central 
roles in determining HSC activity and fate. Significant progress could be obtained for HSC maintenance 
in-vitro and transplantation through the study of HSC metabolism. 
In the BM, HSCs reside in a hypoxic environment and they have therefore adapted to live in hypoxic 
conditions, so they must adjust to respond to higher oxygen levels once they are exposed to it. Moreover, 
it is known that hypoxia can promote HSC quiescence and this is essential for HSC function (Hermitte 
et al. 2006; Shima et al. 2010). However, as cells require more energy to proliferate, it seems logical 
that HSC metabolism would change significantly during cell activation and differentiation in-vivo. 
Several studies demonstrated how HSC metabolism differs from downstream progenitors. HSCs 
generate energy through anaerobic metabolism relying on glycolysis rather than oxidative 
phosphorylation. This is necessary to maintain a quiescent state and a dysregulation of this metabolism 
would affect HSC maintenance and self-renewal (Simsek et al. 2010; Suda, Takubo, and Semenza 2011). 
This unique metabolic balance allows to maintain low levels of ROS, which would otherwise impair 
HSC function and promote differentiation (Kobayashi and Suda 2012; Ahlqvist, Suomalainen, and 
Hämäläinen 2015). Autophagy and other regulatory molecules like FOXO , BMI1 and ATM are also 
some of the players involved in ROS regulation in HSCs (Ludin et al. 2014).  
The anaerobic metabolism that relies on glycolisis, characteristic of quiescent HSCs, is regulated by 
HIF-1α (Hypoxia Inducible Factor-1 α), a TF activated in response to reduced levels of oxygen 
(Semenza 2011). HIF-1α is highly expressed in quiescent HSCs and its deletion in mouse HSCs results 
in loss of quiescence and decreased repopulation ability mainly due to the incapacity to switch from 
aerobic towards anaerobic metabolism (Takubo et al. 2010; Suda, Takubo, and Semenza 2011). HIF-1α 
expression in HSCs was also found to be regulated by MEIS1, a stem-cell associated factor expressed 
which is downregulated upon differentiation. MEIS1 loss has been associated with HIF downregulation, 
increased ROS production and loss of quiescence (Simsek et al. 2010). This evidence supports the fact 
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that the unique metabolism of HSCs is not only consequence of their hypoxic environment they reside 
in, but an important property of quiescent stem cells. 
Consistently with their reliance on anaerobic metabolism, HSCs have been reported to have low 
mitochondrial mass (as measured by dye-dependent methods) mainly sustained by active mitochondria 
elimination through mitophagy (K. Ito et al. 2016; T. T. Ho et al. 2017; Snoeck 2017). This was recently 
confuted by one study where the use of dye-independent methods revealed that HSCs and MPPs have a 
high mitochondrial content which appears to be even higher than downstream progenitors and mature 
cells. This was proven to be due to mitochondria dye (Mito-Tracker Green) active efflux mediated by 
mitochondrial membrane efflux pumps, which was proposed to lead to previous inaccurate 
interpretations. Here, they also demonstrated that despite their high mitochondrial mass, HSCs showed 
reduced mitochondrial turnover and respiration (de Almeida et al. 2017). Overall, this study highlights 
the importance of coupling dye-independent methods to classical mitochondrial dye staining to avoid 
mis-interpretation due to dye efflux mediated by influx/efflux pumps present on the mitochondria. 
Although the main function of mitochondria is to maintain cellular respiration, relevant literature has 
shown how the role of mitochondria in HSCs goes beyond the only respiratory function. Recent studies 
demonstrated the role of mitochondria in calcium (Ca2+) homeostasis and identified Mitofusin2 (Mfn2), 
a mitochondrial fusion protein, as an important player for the maintenance of HSCs with lymphoid 
potential thanks to its effect on enhancing the buffering of intracellular calcium (Luchsinger et al. 2016). 
In the same study, Ca2+ levels were also linked with HSC functional heterogeneity. Mouse CD150low 
HSCs, which are enriched with lymphoid biased HSCs, display lower Ca2+ levels than CD150 high HSCs, 
which are enriched with more myeloid biased HSCs (Kent et al. 2009; Beerman et al. 2010; Hock 2010). 
The same group also recently demonstrated that HSCs have lower Ca2+ than progenitor cells and their 
maintenance is strongly enhanced by culture in low Ca2+ media. Ca2+ efflux pumps require glycolysis 
and low Ca2+ has a suppressing effect on mitochondrial respiration, suggesting that HSC metabolic 
configuration is dependent on Ca2+ regulation (Luchsinger et al. 2019). Recent studies demonstrated the 
role of the Ca2+-mitochondria axis in HSC division and self-renewal. A switch in the mitochondria 
membrane potential is in fact required for quiescent HSCs to become activated and this is linked to the 
increase of the intracellular Ca2+ levels. On the other hand, suppression of this pathway is linked to HSC 
self-renewal (Umemoto et al. 2018).  
Overall, in the field, the importance of mitochondria in regulating HSC function and activity is becoming 
increasingly recognised even though HSCs mainly rely on anaerobic metabolism (Filippi and Ghaffari 
2019). Accumulating evidence favours a central role for mitochondria in HSC activation and 
differentiation. A study from Vannini et al. showed that modulation of HSC mitochondrial metabolism 
affects self-renewal and fate choices. Through in-vivo multi-lineage blood reconstitution assays they 
demonstrated that HSC characterised by lower mitochondrial activity retain long-term repopulation 
potential and reduction of the mitochondrial activity by uncoupling of the electron transport chain can 
drive HSC self-renewal through autophagy stimulation. Moreover, in homeostatic conditions and during 
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acute stress, the mitochondrial activity of quiescent and cycling HSCs is quite similar, suggesting that 
metabolic differences in HSC are indicative of fate choices rather than cell cycle states (Vannini et al. 
2016). The same group also recently demonstrated that the NAD+ boosting agent nicotinamide riboside 
(NR) can mediate the reduction of mitochondrial potential and activity in HSCs through increased 
mitochondrial clearance mediated by mitochondrial stress response and autophagy. NR would thus 
stimulate haematopoiesis while increasing asymmetric divisions in LT-HSCs (Vannini et al. 2019). This, 
once again, highlights the link between HSCs fate choices and mitochondrial regulation. 
Mitochondria were also found to be asymmetrically segregated during cell division in adult stem cells 
and they can also be remodelled through fusion or fission (Katajisto et al. 2015; H. Zhang, Menzies, and 
Auwerx 2018). However, these mechanisms are still unclear in haematopoiesis and more studies are 
needed to better understand mitochondria’s role in HSC biology. Modulation of mitochondria activity 
and metabolism in HSCs has important implications for their in-vitro maintenance and for stem cell 
therapies. 
1.4 Cell cycle and quiescence regulation in HSCs 
As previously discussed, an important property of HSCs is to reside in a quiescent state in homeostatic 
conditions. However, quiescence is a reversible state in which the cell, in response to external stimuli 
can decide to progress into the cell cycle. A disruption of quiescence in HSCs is highly detrimental for 
the organism and it leads to defects in self-renewal resulting in HSC exhaustion, as seen in knock-out 
models for many genes (Orford and Scadden 2008; Rossi et al. 2012). Thus, the regulation of the cell 
cycle in HSCs plays a critical role in the maintenance of a balance between self-renewal and 
differentiation. Most of the studies related to cell cycle regulation in HSCs have been conducted in mice 
and a detailed description of these mechanisms is still lacking in the human counterpart. 
The mammalian cell cycle is classically divided into two main phases, the synthesis phase (S) and the 
mitotic segregation phase (M) separated by two gap phases called G1 and G2, preceding S and M phase 
respectively (Figure 7, right). A G0 phase, or quiescent phase, has also been described as a non-cycling 
state outside the cell cycle. This is a reversible state and cells can re-enter the cell cycle upon sensing 
appropriate stimuli (Cheung and Rando 2013; Hao, Chen, and Cheng 2016). Cell cycle progression is 
highly regulated and the transition from G1 to S is the most regulated step. A crucial aspect of cell cycle 
regulation is the existence of DNA damage and replication checkpoints at the transition from G1 to S 
and from G2 to M and the existence of a restriction point called “R point”, after which a cell becomes 
committed to enter the cell cycle and progresses through it independently from external signals. Upon 
sensing errors in DNA replication or chromosome segregation, the activation of these checkpoints will 
arrest the cell cycle to repair possible defects. The R point, which coincides with the phosphorylation of 
the Retinoblastoma protein (RB), divides the G1 phase into a mitogen-dependent early G1 phase and a 
late G1 mitogen-independent phase (Figure 6). Cyclins and cyclin-dependent kinases (CDKs) are the 
main regulators of the cell cycle and the kinase activity of CDK/cyclin complexes is controlled by CDK 
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inhibitors (CKIs), which belong to either the INK4 or CIP/KIP families (Pietras, Warr, and Passegué 
2011; Hao, Chen, and Cheng 2016). CDKs are responsible for the phosphorylation of transcriptional 
inhibitors and they promote the activation of transcriptional waves leading to the production of important 
regulators of downstream cell cycle events. D-type cyclins together with CDK4 and CDK6 regulate the 
transition from early to late G1 inactivating RB through its phosphorylation and thus promoting the 
expression of cyclin E which, together with CDK2 will hyper-phosphorylate RB confirming the entrance 
in late G1 phase of the cell cycle (Figure 6) (Malumbres and Barbacid 2009; Lim and Kaldis 2013). 
Interestingly, while cyclin D-CDK4/CDK6 were thought to be essential for cell cycle progression, cyclin 
D-CDK4/CDK6 independent progression into the cell cycle has also been reported in many cellular 
compartments. From these studies also emerged how, instead, HSC cell cycle progression is dependent 
on the presence of cyclin D-CDK6/CDK4 as mice lacking these regulators presented perturbations of 
the hematopoietic system (Malumbres et al. 2004; Kozar and Sicinski 2005; Tigan et al. 2016). 
Figure 6: Regulation of HSC cell cycle entry. 
Entrance in the cell cycle is finely regulated by the interplay of cell-intrinsic and extrinsic mechanisms in HSCs. A schematic representation 
of this regulation is shown here. Solid arrows indicate direct activation or inhibition events, dashed arrows indicate transcriptional regulation. 
Green shaded circles identify functionally related groups of cell cycle activators while cell cycle inhibitors are grouped into red shaded circles. 
Quiescence, exit from quiescence (G0 exit) and activation phases as defined in this work are shown  (adapted from Pietras, Warr, and Passegué 
2011). 
The cell cycle activity of HSCs is carefully modulated by a complex interplay of cell-intrinsic 
mechanisms and cell-extrinsic factors produced by the microenvironment. HSC entrance in the cell cycle 
corresponds to the transition from G0 to G1 phase, that corresponds to G0 exit (Figure 6) and is regulated 
by the competition of activators and inhibitors of cyclin-CDKs complexes. Extrinsic signals important 
for HSC maintenance coming from the surrounding niche in the BM, like thrombopoietin (TPO), stem 
cell factor (SCF) or transforming growth factor β (TGF-β), contribute to the regulation of quiescence in 
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HSCs acting on the regulation of the cyclin D-CDK4/CDK6 complex. This complex controls the 
entrance in the late G1 phase as it can phosphorylate RB thus passing the restriction point (Figure 6). 
RB and other members of its family (p107 and p130) of transcriptional repressors restrict cell cycle 
entry by repressing E2F driven transcription of positive cell cycle regulators like E-type cyclins, whose 
role is crucial in late G1 and S phase. The cyclin E-CDK2 complex can then hyper-phosphorylate RB 
with the effect of enhancing E2F mediated transcription that will lead the progression from late G1 to S 
phase (Figure 6). A firm role for RB family members in the regulation of HSC cell cycle was established 
after demonstrating that conditional deletion of the entire RB family in adult mice leads to an increased 
HSC proliferation (Viatour et al. 2008).  
Moreover, the role of CKIs of the INK4 and CIP/KIP families is also important as they negatively 
regulate the activity of CDKs complexes. In particular, the members of the INK4 family (p15INK4B, 
p16INK4A, p18INK4C and p19INK4D) function as antagonists of the cyclin D-CDK4/6 complex (Figure 6), 
thereby blocking RB phosphorylation and entry into S phase. Their regulation has been demonstrated to 
be important in order to maintain a proper balance between quiescence and proliferation in the HSC 
pool (Yuan et al. 2004; Oguro et al. 2006). On the other hand, the CIP/KIP (p21CIP, p27KIP1, p57KIP2) 
family, which is highly expressed in quiescent cells, also restrain the entry into S phase but acting on 
the inhibition of the cyclin-E-CDK2 complex (Figure 6) (Matsumoto et al. 2011; P. Zou et al. 2011). 
The expression of CIP/KIP family members is in turn regulated by other transcription factors including 
HES1, JUNB and FOXO3, which are activated by extrinsic growth-repressive signals like TGF-β. 
Furthermore, HSC cell cycle activity is also regulated by p53, which becomes active in response to 
cellular damage and thus inhibits the progression of the cell cycle favouring quiescence maintenance 
through a p21 independent mechanism (Liu et al. 2009a) (Figure 6). The role of all these factors in HSC 
cell cycle regulation has been widely validated in knock out models in-vivo (Pietras, Warr, and Passegué 
2011). In conclusion, the regulation of the cell cycle in HSCs is quite complex and it involves the 
interplay of intrinsic and extrinsic factors. A better understanding of this fine regulation would give 
further insight on how HSCs decide to exit quiescence and progress into the cell cycle and whether this 
regulation is related with cell fate decisions. 
1.4.1 Quiescence and activation in HSCs 
While the concept of quiescence has been well described in the stem cell context, the concept of 
activation still lacks a clear definition as it is generally defined both as the entrance in the cell cycle or 
increased frequency of cycling of HSCs. Because I will base most of my work on the comparison 
between these two states, a better definition of quiescence and activation is needed for the purpose of 
this study. 
Quiescence has been extensively studied over the years and it is recognised as a protective phase for 
long-lived adult stem cells. The balance between quiescence and proliferation in stem cell populations 
is tightly regulated in order to prevent exhaustion of the stem cell pool and excessive cell growth. 
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Quiescence was initially defined as a deeply inactive and dormant state of the cell, located outside of 
the cell cycle in a phase called G0. However, an increasing number of studies has demonstrated that 
quiescence is a poised state, which allows a rapid cell activation and differentiation upon sensing 
appropriate stimuli (Nakamura-Ishizu, Takizawa, and Suda 2014; van Velthoven et al. 2019). As it is 
often cause of confusion, it is important to remember that quiescence and senescence are not the same 
thing. Quiescent cells can re-enter the cell cycle whereas senescent cells are quiescent but terminally 
differentiated and incapable of entering any other cell cycle phase (Terzi, Izmirli, and Gogebakan 2016; 
Cho et al. 2019). 
Common characteristics of quiescent stem cells include low RNA content and thus reduce protein 
synthesis, reduced metabolism and lack of proliferation markers (Figure 7, left) (Passegué et al. 2005; 
Simsek et al. 2010; Cheung and Rando 2013). Quiescent HSCs rely on anaerobic glycolysis as major 
source of energy and they have lower mitochondrial membrane potential and thus lower mitochondrial 
activity (see chapter 1.3.2 for HSC metabolism). The use of glycolysis has been shown to have protective 
advantages for resting HSCs as it minimizes the production of DNA-damaging reactive ROS, by-
products of mitochondrial oxidative phosphorylation. On the contrary, when HSCs become activated 
they rapidly switch from anaerobic glycolysis to mitochondrial oxidative phosphorylation to facilitate 
the robust energy demand associated with cell cycle progression and differentiation (Folmes et al. 2012; 
Yu et al. 2013; Warr and Passegué 2013).   
Recent studies conducted in muscle stem cells (MuSCs) showed the existence of different depths of 
quiescence. These cells can cycle between two different quiescence states: the G0 phase and a more 
primed GAlert phase characterised by increased transcriptional activity and metabolic activity than G0. 
When in the GAlert phase, cells can exit quiescence and respond to stress more easily and thus contribute 
to tissue repair in a more efficient way (Rodgers et al. 2014). Transition from G0 to GAlert is controlled 
by mTORC1 activity and activation of this pathways in HSCs resulted in increased mitochondrial 
activity and thus transition to a GAlert state (Rodgers et al. 2014). The mechanisms controlling quiescence 
depth are still poorly known. Two recent studies demonstrated that quiescence depth can be regulated 
by the activation threshold of the RB-E2F switch. First, as described above in 1.2.2, both LT-HSCs and 
ST-HSCs are in a quiescent state but ST-HSCs can more rapidly enter the cell cycle thanks to their 
higher levels of CDK6 (Laurenti et al. 2015), which controls RB phosphorylation. However, as the 
mTORC activity is similar between these populations, the ST-HSC primed state does not correspond to 
what is defined as GAlert state (van Velthoven et al. 2019). During quiescence the hyperphosphorylation 
of RB inhibits E2F transcriptional activators which are then activated though CDK4/6 phosphorylation 
upon sensing mitogenic stimuli. Deeply quiescent cells then need a stronger stimulation to re-enter the 
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cell cycle than other less quiescent cells (Laurenti et al. 2015). A graphical representation of the cell 
cycle and the more recently identified quiescence cycle is shown in Figure 7.  
Figure 7: Characteristics of quiescent and activated stem cells and representation of the cell cycle. 
A schematic comparison of the characteristics of quiescent and activated stem cells is shown on the left. Arrows are indicative of upregulation 
or downregulation of such processes or characteristics. A schematic representation the cell cycle and quiescence cycle is shown on the right. 
Different levels of quiescence are shown in correlation to mTORC activity, CDK6 levels and protein synthesis (from van Velthoven et al. 
2019). 
Recent studies provided better insights into the molecular regulation of quiescence suggesting that this 
state is maintained thanks to the activity of many different intrinsic mechanisms but also through 
extrinsic signals (Cho et al. 2019). Epigenetic regulation seems to play an important role in keeping 
quiescent cells “ready” to enter the cell cycle in other stem cells. Several genes result to be in a 
transcriptionally poised state which is supported by a permissive chromatin environment that will 
facilitate gene transcription during activation (Srivastava, Mishra, and Dhawan 2010; Kheir and Lund 
2010; Cho et al. 2019). Autophagy has also been identified as important for quiescence maintenance in 
many adult stem cells including HSCs due to its active role in ROS reduction and removal of 
mitochondria (Mortensen et al. 2011; García-Prat et al. 2016; T. T. Ho et al. 2017). Genetic approaches 
and high-throughput analyses of several adult quiescent stem cells provided information about 
molecular signatures common to quiescent stem cells, including HSCs. These analyses show a down 
regulation of genes involved in DNA replication and cell cycle progression like Cyclins A2, B1 and E2, 
important regulators of the DNA checkpoints during the cell cycle. Moreover, other genes were 
identified as down-regulated including genes correlated with the proliferation status and mitochondrial 
function, whose lower expression reflects the low metabolic activity of quiescent cells (Forsberg et al. 
2010; Cheung and Rando 2013; van Velthoven et al. 2017).  
Due to the long life of quiescent HSCs, it is important for these cells to protect themselves from 
environmental stress, like ROS. The FOXO family of transcription factor has been found to play a role 
in HSC protection against ROS. Indeed, HSCs depleted of FOXO family members (FOXO1, FOXO3 
and FOXO4) exhibit a marked increase in ROS and the propensity to exit quiescence (Tothova et al. 
2007; Cheung and Rando 2013).  
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1.4.2 Definition of HSC activation in the context of this study 
Despite recent advances in the understanding of mouse HSC quiescence, no studies have been conducted 
in human HSCs. Moreover, to date, there is only very limited information regarding G0 to G1 transition. 
We have defined “exit of quiescence” as the process of abandoning the quiescent status and entering the 
mitogen-dependent early G1 phase right before the restriction point, which involves the phosphorylation 
of RB by the cyclin D-CDK4/6 complex (Figure 6). We have chosen this definition as no G0/G1 check 
points or markers have been identified to date to distinguish these two phases. In contrast to quiescence, 
it is still debated what the activation process consists of. Is a cell activated when it is in any of the phases 
of the cell cycle (G1, S, G2 or M) or just right after exiting quiescence? Is the activation state defined by 
the activation of specific signalling pathways or TFs? What are the cellular and molecular properties of 
an activated stem cell or HSC? None of the answers to these questions is reported in the literature. For 
the purpose of this study, I defined “activation” as the process of exiting quiescence and entering the 
cell cycle (in any of the cell cycle phases) including everything that could correlate with this action, like 
the activation of pathways promoting cell growth or an increase in the metabolic activity. When studying 
quiescence in-vitro it is important to remember that the removal of stem cells from their niche and their 
purification, which for HSCs usually requires flow cytometry sorting, already results in significant 
molecular and transcriptional changes within the cells. Although cell cycle analysis shows that HSCs 
are still quiescent, the process of activation most likely has already been initiated and the properties of 
such cells may not reflect their in-vivo state. This poses indeed challenges to the study of quiescence 
and quiescence exit in-vitro and needs to be put into consideration when interpreting results. 
In conclusion, it is important to develop new strategies in order to define the molecular pathways 
involved in the maintenance of a quiescent status and transition to the G1 phase in human HSCs. 
1.4.3 Cell cycle and cell fate decisions 
The high degree of heterogeneity found in both cell cycle and functional properties within the HSC pool 
suggests a possible link between the kinetics of cell cycle progression and cell fate choices. However, 
to date, it is still unclear if there are molecular regulators responsible of coordinating cell cycle 
progression and cell fate decisions in the HSC pool, including the decision to self-renew or to undergo 
differentiation towards a specific lineage. 
Strong evidence of such coordination exists in other systems, with studies on human and mouse 
Embryonic Stem Cells (mESCs) and Neural Stem Cells (NSCs). These works highlighted the 
importance of the G1 phase of the cell cycle in the initiation of cell fate decisions. Indeed, it has been 
demonstrated that, while S, G2 and M phases lengths are comparable between different cell types, the 
entry and progression through G1 varies from cell to cell. In fact, G1 is significantly truncated in 
pluripotent stem cells when compared to committed or differentiated cells. mESC, and in general 
pluripotent stem cells, divide rapidly and spend most of their cell cycle in the S phase where they 
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replicate their DNA; only little time is spent in the gap phases. In these cells E- and A- type cyclins are 
highly expressed throughout the cell cycle and inhibition of CDKs through CDKIs is almost absent. This 
results in constitutive activation of CDKs which facilitates inactivation of the RB pathways and thus a 
rapid transition through the G1 phase (K. A. Becker et al. 2006; Neganova et al. 2009; Boward, Wu, and 
Dalton 2016). Expression of CDKIs or knockdown of CDKs in human ESCs has been found to promote 
differentiation, suggesting that the G1 phase may be important for fate specification (Neganova et al. 
2009; Ruiz et al. 2011; Boward, Wu, and Dalton 2016).  
Several studied thus identified the G1 transition time to be important in the “decision making process”, 
the process where the cells decides commit to a certain fate (Blomen and Boonstra 2007). For pluripotent 
stem cell the G1 phase is a “window of opportunity” where they can decide to self-renew or respond 
more efficiently to differentiation cues. Experiments in support of this show that ESCs and NSCs are 
characterised by a short G1 phase that allows them to maintain their self-renewal potential, while the 
lengthening of their transition time through G1 has been associated with initiation of differentiation 
(Lange and Calegari 2010; Calder et al. 2013; Coronado et al. 2013). Several reports described how a 
short G1 phase is an important feature of pluripotency and what is the process by which pluripotent stem 
cells initiate their differentiation programs in this phase (Dalton et al. 2015), but only few recent studies 
provided further insights in the understanding of the molecular mechanisms driving cell fate decisions 
during G1 (Pauklin and Vallier 2013; Singh et al. 2013). These studies took advantage of the 
Fluorescence Ubiquitin Cell Cycle Indicator system FUCCI report system, which allows to sort cells in 
different cell cycle phases but also to monitor the length of each phase of the cell cycle without altering 
cellular properties (Sakaue-Sawano et al. 2008). These data revealed how important players of the cell 
cycle machinery contribute to a differential compartmentalisation of differentiation by driving key 
transcriptional factors. In one of these studies it was found that, in human ESCs, the complex cyclin D-
CDK4/6 has a central role in limiting the nuclear localisation of key signal factors like SMAD2/3, whose 
control results in a different regulation of genes involved in endodermal differentiation. When the level 
of cyclins D is low, in early G1, SMAD2/3 promotes endodermal differentiation whereas, when 
SMAD2/3 nuclear import is blocked due to the higher expression of cyclin D in late G1, hESCs are only 
receptive for neuroectodermal initiation. This allowed to confirm that hESCs differentiation occurs 
during the G1 phase and, in these cells, early G1 and late G1 have different differentiation capacities, 
implying that cell fate choices primarily occurs in early G1 phase when cyclins D are dynamically 
expressed (Pauklin and Vallier 2013). Taken together, these evidences uncover the first molecular 
mechanisms involved in cell cycle regulated cell fate decisions in hESCs, but they also suggest that G1 
phase could be the main window for cell fate choices also in other stem cells. Moreover, this is consistent 
with accumulating evidence showing that CDKs display other non-canonical functions. Specifically, 
CDK6 has emerged as directly involved in transcriptional regulation in cancer cells and in HSCs, a role 
that has been demonstrated to be independent of CDK6’s kinase activity (Kollmann et al. 2013). Among 
its many roles, CDK6 is also involved in the process of differentiation through the modulation of gene 
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expression changes and epigenetic status that contribute to the determination of cell fate. Evidence 
shows that decreased levels of CDK6 are required for erythroid differentiation (Choe et al. 2010) but 
also indicate that CDK6 can prevent myeloid differentiation though the binding of RUNX1 (Fujimoto 
et al. 2007). More CDK6 cell-cycle independent functions are being investigated and new inhibitors 
against the non-kinase activity of CDK6 are being considered for development (Tigan et al. 2016). 
Recently, new insight emerged into mechanisms linking cell fate decisions and cell cycle control which 
were not only linked to the G1 phase but also to the transition from S to G2 phase. Gonzales et al. 
identified a role for S to G2 phase regulators into control of pluripotency and differentiation of hESCs. 
Several epigenetic mechanisms including chromatin remodelling and histone acetylation resulted as 
essential for the transition from pluripotency to differentiation during S and G2 phase. Moreover, 
ATR/ATM factors, which are involved in DNA damage checkpoints, were shown to enhance the TGF-
β/ACTIVIN/NODAL pathway activity through p53 during the same phases (Gonzales et al. 2015; 
Vallier 2015).  
Although hESCs and adult human HSC cell cycle dynamics are highly divergent, the delineation of a 
relationship between the cell cycle machinery and cell fate decision in human HSCs could provide better 
insights in the molecular regulation of HSC differentiation. 
Recent studies in human HSCs contributed to understand how HSC function is controlled by the kinetics 
of cell cycle progression and in particular whether exit from quiescence rather than transition time 
through G1 is the most important period for the decision of HSC fates (Laurenti et al. 2015; Mende et 
al. 2015). The overexpression of CDK6, a major regulator of quiescence exit, in LT-HSCs, conferred a 
competitive advantage for the expansion of LT-HSCs in-vivo without altering differentiation, 
contrasting with previous work reporting that increased cycling is associated with impaired LT-HSC 
maintenance. On the other hand, overexpressing both cyclin D1 and CDK4 in human HSCs results in a 
shortened transition time through G1 associated with competitive advantage and increased myeloid 
differentiation (Mende et al. 2015). Collectively, these evidences suggest the idea that not only early G1 
phase but also transition from G0 to early G1 is a sensitive period during which cell fate decisions are 
taken and genes involved in the regulation of this transition phases might have an impact in cell fate 
decisions by altering the time spent in this sensitive period. However, in the HSC field it is still not 
known if cell division precedes differentiation and how these relate to each other’s. 
More recent in-vivo tracking studies in Ki67RFP knock-in mice followed HSC differentiation, divisional 
history and cell cycle control at the single cell level to identify the correlation between HSC 
differentiation and cell cycle control. They demonstrated that, in-vivo, HSCs can differentiate into 
restricted myeloid and megakaryocyte- erythroid progenitors in the G0/G1 phases and before entering 
the S phase of the cell cycle (Grinenko et al. 2018). They suggest that HSC division and differentiation 
are independent processes and fate decisions are made by HSCs before committing to divide and thus 
before the S phase of the cell cycle. If similar behaviours are also seen in human HSCs is not known, 
but they open new directions in the study of similar behaviours in human HSCs. The main goal is now 
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to understand if these cell cycle phases are just sensitive phases where the cell is more exposed to 
specific cell fates signals or if important regulators of cell cycle progression and exit from quiescence 
are part of a more complex picture that sees them involved in other roles independent from the cell cycle. 
In order to study this in HSCs, the development of methods able to identify variations in the early G1 






In the past decade, advances in single cell transcriptomic have complemented an array of functional 
experiments demonstrating a high degree of heterogeneity within the HSC compartment of both mouse 
and human. However, how this functional diversity is regulated at the cellular and molecular level and 
when HSC multipotency is lost is still not known.  
Moreover, despite decades of studies on how HSCs maintain their quiescent status in the mouse model 
and more recently in human, still very little is known about how the molecular networks regulating 
quiescence change during the progression from quiescence to division, here termed activation. 
Activation has previously been associated with loss of self-renewal and initiation of differentiation 
programmes, but to date no studies have formally examined if cell fate decisions occur during this 
activation process.  
In this thesis I present the work I have done in human HSCs towards two different aims: 
A) Dissect human HSC heterogeneity in the purest HSC compartment (CD49+ HSCs/LT-HSC) 
reported to date and understand when the first steps of lineage restriction occur. 
B) Build a comprehensive picture of the molecular and cellular changes occurring during 
quiescence exit and cell cycle progression and investigate when and if human HSC self-renewal 
is lost upon activation. 




NOTE: Sections of this chapter have been adapted from Belluschi et al., Nat. Communications, 2018. 
3.1 Human cord blood samples  
De-identified umbilical cord blood (CB) samples were obtained with informed consent from healthy 
donors through the Cambridge Blood and Stem Cell Biobank (CBSB) in accordance with regulated 
procedures approved by the relevant Research and Ethics Committees (07/MRE05/44 research study). 
CB units received on the same day were pooled independently of sex and processed as a single sample. 
CB samples used for single cell RNA-sequencing (scRNA-seq) experiments were pooled by sex (males 
only or females only). 
3.2 Human CB CD34+ cells selection 
Upon receiving CB, mononuclear cells (MNCs) were isolated by Lymphoprep (Stem Cell Technologies) 
or Pancoll (PAN-biotech) by density gradient centrifugation of pre-diluted CB (1:1 ratio with PBS). The 
collected MNCs fractions were then depleted of red blood cells (RBCs) after 15 minutes incubation at 
4˚C with Red Blood Cells Lysis Buffer (BioLegend). In order to proceed with the CD34+ selection, a 
minimum number of 108 cells were required. If this condition was not satisfied MNCs were stored at -
150˚C. 
CB CD34+ cells were positively selected using the Micro Beads CD34+ selection kit (Myltenyi Biotec) 
and the AutoMACS cell separation technology (Myltenyi Biotec) according to the following adapted 
protocol (Table 3). CB CD34+ cells were then stored at -150˚C until use. 
Reagents Quantity 
CD34 Micro Beads 30 μl/108 cells 
FcR Blocking Reagent 30 μl/108 cells 
PBS + 3% Fetal Bovine Serum (FBS) 90 μl/108 cells 
Table 3: Adapted protocol for CD34+ cells selection. 
3.3 Fluorescence-activated cell sorting (FACS) and flow cytometry analysis 
3.3.1 Sample preparation for sorting 
To isolate different cell populations from CD34+ CB cells, frozen CB CD34+ samples were thawed by 
drop-wise addition of pre-warmed Iscove's Modified Dulbecco's Medium (IMDM, Life Technologies) 
+ 0.1 mg/ml DNase (Sigma) + 50% Fetal Bovine Serum (FBS, Life Technologies) and then re-
suspended after counting at a concentration of 2x106 cells/ml in PBS + 3% FBS antibody mix. Cells 
were then incubated 20 minutes in the dark at room temperature (RT) and washed with 10 volumes of 
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PBS + 3% FBS. Depending on the experiment CD34+ CB cells were stained with antibodies against 
different panels of surface markers (Table 4) and sorted on BD FACS Aria III or on BD FACS Aria 
Fusion sorters available at the NIHR Cambridge BRC Cell Phenotyping Hub facility. For single cell 
experiments, cells were sorted using single cell purity and index sorting to allow retrospective 
correlation between the transcriptomic or functional information obtained from each single cell by in-
vitro functional assays or scRNA-seq and its cell surface markers expression at the time of the sort. 
Purity mode was used for all bulk sorts. All sorts showed >95% purity. 
The following markers were used to sort previously defined populations: HSCs/MPPs (CD19- CD34+ 
CD38- CD45RA-), CD49f+ HSCs/LT-HSCs (CD19- CD34+ CD38- CD45RA- CD49f+ CD90+), CD49f- 
HSCs/ST-HSCs (CD19- CD34+ CD38- CD45RA- CD49f- CD90-), LMPPs (CD19- CD34+ CD38-
CD45RA+ CD10+), MLP (CD19- CD34+ CD38-CD45RA+ CD10-), GMP (CD19- CD34+ CD38+ CD10- 
CD7- CD45RA+) and CMPs/MEPs (CD19- CD34+ CD38+ CD10- CD7- CD45RA-), after gating out dead 
cells based on Zombie Aqua (Biolegend). 
Several combinations of antibodies were used depending on the type of experiment 
Antibody panel combination Antibody (clone) Dilution Fluorochrome 
A, B, C CD19 (HIB19) 1:300 Alexa 700 
A, B, C CD34 (581) 1:100 APC-Cy7 
A, B, C CD38 (HIT2) 1:100 PE-Cy7 
A, B,  CD45RA (HI100)* 1:100 FITC 
C CD45RA (HI100) 1:100 PE 
A, B,C CD49f (GoH3)* 1:100 PE-Cy5 
A, C CD90 (5E10)* 1:100 APC 
B CD90 (5E10) 1:50 PE 
A, B CD10 (HI10a)* 1:100 BV421 
A, B CD7 (M-T701)* 1:100 BV421 
A CLEC9A (8F9) 1:75 PE 
A, B CD117 (104D2) 1:100 BV650 
A, B,C Zombie  1:2000 Aqua 
Table 4: Antibodies and antibody panels used for isolation of cell populations derived from CD34+ cells.  
All the antibodies used for cell sorting are listed in this table. Several combinations of antibodies were used depending on the type of 
experiment. For each cell surface marker directed antibody, clone, dilution and fluorochrome are specified. All the antibodies listed were 
purchased from BioLegend except those indicated by * that were purchased from BD bioscience. Before use all the antibodies were titrated 
using appropriate control samples from human CB. 
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3.3.2 FACS gating strategies  
The following gating strategies were used to sort previously known populations including: CD34+ 
CD38+ progenitor cells, CD34+ CD38- cells, HSC pool cells, phenotypic LT-HSCs (CD49f+ HSCs) and 
ST-HSCs (CD49f- HSCs) GMPs, MLPs, LMPPs 
Figure 8: Gating strategy used to isolate HSC pool cells, phenotypic LT-HSCs and ST-HSCs, GMPs, MLPs and LMPPs. 
A, B) FACS plots are representative examples of sorting strategies used to isolate the indicated populations. Gates and percentage of cell 
populations in each gate are shown. A) Representative example of gating strategy used to isolate HSC/MPPs, CD49f+ HSCs and CD49f- HSCs 
from CD34+ CB cells. CD49f+ HSCs are defined as the highest 30% CD90+ CD49f+ population, and CD49f- HSCs as the lowest 30% CD90- 
CD49f- population. B) Representative example of the sorting strategy used to isolate LMPPs and MLPs progenitors at day 0 from CD34+ CB 
cells.  
3.3.3 Flow cytometry analysis 
Flow cytometry analyses were performed using the BD LSR II Analyser with the BD LSR II HTC 
Analyser (BD Biosciences) in case of high-throughput analyses. The BD LSR Fortessa available at 
NIHR Cambridge BRC Cell Phenotyping Hub facility was also used occasionally. Unstained cells and 
compensation beads (BD Biosciences) were used for compensation and as controls to set appropriate 
gates. Data were analysed with FlowJo software (v 9.9 or v10). Where large number of samples were 
analysed, FlowJo data were exported and further analysed using R. 
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3.4 Single cell in-vitro functional assays  
3.4.1 Single cell differentiation assays 
Single cells were sorted into 96-well round-bottom plates (when monitoring the time of first division) 
or flat-bottom plates in 100 μl/well MEM (Myeloid (My)-Erythroid (Ery)-Megakaryocytic (Meg)) 
medium in order to support differentiation toward My-Ery-Meg lineages. MEM cytokine medium was 
prepared as follows: StemPro medium with nutrients supplement (Life Technologies) supplemented 
with cytokines (SCF 100 ng/ml, Flt3-L 20 ng/ml, TPO 100 ng/ml, IL-6 50 ng/ml, IL-3 10 ng/ml, IL-11 
50 ng/ml, GM-CSF 20 ng/ml, IL-2 10 ng/ml, IL-7 20 ng/ml (all Miltenyi Biotec), EPO 3 units/ml (Eprex, 
Janssen-Cilag), h-LDL 50 ng/ml (Stem Cell Technologies), 1% L-Glutamine (Life Technologies) and 
1% Pen/Strep (Life Technologies). After FACS sorting, plates were centrifuged for 5 minutes at 400 g 
and incubated at 37˚C.  
To monitor the time of first division, single cells were visualised and counted manually every 8-12 h 
over 4 days using an inverted microscope. The time of first division was recorded for each cell and all 
the empty wells were excluded from the experiment. If the time of first division was initially recorded, 
cells were then transferred to a 96-wells flat bottom plate at day 4 after division kinetics analysis with 
addition of 50 μl of medium and cultured for a total of 3 weeks at 37˚C. 
S1_1, S2_1, Diff1, S2_2, Diff2 populations were derived from bulk CD49f+ Subset1 and CD49f+ 
Subset2 cultured for 5 days in reduced cytokine MEM medium (lacking IL-11, IL-2 and IL-7). Single 
CD49f+ HSCs, CD49f+ Subset 1, CD49f+ Subset2, S1_1, S2_1, Diff1, S2_2, Diff2 cells were then sorted 
into 96-well plates in 100 μl/well MEM cytokine medium and cultured for 3 weeks at 37˚C.  
The type (lineage determination) and the size of the colonies formed were assessed after three weeks 
culture by high-throughput flow-cytometry using the BD LSR II HTC Analyser. All single cell derived 
colonies were harvested into 96 u-bottom plates. Each colony was stained using the antibody panel 
shown in Table 5. Plates were incubated for 20 minutes in the dark at RT with 50 μl/well of antibody 
mix and then washed with 100 μl/well of PBS + 3% FBS. 
Lineage Antibody (clone) Dilution Fluorochrome 
Megakaryocytic CD41(HIP8) 1:1000 FITC 
Erythroid GlyA (HIR2) * 1:1000 PE 
hHSC marker CD45 (HI30) 1:300 PE-Cy5 
Monocytic CD14 (M5E2) 1:1000 PE-Cy7 
NK cells CD56 (HCD56) 1:200 APC 
Myeloid CD11b (ICRF44) 1:300 APC-Cy7 
Granulocytic CD15 (MC-480) 1:200 BV421 
Table 5: Antibodies used to assess the differentiation output in the MEM differentiation assay.  
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For each cell surface marker directed antibody, clone, dilution and fluorochrome are specified. All the antibodies listed were purchased from 
BioLegend except those indicated by * that were purchased from BD bioscience. Before use all the antibodies were titrated using appropriate 
control samples from human CB. 
3.4.2 Single cell differentiation assay analysis 
The type (lineage composition) and the size of the colonies formed were assessed by high-throughput 
flow-cytometry. The colony output was determined using the gating strategy shown in Figure 9. A single 
cell was defined as giving rise to a colony if the sum of cells detected in the CD45+ and GlyA+ gates 
was ≥30 cells. Ery colonies were identified as CD45-  GlyA+≥30 cells, Meg colonies as CD41+≥30 cells, 
My colonies as [(CD45+ CD14+) + (CD45+ CD15+)] ≥30 cells, NK colonies as CD45+ CD56+≥30 cells. 
My colonies were further classified as follows: Granulocytes (Gran) colonies were identified as CD45+ 
CD15+≥30 cells and CD45+ CD14+≤ 30, Monocyte (Mono) colonies as CD45+ CD15+≤30 cells and 
CD45+ CD14+≥30 and Monocyte/Granuocyte (MonoGran) as CD45+ CD15+≥30 cells and CD45+ 
CD14+≥30 cells. In the B cell assay, B cells were identified as CD45+ CD19++≥30 cells, My colonies as 
CD45+ CD11b+≥30 cells and NK colonies as CD45+ CD56+≥30 cells. All high-throughput screening 
flow cytometry data was recorded in a blinded way, and at analysis correlation between the colony 
phenotype and originating population was only performed at the final stage. 
The analysis was done using FlowJo (v9.9) software. All the data obtained from the analysis were 
exported onto an excel file and when appropriate, correlated with the first time of division. The analysis 
was done using the R Studio software.  
Figure 9: Gating strategy used for lineage determination in the MEM assay. 
Representative examples of the gating strategies used to determine the lineages of colonies derived from CD49f+ HSC single cells is shown. 
Erythroid colonies were identified as GlyA+≥30 cells, megakaryocytic colonies as CD41+≥30 cells, myeloid colonies as [(CD45+ CD14+) + 
(CD45+ CD15+)]≥30 cells, NK colonies as CD45+ CD56+≥30 cells. Two representative examples (one My/NK and one Ery/Meg colony) are 
shown. 
 45 
3.5 Cell size measurement 
In order to measure the cell size of phenotypic LT-HSCs and ST-HSCs, 100 cells/well were sorted into 
a 384 well-plate directly into 50 μl of MEM cytokine medium prepared as described in paragraph 3.4.1 
in presence or absence of Palbociclib 200 nM (PD0332991, Sigma). 
Cell images were recorded every 24 hours in bright field (BF) with a 20x magnification on a Leica 
DMI300 B microscope using the MetaMorph Microscopy Automation and Image Analysis Software. 
The cell size was then measured on 25 cells/well using ImageJ and expressed as cell diameter size (μm). 
3.6 Mitochondrial mass and mitochondrial activity measurements 
Phenotypic LT-HSCs and ST-HSCs were sorted as previously shown in Figure 8. 
As different dyes for mitochondrial mass (MitoTracker green FM) and mitochondrial activity (TMRM) 
are detected in the FITC or in the PE channel, the CD45RA antibody in the sorting panel C (see Table 
4) was used either in the PE or in the FITC channel in order to leave one of these channels free for dye 
detection at 0 h after the sort. 
The cells were then stained in 100 μl and analysed for the two above mentioned parameters on day 0 
right after the sort, at 24 h and after 48 h in culture with MEM cytokine medium in presence and absence 
of Palbociclib 200 nM (PD0332991, Sigma). 
The dyes and the adapted staining protocol used to determine the mitochondrial mass and the 
mitochondrial activity are shown in Table 6. After the staining the cells were washed with 1 ml of PBS 
+ 3% FBS, re-suspended in 500 μl of PBS + 3% FBS and analysed by flow cytometry.  
Dye Concentration Staining Manufacturer Channel 
MitoTracker Green FM 20 [nM] 
40 min 37˚C 
in medium 
Life Technologies FITC 
TMRM 100 [nM] 
40 min 37˚C 
in medium 
Life Technologies PE 
Table 6: Dyes used to assess mitochondrial mass (MitoTracker Green FM), mitochondrial activity (TMRM). 
The dyes used are listed in the table. For each one final concentration, staining conditions, manufacturer and channel are specified. 
3.7 Index sorting analysis 
Correlation analyses between index sorting data, division time and differentiation assays were 
performed with R (version 3.3.2). Cell-surface marker levels information from the indexed cells was 
recorded in .csv files during FACS sorting. Data collected from different sorts and on different days 
were normalised using a normalisation pipeline established in (Nestorowa et al. 2016): data obtained 
from each experiment were logicle transformed with the estimateLogicle function (m=5.1) of the 
FlowCore package and then then normalised using the ComBat function from the sva package. Principal 
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Component Analysis (PCA) was performed with the prcomp function on the normalised data, and vector 
loadings were obtained from the prcomp rotation variable. Dimensionality reduction analysis to produce 
a diffusion map was performed in the bglab package following methods described by (Haghverdi, 
Buettner, and Theis 2015) using a local sigma informed by the 5 nearest neighbours. 
3.8 Mice 
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice were purchased from Charles River or bred and maintained 
at the University of Cambridge animal facility. Experimental cohorts consisted of age-matched female 
mice of 12-16 weeks of age at the time of transplantation. All mice were housed in a Specific-
Pathogen-Free (SPF) animal facility and experiments were conducted under UK Home Office 
regulations. This research has been regulated under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare 
and Ethical Review Body (AWERB).  
3.9 Xenograft transplantation assays  
3.9.1 CD49f+ Subset1 and CD49f+ Subset2 transplantation assays 
To assess human CD49f+ engraftment in-vivo, NSG mice were sublethally irradiated (2.4 Gy). After 24 
h from irradiation mice were anesthetised with isoflurane and injected intrafemorally (IF) with the 
indicated doses of the specified populations and injected subcutaneously with 0.1 mg/kg buprenorphine 
(Animalcare). As all mice shared the same genetic background and were age-matched females, no 
specific randomisation nor blinding was performed. For Limiting Dilution Analysis (LDA) experiments, 
all sorted subsets where maintained overnight in X-VIVO 10 medium (Lonza) supplemented with 1% 
BSA (Roche), 1% L-glutamine (Life Technologies), 1% Pen/Strep (Life Technologies), SCF 100 ng/ml, 
Flt3-L 100 ng/ml, TPO 50 ng/ml and IL-7 10 ng/ml before injection.  
Mice transplanted with saturating doses of CD34+ HSCs were given intraperitoneal injections of either 
PBS or EPO (20 units/injection, Eprex, Janssen-Cilag) every other day for 2 weeks prior sacrifice. For 
LDA experiments, mice analysed at 20 weeks post-transplantation received 8 intraperitoneal EPO 
injections (20 units/injection) in the 4 weeks prior to sacrifice. At 20 weeks post transplantation the 
injected femur was harvested, and the BM was flushed out.  
3.9.2 Cultured LT-HSCs transplantation assays 
To assess human cultured LT-HSC engraftment in-vivo, NSG mice were sublethally irradiated (2.4 Gy). 
After 24 h from irradiation mice were anesthetised with isoflurane and injected intrafemorally (IF) with 
the indicated doses of the specified populations and injected subcutaneously with 0.1 mg/kg 
buprenorphine (Animalcare). As all mice shared the same genetic background and were age-matched 
females, no specific randomisation nor blinding was performed. LT-HSCs were sorted in bulk and 
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cultured for 24 or 72 h in MEM media (section 3.4.1) with or without PD0332991 until the injection 
day. At 18 weeks post transplantation the injected femur was harvested, and the BM was flushed out.  
3.9.3 Secondary transplants 
Secondary transplantation was performed by purifying CD34+ cells from individual primary animals 
using the Micro Beads CD34+ selection kit (Miltenyi Biotec), then CD34+CD38- cells were sorted by 
flow cytometry from each primary mouse. All the cells sorted from each mouse (1000-30000 cells) were 
IF injected into secondary recipients. Animals were then sacrificed 12 weeks post-secondary 
transplantation.  
3.9.4 In-vivo engraftment analysis 
Cells obtained from BM and injected bone (IB) from all assays were stained using the panel shown in 
Table 7. 
Lineage Antibody (clone) Dilution Fluorochrome 
B cells CD19 (HIB19) 1:300 Alexa 700 
B cells CD19 (HIB19) 1:200 FITC 
Erythroid GlyA (HIR2) * 1:1000 PE 
hHSC marker CD45 (HI30) 1:300 PE-Cy5 
hHSC marker CD45 (HI30) 1:500 BV510 
Monocytic CD14 (M5E2) 1:1000 PE-Cy7 
T cells CD3 (HIT3a) 1:100 APC-Cy7 
Myeloid` CD33 (P67.6) * 1:200 APC 
Table 7: Antibodies used to assess the engraftment of transplanted mice. 
For each cell surface marker directed antibody, clone, dilution and fluorochrome are specified. All the antibodies listed were purchased from 
BioLegend except those indicated by * that were purchased from BD bioscience. Before use all the antibodies were titrated using appropriate 
control samples from human CB. 
To ensure appropriate detection of low levels of human engraftment, two distinct antibodies against the 
human HSC marker CD45 were used. Cells were considered of human origin if positive for both 
(CD45++). Mice were considered engrafted if (%CD45++ + %GlyA+) ≥ 0.01 % and at least 30 cells were 
recorded in these gates. Mice used as controls and not injected were sometimes included and defined as 
irradiated but non-transplanted mice. BM staining of control mice was sometimes used to define staining 
background. None of these mice met the criteria for engraftment. 
To determine the lineage composition of the human graft, the following parameters were adopted: My 
lineage: CD45++ CD33+ ≥ 30 cells; Ly lineage: CD45++ CD19++ ≥ 30 cells (positive for 2 distinct CD19 
antibodies); Ery lineage: CD45- GlyA+ ≥ 30 cells or CD45- CD71+ GlyA+ ≥ 30 cells. 
 48 
3.10 Bulk RNA-sequencing analysis 
Bulk RNA-seq expression data from LT- and ST-HSCs at 0 h (q), 72 h (a) and 72 h with 200nM 
PD0332991 (pq) were obtained from John Dick’s Lab (Princess Margaret Cancer Centre, University 
Health Network, University of Toronto). These data were generated from 500 cells. Library preparation 
was done following the Smart-Seq2 protocol (Picelli et al. 2013) and using the low input Nextera Kit 
(Illumina). Differential expression between q vs a, q vs pq from both LT- and ST-HSCs and aLT-HSCs 
vs aST-HSCs populations was performed with DESeq v1.6.1, using a read counts cut-off of 25. 
Venn diagrams were created to show the number of genes differentially expressed that are in common 
between different comparisons. Functional annotation was performed with DAVID (v 6.8) .  
To measure how similar the activation process is at the transcriptional level between LT- and ST-HSCs, 
the fold-change in expression for each gene between the quiescent and activated state was calculated 
and correlation plots were drawn. The correlation coefficient was calculated with the cor.test function 
(two-sided Pearson method). 
3.10.1 Short Time-series Expression profile analysis 
Temporal expression profile analysis of bulk RNA-seq gene expression data was performed using the 
Short Time-series Expression Miner version 1.3.12 (Jason Ernst and Bar-Joseph 2006) on 13121  genes. 
This software uses a clustering method (J. Ernst, Nau, and Bar-Joseph 2005) that can differentiate 
between real and random patterns and clusters genes by assigning them to a series of pre-defined 
expression profiles. Similar profiles are grouped together to form clusters and biological significance of 
the genes associated with the cluster is assessed using a Gene Ontology (GO) enrichment analysis. 
If the number of genes assigned to a profile exceeds the number of genes that are expected to occur by 
chance, the profile is significant. Analysis was done using STEM default parameters. The significance 
level for profile assignment was set to be 0.05.  
3.10.2 Gene Set Enrichment Analysis (GSEA) on bulk RNA-seq data 
Gene Set Enrichment Analysis (GSEA) allows to determine if a set of genes shows statistically 
significant differences between two biological states. Raw expression files were used and the analysis 
was run with either the C2 curated gene sets sub collection of canonical pathways or the C3 transcription 
factor motif gene sets from the MSigDB60 (Subramanian et al. 2005). Significantly enriched gene sets 
at FDR< 25% were taken into consideration for biological interpretation. 
3.11 ScRNA-sequencing library preparation 
The protocol used to prepare libraries for scRNA-seq was adapted from the Smart-seq2 protocol of 
(Picelli et al. 2013). Single cells were sorted into 96 well PCR plates in a configuration determined to 
minimise batch effects due to the position of the cells on the plate. Single cells were sorted into 4 μl of 
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lysis buffer/well prepared containing 0.4% (v/v) Triton X-100, 2 U/μl RNase inhibitor (Clontech), 5 
mM DTT, 1 mM dNTP and stored at −80 °C. ERCC used as external RNA controls (Ambion, Life 
Technologies) were diluted to a final concentration of 1:3,000,000. The PCR purification step after 
cDNA amplification was done with 20 μl of Ampure XP beads (ratio 1: 0.6/0.7, Beckman Coulter). The 
success of cDNA preparation was confirmed by optimal cDNA signal detected by a 2100 Bioanalyzer 
with High-sensitivity DNA chip (Agilent). cDNA concentration for each single-cell was determined 
using the Picogreen quantification kit (ThermoFisher). An optimal range of 0.07-0.120 ng/µl was 
considered good to proceed with library preparation. Dilution plates were calculated and prepared in 
order to have most of the cells in the plate within the ideal cDNA concentration range needed for library 
preparation. Illumina library preparation was carried out following the Illumina Nextera XT DNA 
sample preparation protocol. Library size distribution was checked on an Agilent high-sensitivity DNA 
chip and the concentration of the indexed library was determined using the KAPA library quantification 
kit (Kapa Biosystems). The sequencing was done using the Illumina Hiseq 4000 system and performed 
by CRUK Cambridge Institute Genomics Core. 
3.12 Single cell RNA-sequencing analysis 
3.12.1 Single cell RNA-sequencing analysis for CD49f+ HSCs, CD49f+ Subset1, 
CD49f+ Subset2, Subset2, MLPs and LMPPs 
NOTE: Bioinformatic analysis was performed by Elisa Laurenti and Kendig Yen Chi Sham. 
Reads alignment was performed using GSNAP (T. D. Wu and Nacu 2010), and read counts were 
generated with HTseq (S. Anders, Pyl, and Huber 2015). All analyses below were performed in R 
(version 3.3.2) with the bglab package (https://github.com/wjawaid/bglab). Blinded quality control 
(QC) was performed on the single cell/sample group and single cells/samples were retained for further 
analysis if  > 2x105 reads mapped to a gene feature, there were > 20% of genes over the total number of 
reads and < 20% of mitochondrial genes over mitochondrial + nuclear genes. Data were normalised for 
sequencing depth using size factor calculated on endogenous genes (Simon Anders and Huber 2010). 
Batch effects were corrected using the ComBat function from the sva package on all genes that had >1 
count. Highly variable genes (HVGs) were selected fitting a GAM model assuming a quadratic 
relationship between log coefficient of variance (CV) and log mean expression for ERCC spike-in genes, 
with the function techVar (bglab package) setting the MeanForFit parameter at 10 (Brennecke et al. 
2013). All dimensionality reduction techniques were applied to HVGs. Differential expression between 
the 2 populations was performed with DESeq2 using the doDESeq wrapper function of the bglab 
package (Love, Huber, and Anders 2014). Genes were considered differentially expressed if FDR < 
0.05. Expression of selected genes was represented using violin plots (vioplot package) of the log10 (1 
+ normalised_counts). 
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ICGS analysis was run with AltAnalyze software (http://altanalyze.readthedocs.io/en/latest/ICGS/) 
using normalised and batch corrected counts as input and default parameters. Cell cycle genes were 
excluded using the most stringent parameter. For the analysis including CD49f+ Subset1 and CD49f+ 
Subset2 single cells, the software identified 6 minor clusters that were regrouped into 3 major clusters.  
For GSEA, genes were ranked by the DESeq2 statistic and pre-ranked GSEA was run using either the 
C2 curated gene sets sub collection of canonical pathways or the C3 motif gene sets from the MSigDB60 
(Subramanian et al. 2005) population specific signatures (Laurenti et al. 2013, 2015) or lineage-priming 
module (Velten et al. 2017). 
3.12.2 Single cell RNA-sequencing analysis for LT-HSC time course  
For the generation of the time course scRNA-seq data two experiments were performed and sequenced 
separately (A and B below). 
Alignment was performed using G-SNAP (T. D. Wu and Nacu 2010) and read counts were generated 
using HTSeq (S. Anders, Pyl, and Huber 2015) with Ensembl genes (Zerbino et al. 2018) 
Quality control (QC) was performed independently for each experiment in R (version 3.6.0) 
(https://www.r-project.org) with bglab package ([https://github.com/wjawaid/bglab]). This was 
performed blinded of the single-cell/sample group and single cells were retained for further analysis if: 
 > 2 × 105 reads mapped to a gene feature, ratio of genes to total number of reads greater than 0.3 (A) or 
0.2 (B), ratio of mitochondrial genes to mitochondrial and nuclear gene less than 0.15 (A) and 0.2 (B), 
number of nuclear genes to total mapped genes ratio greater than 0.75 (A) and 0 (B), number of genes 
with 10 reads per million greater than 2000 (A) and 0 (B), spike-ins to mapped reads ratio less than 0.2 
(A) and 1 (B), nuclear genes to mapped reads ratio greater than 0 (A and B).  
Exp A LT 0 h LT 6h LT 24h LT 48h LT 72h PD LT 72h UNTR 
Before QC 72 72 72 72 72 72 
After QC 29 49 28 20 27 42 
 
Exp B LT 0h LT 6h LT 24h PD LT 24h UNTR LT 72h UNTR 
Before QC 95 95 95 95 95 
After QC 57 87 80 58 82 
Excluding additional outliers 56 85 80 58 82 
Table 8: Number of cells analysed by scRNA-seq before and after quality control in all the time points and conditions analysed. 
The number of cells sequenced and the number of cells that passed QC are shown separately for Experiment A (top) and B (bottom). 
For data visualisation and pseudotime calculation, the two datasets were combined using the Scanpy 
module in python (Wolf, Angerer, and Theis 2018). Genes were filtered out if expressed in < 3 cells 
(scanpy method: filter_genes, parameters: min_cells = 3). Counts were logarithmized to the base e after 
adding a pseudo-count of 1 (scanpy method: log1p, default parameters). Batch correction was performed 
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with Scanpy function combat with parameters: covariates = timepoint. The original implementation of 
the algorithm in python can be found at https://github.com/brentp/combat.py. HVGs were selected using 
the Scanpy method: highly_variable_genes. 
 Parameters for scanpy function: highly_variable_genes 
Combat without PD minimum_mean=0.05, maximum_mean=13, minimum_dispersion=0.1, maximum_dispersion=3 
Combat with PD minimum_mean=0.05, maximum_mean=6, minimum_dispersion=0.1, maximum_dispersion=3 
Table 9: Table of the parameters used for the Scanpy function highly variable genes. 
PCA was calculated for the combined datasets (Scanpy method: pca, parameters: SVD solver=’arpack’). 
Nearest neighbours for each cell were calculated with the python package bbknn with parameters: 
approx= False, metric='euclidean' (Park et al. 2018). Diffusion map was calculated in 3 dimensions 
(Scanpy method: diffmap). The dpt function in Scanpy was used to obtain the pseudotime index for each 
cell (parameters: n_dcs= 3 (to match diffusion map dimension)). UMAP visualisation was performed 
using the function sc.tl.umap (data_neighbor, n_components=3). 
For differential expression analysis between different time points, raw counts generated from high-
throughput sequencing (HTSeq) were used for filtering out genes that were expressed in < 3 cells. 
Differential expression results were generated by DESeq2 (Love, Huber, and Anders 2014) and where 
applicable, the batch effect was accounted for.  
Analysis Design matrix input for DESeq2 
no PD design = ~ batch + timepoint 
Exp A design = ~ timepoint 
Exp B design = ~ timepoint 
 
Table 10: Design matrix input for DESeq is shown for each analysis performed. 
Cell cycle phase assignment was done using scanpy.api.tl.score_genes_cell_cycle function, 
implementing an approach used by Seurat package (Satija et al. 2015). The list used for the function 
can be found here: 
https://github.com/theislab/scanpy_usage/blob/master/180209_cell_cycle/data/regev_lab_cell_cycle_g
enes.txt. The list contains a total number of 97 genes, compiled as per (Tirosh et al. 2016). 
The DESeq2 object from the differential analysis above without 48 h and PD timepoints was used for 
gene expression pattern analysis. The function vst was applied to normalise gene counts with parameter: 
blind=FALSE. All differentially expressed genes between any pair of timepoints were extracted from 
the DESeq2 object. The list was then filtered for adjusted p-value < 0.05. The final list contained 10010 
unique genes. The degPatterns function in the R package DEGreport (Pantano 2019) was called with 
parameters: time=’timepoint’, eachStep=TRUE and 11 gene expression clusters were found. 
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3.12.3 ClueGO analysis 
Non-redundant biological terms analysis on differentially expressed genes within each pattern of 
expression identified using the DEGreport R package (see section 3.12.2) was performed with the 
Cytoscape plug-in, ClueGO (v 2.5.2) (Bindea et al. 2009). P-value < 0.1 was used to select significant 
pathways. The analysis was run against KEGG, REACTOME, Biological processes, Immune System 
Processes and Molecular Function Terms ontologies. The GO Term Fusion option was used. 
3.13 Statistical analysis 
Statistical analysis was performed with R or Graph Pad Prism, after verification that statistical tests were 




NOTE: in this section results will be presented in two separate chapters. Chapter A will address results 
addressing Aim A and Chapter B the results addressing Aim B. 
Chapter A: The first myelo-lymphoid lineage restriction already occurs in the 
human haematopoietic stem cell compartment 
NOTE: Sections of this chapter report data published in Belluschi et al., Nat. Communications, 2018. 
The work related to this publication was done in collaboration with Emily Calderbank, PhD student in 
Elisa Laurenti group. While I mainly worked on the characterisation of functional and molecular 
heterogeneity of the CD49f+ HSC compartment, similar experiments to characterise the HSC/MPP pool 
were done by Emily Calderbank. Here, I will present results obtained from the analysis of the CD49f+ 
HSC compartment, however, to better understand the results of the work published, references to data 
obtained from the analysis of the HSC/MPP pool will be presented too.  
4.1 Functional and transcriptional characterisation of the CD49f+ HSC 
compartment at the single cell level 
4.1.1 My/Ly and My/Ery in-vitro differentiation is determined by pre-existing 
heterogeneity within the CD49f+ HSC compartment  
The purest human HSC compartment known to date consists of phenotypic LT-HSCs and it is also 
referred to as the CD49f+ HSC compartment. Evidence in the field showed heterogeneity and variability 
at the single cell level within the human HSC/MPP pool and the CD49f+ HSC compartment in relation 
to cell division properties, cell surface markers expression and cell fate decisions (Notta et al. 2016; 
Velten et al. 2017) (see section 1.2). This suggests a possible link between these properties. However, 
to date, no one has comprehensively characterised these two compartments in terms of in-vitro 
differentiation potential and division kinetics at the single cell level. As published data from Laurenti et 
al. have shown, the kinetics of first division are differentially regulated within the HSC/MPP pool and 
specifically between CD49f+ HSCs and CD49f- HSCs (Figure 3). Here I present a comprehensive 
analysis of the differentiation potential and time to first division of single CD49f+ HSCs.  
To characterise the in-vitro differentiation potential of single CD49f+ HSCs (CD19- CD34+ CD38- 
CD45RA- CD90+ CD49f+) towards myeloid (My), lymphoid (Ly), megakaryocytic (Meg) and erythroid 
(Ery) lineage I optimised and repurposed an assay developed for the assessment of My, Ery and Meg 
potential (Notta et al. 2016). Moreover, to detect variability in division kinetics, the time of first division 
for each single cell was recorded before assessing the differentiation potential through in-vitro functional 
assays (Figure 10 A). This is important to identify possible correlations between cell cycle progression 
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and cell fate decisions that could be present in HSCs, similar to what has been previously demonstrated 
in other stem cells (Pauklin and Vallier 2013; Dalton et al. 2015).  
819 CD49f+ HSCs from 4 independent CD34+ human CBs samples were index-sorted and for each cell 
the time to first division, the differentiated colony output and the cell surface intensity of 8 proteins 
(CD19, CD34, CD38, CD45RA, CD90, CD49f, CD10, CLEC9A) was recorded. CLEC9A, a surface 
receptor for which the mRNA expression was found to be significantly higher in CD49f+ HSCs (CD19- 
CD34+ CD38- CD45RA-  CD90+ CD49f+) than in CD49f- HSCs (CD19- CD34+ CD38- CD45RA- CD90- 
CD49f-  (Figure 10 B) was included in this panel. The expression of CLEC9A, a SYK-coupled C-type 
lectin receptor, was only reported within the dendritic cell compartment to date. Flow cytometry analysis 
confirmed that approximately 80% of CD49f+ HSCs are CLEC9A+ compared to 50% of CD49f- HSCs 
while in progenitor populations showed an even lower expression of this marker (Figure 10 C). Single 
cells were cultured in liquid medium supporting the growth of My, Ery, Meg and NK cells and the 
colony output was assessed after 3 weeks of culture via high throughput screening flow cytometry 
(markers to distinguish differentiated cell types are listed in Table 5). Approximately 80% of single 
cultured CD49f+ HSCs were able to produce a colony, indicating that the remaining 20 % of the cells 
produced very small colonies ([CD45+ and GlyA+] <30 cells, see Methods) that were not considered in 
the analysis or died due to FACS related stress before dividing and differentiating (Figure 10 D). 
Analysis of the colonies produced showed that less than 1% of CD49f+ HSCs can originate quadrilineage 
colonies and around 10% of multilineage colonies were of the My/NK/Ery type while My/NK and 
My/Ery colonies were present in similar proportions and My/Ery/Meg accounted for around 20% of the 
multilineage colonies. The only unilineage colonies produced in this assay were My-only (Figure 10 E). 
Interestingly, Ery and NK cells were always found together with My cells, whereas Meg differentiation, 
less efficient than all other lineages, was almost always associated with Ery output. I also included 
markers to distinguish monocytic (Mon), granulocytic (Gran) or mixed MonGran colonies: more than 
80% of the My colonies were represented by MonGran (Figure 10 F).  
Interestingly, the combined analysis of the time to first division and the colony output revealed that 
single CD49f+ HSCs generating colonies containing Ery cells complete their first division significantly 
later than those producing colonies containing NK cells (p<0.001, Figure 10 G, H). Despite the marked 
delay in the time to first division of cells differentiating towards the Ery lineage, colonies of the My/Ery 
type were significantly larger than any other type of colony (Figure 10 I) suggesting that a maximal 
expansion is present along the Ery differentiation branch.  
Overall, in this assay, single CD49f+ HSCs show a reproducible pattern of colony formation which is 
indicative of pre-existing heterogeneity in the differentiation output of cells within this compartment. 
This variability not only extends to the type of colony produced but also to the time of first division, 
suggesting a possible correlation between cell cycle regulation and fate choices in HSCs. 
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Figure 10: In-vitro differentiation output characterisation of single CD49f+ HSCs. 
A) Experimental design used to characterise the differentiation output of single CD49f+ HSCs. Single cells were sorted at 0 h and the surface 
markers expression was recorded by index sorting. The time of first division for each single cell was monitored and recorded over 100 h in 
culture and the type of colony obtained was assessed by high-throughput flow cytometry after 3 weeks of culture. B) A representative example 
of CLEC9A cell surface expression in CB derived CD49f+ HSCs (top left, n=307 cells) and CD49f- HSCs (top right, n=296 cells) is shown 
together with the percentage of CLEC9A+ cells (blue gate). C) Percentage of CLEC9A+ cells within the indicated populations. Mean ± SEM is 
shown. Statistical significance is calculated by one-way ANOVA with Tukey’s multiple comparison (**p<0.01, ***p<0.001). D) In-vitro 
single cell differentiation assay clonogenic efficiency of single CD49f+ HSCs (n=1104 cells from 4 independent CB samples). Mean ± SEM is 
shown. E) Percentage of colonies of the indicated type obtained from in-vitro differentiation of single CD49f+ HSCs (n =819 colonies from 4 
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independent CB samples). Mean ± SEM is shown. F) Percentage of My colonies of the MonoGran, Mono, Gran and undetermined (-) type 
derived from single CD49f+ HSCs (n=725 colonies from 4 independent CB samples). Mean ± SEM is shown. G) Mean time of first division 
of single CD49f+ HSCs producing colonies containing cells from the indicated lineages (EC50 of non-linear fit of cumulative first division 
kinetics); n=4 experiments with independent CB samples (with respectively 19, 98, 34, 230 single cells per experiment). Statistical significance 
is calculated by two-sided paired t-test (***p < 0.001). H) Representative example of first division kinetics for single CD49f+ HSCs producing 
colonies containing one of the two indicated lineages (Ery n=91, NK n=139). The graph is a non-linear fit cumulative curve. Statistical 
significance is calculated by extra sum-of-square F test (***p<0.001). I) Size of the different types of colonies derived from single CD49f+ 
HSC from 4 different experiments and independent CB samples. Size is shown as number of cells per colony. Median, interquartile and 5-95 
percentiles are shown. Statistical significance is calculated by Kruskal- Wallis test with multiple comparison (**p<0.01, ***p<0.001). 
4.1.2 Pre-existing heterogeneity within the CD49f+ HSC compartment 
correlates with cell surface expression of CD34 and CLEC9A 
Evidence of a reproducible pattern of colony formation suggested pre-existing heterogeneity in lineage 
output within the CD49f+ HSC compartment which could potentially correlate with the expression of 
specific cell surface markers. To investigate this, a principal component analysis (PCA) of the cell 
surface markers expression at the time of sort was performed. This showed that single CD49f+ HSCs 
generating My-only colonies are evenly scattered across the PCA space whereas those producing 
My/Ery colonies and My/Ly colonies are unequally distributed along the two principal components PC1 
and PC2 (Figure 11 A). Cells producing multilineage My/NK/Ery or My/NK/Ery/Meg colonies show a 
similar distribution as those producing My/Ery colonies (Figure 11 A). Overall, this indicates a 
functional polarisation of these cells within the PCA space with cells producing predominantly 
multilineage and My/Ery colonies on one side and cells producing My/Ly colonies on the other side. A 
similar functional polarisation was observed when single cells of the less pure HSC/MPP compartment 
were analysed similarly, indicating that this pre-existing level of heterogeneity extends also beyond the 
CD49f+ HSC compartment. Although, because of the fast kinetics of division of the HSC/MPP 
compartment, no correlation between the time of first division and cell fate was identified in this 
compartment (data not shown). 
Analysis of the PCA vector loadings showed that cell surface expression of two markers, CD34 and 
CLEC9A, drives most of the variance on PC1 and PC2 within CD49f+ HSCs (Figure 11 C). A 
comparison of the cell surface expression of these two markers between CD49f+ HSCs that generated 
Ery or My/Ery  and or My/NK or NK colonies showed that the former had significant lower levels of 
CD34 and higher levels of CLEC9A (Figure 11 D). Moreover, milder but still significant shifts in the 
expression of these two markers were also present between cells that generated My/NK colonies with a 
Ly-bias (the number of My cells < number of Ly cells), where the number of NK cells in the colonies 
exceeds the number of My cells, and those with My-bias (My cells > number of Ly (NK) cells) but also 
between cells giving rise to My/Ery colonies with an Ery-bias, where the number of Ery cells in the 
colony exceeds the number of My cells, and those with a My-bias (Figure 11 E). 
In summary, these results uncover a pre-determined functional polarisation within the CD49f+ HSC 
compartment that separates single cells with My/Ly potential from those with My/Ery or multilineage 
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potential. Moreover, the lineage output seen in in-vitro functional assays correlates with different levels 
of expression of CLEC9A and CD34 surface markers, also indicating that single cells with distinct 
lineage outputs are distributed over a continuum of anticorrelating CLEC9A and CD34 cell surface 
expression. 
 
Figure 11: The continuum of differentiation outputs within the human CD49f+ HSCs compartment correlates with gradual changes in 
surface expression of CLEC9A and CD34 markers. 
A-C) Principal component analysis (PCA) of the surface marker expression recorded at the time of sort of single CD49f+ HSCs (n=714 colonies 
from 4 independent CB samples). Each type of colony produced by a single cell after culture is indicated by different colours (here, My/NK/Ery 
includes My/NK/Ery and My/NK/Ery/Meg colonies). Top and bottom panels indicate respectively density plots and boxplots of PC1 and PC2 
values from single cells producing the indicated types of colonies. Statistical significance is calculated by Kruskal–Wallis test with multiple 
comparisons (*p < 0.05). B) Single cells that produced My only colonies are showed here (n=309 colonies). C) The two cell surface markers 
with the highest PC loadings are shown here. D) Normalised intensity of CLEC9A (left) and CD34 (right) surface expression at the time of the 
sort for single CD49f+ HSCs producing the indicated colonies (n=714 colonies from 4 independent CB samples). The median fluorescence 
intensity shift between My/Ery and My/NK is 40% for CLEC9A and 13% for CD34. Statistical analysis is calculated by Kruskal-Wallis test 
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with multiple comparison (**p<0.01). E) Normalised intensity of CLEC9A (left) and CD34 (right) surface expression at the time of the sort 
for single CD49f+ HSCs producing the indicated colonies. My/NK colonies are defined: as My-biased if the number of My cells > number of 
Ly (NK) cells within that colony; as Ly-biased if the number of My cells < number of Ly cells. Similarly, My/Ery colonies are defined as Ery-
biased if the number of My cells < number of Ery cells (n=93 My/Ery colonies and n=170 My/Ly colonies from 4 independent CB samples). 
Median fluorescence intensity shifts between My/NK: My-biased and My/NK: Ly-biased is 25% for CLEC9A and 4% for CD34; between 
My/Ery: My-biased and My/Ery: Ery-biased is 4% for CD34. Median, interquartile and 5-95 percentiles are shown. Statistical significance is 
calculated by two-sided unpaired t-test (*p<0.05, ***p<0.001).  
4.1.3 Anticorrelating cell surface expression of CLEC9A and CD34 defines a 
continuum of lympho-myeloid priming within the transcriptional space of 
CD49f+ HSCs 
After identifying pre-existing heterogeneity within the CD49f+ HSC compartment and its correlation 
with CLEC9A and CD34 surface expression, I performed scRNA-seq to investigate if these observations 
would also be mirrored at the transcriptional level. 
I index-sorted a total of 192 single CD49f+ HSCs and performed scRNA-seq using an adapted version 
of the SmartSeq2 protocol (Picelli et al. 2013). Quality control (QC) analysis showed that 88% of the 
cells passed QC (see methods). To compare the results seen at the functional level with the 
transcriptomic data obtained from the analysis of single CD49f+ HSCs, three different dimensionality 
reduction techniques were used (tSNE, PCA and diffusion map). The surface expression of CD34 and 
CLEC9A, as recorded by index sorting, was overlaid on the cells represented in the transcriptional space. 
The transcriptional space of CD49f+ HSCs is a continuum where CLEC9A levels progressively decrease 
from one extreme to the other while CD34 levels progressively increase in the opposite direction to 
CLEC9A (Figure 12 A-F). This is in concordance with previous results obtained from the in-vitro 
functional assays. Iterative Clustering and Guide-gene Selection (ICGS) algorithm (Olsson et al. 2016) 
was then applied to identify, in an unbiased manner, possible clusters of cells driven by expression of 
specific gene signatures within this dataset. From this analysis two clusters comprising 53 and 116 cells 
were identified and classified respectively as Cluster I and Cluster II (Figure 12 H). The surface 
expression of CLEC9A and CD34 was compared between cells of each cluster. Cell within Cluster I 
showed significantly higher levels of CLEC9A surface expression but lower levels of CD34 than cells 
within Cluster II (Figure 12 G). 
In conclusion, the transcriptomic analysis of CD49f+ HSCs showed that the transcriptional landscape of 
these cells is represented as a continuum of transcriptional states which is polarised at its extremes. Here, 
opposing gradients of CLEC9A and CD34 cell surface expression correlate with differences in genes 
expression and the observed polarisation of the transcriptional landscape matches the one previously 
identified from single cell in-vitro differentiation assays in CD49f+ HSCs. 
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Figure 12: Anticorrelating CLEC9A and CD34 surface expression polarises the transcriptional space of single CD49f+ HSCs. 
A, B) tSNE 3D representation of the transcriptional landscape of CD49f+ HSCs. CLEC9A (A) and CD34 (B) surface expression levels at the 
time of sort are overlaid on the tSNE plot (n= 169 cells). C, D) CLEC9A cell surface marker expression overlaid on 3D PCA (C) or diffusion 
map (D) representation of CD49f+ HSCs. E, F) CD34 cell surface marker expression overlaid on 3D PCA (E) or diffusion map (F) 
representation of CD49f+ HSCs. G) Cell surface expression levels of CLEC9A (left) and CD34 (right) in the two indicated ICGS clusters of 
single CD49f+ HSCs. Median, interquartile and 5–95 percentiles are shown. Statistical significance is calculated by two-sided unpaired t-test 
(***p < 0.001). H) Expression heatmap of guide genes selected by the ICGS algorithm performed on CD49f+ HSCs (n=169 cells). Columns 
represent single cells and rows represent genes. The top panel bar shows the two clusters identified by ICGS (Cluster I and Cluster II). 
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4.2 Subsets of CD49f+ HSCs with My/Ly and My/Ery differentiation in-vitro can 
be prospectively purified based on the surface expression of CLEC9A and CD34 
A bilineage output in-vitro could indicate that the single cell of origin is either a multipotent HSC with 
a strong lineage bias or also a lineage restricted HSC. To discriminate between these hypotheses, I 
looked into developing new prospective purification strategies to isolate subset populations of the 
CD49f+ HSC compartment with specific behaviours in-vitro. 
The correlation between the surface expression of CLEC9A and CD34 and the type of colony produced 
prompted me to search for possible flow cytometry gating strategies based on the expression of these 
two markers that would enrich for subsets of CD49f+ HSCs with preferential differentiation towards 
My/Ly and My/Ery. Using the single cell data obtained from previously shown in-vitro functional assays 
(Figure 10), all possible gating thresholds along the CLEC9A/CD34 spectrum were analysed in-silico 
to identify the sorting strategies that would maximise the enrichment for bipotent lineage output in-vitro 
(My/Ery or My/NK) (analysis done by Blanca Pijuan-Sala). From this analysis, I chose two gating 
strategies for a CD34lo CLEC9Ahi fraction (hereafter referred to as CD49f+ Subset1) and a CD34hi 
CLEC9Alo fraction (hereafter referred to as CD49f+ Subset2). These were predicted to yield the highest 
enrichment respectively for single cells with My/Ery and My/Ly potential in-vitro. Similar populations 
were also identified within the HSC/MPP compartment and they were named Subset1 (CD34lo 
CLEC9Ahi fraction) and Subset2 (CD34hi CLEC9Alo fraction) (Figure 13 A). Intermediate fractions 
between these two gates were predicted to contain equal proportions of HSCs with My/Ly and My/Ery 
output and they were thus excluded from further analyses.  
Having predicted the best gating strategies to isolate cells with specific in-vitro behaviours I 
characterised both CD49f+ Subset1 and CD49f+ Subset2 cells through single cell functional assays. A 
significant difference in the clonogenic efficiency of these populations was identified, with CD49f+ 
Subset1 having a higher clonogenic efficiency than CD49f+ Subset2 (Figure 13 B). As hypothesized, 
CD49f+ Subset1 cells produced significantly more colonies containing Ery cells than CD49f+ Subset2 
cells, whereas CD49f+ Subset2 cells made significantly more colonies containing NK cells (Figure 13 
C, E). Moreover, CD49f+ Subset1 cells produced a higher proportion of bilineage My/Ery and unilineage 
Ery colonies than CD49f+ Subset2 cells while on the other hand, CD49f+ Subset2 cells generated a 
higher proportion of bilineage My/NK and unilineage NK colonies than CD49f+ Subset1 cells (Figure 
13 C). When looking at My colonies CD49f+ Subset2 cells produced less My colonies containing both 
monocytes and granulocytes (MonoGran), but more colonies containing only monocytes (Mon) than 
CD49f+ Subset1 (Figure 13 D). Division kinetics were also assessed within these prospectively isolated 
populations and, as predicted, on average CD49f+ Subset1 cells divided significantly later than CD49f+ 
Subset2 cells (Figure 13 F, G). 
In parallel, the same differentiation assays were conducted on Subset1 and Subset2 populations. These 
yielded similar results to those obtained with CD49f+ HSC (data not shown). Moreover, the colony 
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output of HSC/MPP subsets was also assessed by CFU- assay and by single cell differentiation assays 
in condition that allow a better growth of cell of the Ly lineage (B and NK cells) and My lineage through 
co-culture with a stromal cell line. Results from CFU-assay confirmed that Subset1 cells generate a 
higher number of Ery-only and mixed (My/Ery) colonies than Subset2 cells while the in-vitro 
differentiation results demonstrated that the Ly differentiation potential of Subset2 cells is not  restricted 
to NK cells but includes production of B cells (data not shown).  
In summary, these data demonstrate that single CD49f+ HSC or HSC/MPP cells with either My/Ly or 
My/Ery differentiation outputs in-vitro can be prospectively enriched based on distinct levels of CD34 
and CLEC9A cell surface expression with CD49f+ Subset1 (and Subset1) defined as CD34lo CLEC9Ahi 
and CD49f+ Subset2 (and Subset2) as CD34hi CLEC9Alo. 
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Figure 13: Prospective purification and functional characterisation of CD49f+ Subset1 and CD49f+ Subset2. 
A) Representative example of the gating strategies used to isolate the indicated populations as derived by in-silico analysis. Percentages of 
HSC/MPP and CD49f+ HSC within the identified gates are shown. B) In-vitro single cell differentiation assay clonogenic efficiency of single 
CD49f+ Subset1 and CD49f+ Subset2 cells (n= 5 independent CB samples, 714 total cells plated for CD49f+ Subset1 and 756 for CD49f+ 
Subset2, minimum 54 cells per CB). Statistical significance was calculated by two-sided paired t-test (*p<0.05). C, D) Percentage of colonies 
of the indicated type obtained from in-vitro differentiation of single CD49f+ Subset1 and CD49f+ Subset2 cells (n =5 independent CB samples, 
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n = 628 colonies from CD49f+ Subset1 and n = 522 colonies from CD49f+ Subset2). Statistical significance was calculated by two-sided paired 
t-test (*p<0.05, **p<0.01, ***p<0.001). E) Percentage of colonies generated by CD49f+ Subset1 (red) or CD49f+ Subset2 (blue) single cells 
containing differentiated cells of the indicated lineages. Mean ± SEM is shown. Statistical significance was calculated by two-sided paired t-
test (**p<0.01, ***p<0.001). F) Representative example of first division kinetics for single CD49f+ Subset1 (red) or CD49f+ Subset2 (blue). 
The graph is a non-linear fit cumulative curve. Statistical significance is calculated by extra sum-of-square F test (***p<0.001). G) Mean time 
of first division of single CD49f+ Subset1 (red) or CD49f+ Subset2 (blue) (EC50 of non-linear fit of cumulative first division kinetics); n =5 
independent experiments with independent CB samples. Statistical significance is calculated by two-sided paired t-test (***p < 0.001). 
4.3 Functional and transcriptional characterisation of CD49f+ Subset1 CD49f+ 
Subset2 HSCs at the single cell level 
4.3.1 Transcriptional initiation of lineage priming programmes already occurs 
within the CD49f+ HSC compartment  
After characterising the differentiation output in-vitro of the two newly identified CD49f+ HSC subsets 
I conducted scRNA-seq on CD49f+ Subset1 and CD49f+ Subset2 to investigate their transcriptional 
status. For each population I index-sorted 96 cells that I then used to perform scRNA-seq. After 
sequencing, the cells that passed QC were respectively 81% and 78% for CD49f+ Subset1 and CD49f+ 
Subset2. Data from the sequencing were analysed together with the data obtained from the sequencing 
of the whole CD49f+ HSC compartment (Figure 12). From a 3D dimensionality reduction analysis 
(including tSNE, PCA and diffusion map representations) it is possible to see that CD49f+ Subset1 and 
CD49f+ Subset2 single cells form two separate clusters that occupy opposite poles of the CD49f+ HSC 
transcriptional space. This supports the idea of the polarised continuum of differentiation derived from 









Figure 14: Transcriptional polarisation of the CD49f+ HSC compartment and transcriptional analysis of CD49f+ Subset1 and CD49f+ 
Subset2. 
A-G) ScRNA-seq analysis of CD49f+ HSCs (n = 169), CD49f+ Subset1 (n = 78) and CD49f+ Subset2 (n = 75) cells. A, D) tSNE 3D 
representation of the transcriptional landscape of CD49f+ HSC (grey), CD49f+ Subset1 (red) and CD49f+ Subset2 (blue) cells. All tSNE 
analyses were performed on highly variable genes (2420 genes computed as in Brennecke et al. 2013). B, C) PCA 3D (B) and diffusion map 
(C) representation of single CD49f+ HSCs (grey), CD49f+ Subset1 (red) and CD49f+ Subset2 (blue) cells. PCA and diffusion map analyses 
were performed on highly variable genes (2420 genes computed as in Brennecke et al. 2013). D) Density plots showing the distribution of 
single CD49f+ HSCs (grey), CD49f+ Subset1 (red) and CD49f+ Subset2 (blue) cells along the indicated tSNE components. Statistical 
significance was calculated by two-tailed unpaired t-test comparing CD49f+ Subset1 and CD49f+ Subset2 (p<0.001). E) Normalised 
transcriptional expression (Log10) of CLEC9A (left) and CD34 (right) from 78 CD49f
+ Subset1 single cells and 75 CD49f+ Subset2 single 
cells. F) Cell surface expression measured by index sorting of CLEC9A (left) and CD34 (right) surface markers for the cells analysed with 
scRNA-seq. G) Normalised expression (Log10) of the indicated differentially expressed genes between CD49f
+ Subset1 (red) and CD49f+ 
Subset2 (blue) cells (FDR < 0.05 by DESeq2). 
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ICGS algorithm analysis was conducted again this time on the combined dataset including the two 
subsets and the data from CD49f+ HSC compartment analysis. The algorithm identified three major 
clusters this time and each with a similar number of cells (Figure 15 A, B). Cluster 1, which also 
corresponds to Cluster 1 in Figure 12, resulted to be significantly enriched in CD49f+ Subset1 cells 
whereas Cluster IIa and IIb, which collectively correspond to Cluster II in Figure 12, were enriched in 
CD49f+ Subset2 cells (Figure 15 A, B). Comparison of the gene expression between the identified 
clusters showed that the expression of genes which are usually associated with HSC function such as 
CXCR4 and JUND was higher in Cluster I. Cluster IIb, in contrast, was characterised by the expression 
of genes related to metabolism and, in particular, mRNA metabolism genes like HNRNPC, PABPC1, 
DNA replication genes like NAP1L1 as well as HLA molecules. Overall, this indicated that Cluster IIb 
contains cells with a more active metabolic state at the transcriptional level than Cluster I cells. In 
comparison to these two clusters, Cluster IIa included cells with heterogeneous expression of the genes 
identified as specifically expressed in Cluster I and IIb (Figure 15). Correlation of the transcriptomic 
analysis and CLEC9A and CD34 surface expression resulted to be consistent with data shown in Figure 
12 . In fact, single CD49f+ HSCs within Cluster I displayed significantly higher levels of CLEC9A and 
lower levels of CD34 when compared to single CD49f+ HSCs within Clusters IIa and IIb (Figure 15 D). 
In summary, when looking at the transcriptional space of CD49f+ HSCs, CD49f+ Subset1 and CD49f+ 
Subset2 cells are in different areas and they differentially express genes linked to HSC function and 
activation.  
Because of the differences in lineage differentiation of these two populations in-vitro, lineage-priming 
programmes may be already established within the CD49f+ HSC compartment. To test this, Gene Set 
Enrichment Analysis (GSEA) was performed using population-specific gene signatures obtained from 
highly purified human HSC and progenitor cells and other specific lineage-priming gene modules 
(Laurenti et al. 2013, 2015; Velten et al. 2017). Through this analysis we identified HSC-related gene 
sets and gene modules specific for Ery and Meg differentiation enriched in CD49f+ Subset1 cells (Figure 
15 C). Consistently, JUN, MECOM, MEIS1 and HIF1A, all genes involved in HSC maintenance, were 
showing significantly higher expression in CD49f+ Subset1 cells (FDR<0.05; 96 genes Figure 14 G) 
(Takubo et al. 2010; Kataoka et al. 2011; S.-Y. Lee et al. 2012; Unnisa et al. 2012). Also, MLLT3, the 
earliest regulator of Ery-Meg differentiation reported to date (Pina et al. 2008), showed higher 
expression in CD49f+ Subset1. On the other hand, Ly differentiation-related gene sets were found 
enriched in CD49f+ Subset2 cells (Figure 14 G). In concordance with previous data showing that CD49f+ 
Subset2 cell are more metabolically active than CD49f+ Subset1, mitochondrial (MT-CO2 and MT-
RNR1) and cell cycle genes (CDK6, TFDP1, 35 genes total, Figure 14 G) were found to be expressed 
at significantly higher levels in this population. CDK6 levels, as previously mentioned in section 1.2.2, 
directly regulate the length of HSC exit from quiescence (Laurenti et al. 2015). The finding that higher 
levels of CDK6 are present in CD49f+ Subset2 cells provides a mechanistic principle for the faster 
kinetics of quiescent exit that are observed in this population (Figure 13 F,G). 
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Figure 15: Transcriptional analysis and lineage-priming programme establishment in the CD49f+ HSC compartment. 
A-C) ScRNA-seq analysis of CD49f+ HSCs (n = 169), CD49f+ Subset1 (n = 78) and CD49f+ Subset2 (n = 75) cells. A) Expression heatmap of 
guide genes selected by ICGS. Rows represent genes and columns represent single cells. Selected genes are annotated on the side and the cell 
phenotype is indicated by the uppermost bar of the top panel. The bottom bar of the top panel shows ICGS clusters. B) Percentage of CD49f+ 
Subset1 and CD49f+ Subset2 single cells found in each ICGS cluster. Statistical significance was calculated by two-tailed Fisher test (***p < 
0.001). C) GSEA analysis results showing significantly enriched (Benjamini-Hochberg adjusted p-value <0.05 by pre-ranked GSEA) 
population-specific signatures from (Laurenti et al. 2013) and lineage-priming gene modules derived from (Velten et al. 2017) in CD49f+ 
Subset1 and CD49f+ Subset2 cells. D) CLEC9A (left panel) and CD34 (right panel) cell surface expression levels in CD49f+ HSCs within the 
indicated ICGS clusters (excluding CD49f+ Subset1 and CD49f+ Subset2 cells). Median, interquartile and 5-95 percentile are shown. Statistical 
significance was calculated by one-way ANOVA with Bonferroni correction for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001). 
In conclusion, these results showed that the CD49f+  HSC transcriptional landscape looks like a 
continuum of transcriptional states that gradually progresses from a group of HSCs marked by stem cell 
and early Ery lineage priming programmes (CD49f+ Subset1) to another HSC group that shows 
established Ly-priming and HSC activation programmes (CD49f+ Subset2). Moreover, differences in 
the kinetics of divisions are reflected at the transcriptome level and whether these differences may drive 
fate choices is still not known. 
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4.3.2 Differences in the division kinetics of CD49f+ Subset1 and CD49f+ 
Subset2 are not linked to cell fates decisions 
Due to the differences in the division kinetics of single CD49f+ Subset1 and CD49f+ Subset2 and their 
different expression levels of CDK6 at the transcriptional level, I decided to investigate the link between 
cell cycle properties and cell fate decisions in-vitro. One hypothesis is that, similar to ES cells, the length 
of the cell cycle may determine differentiation output of HSC subsets. Specifically, here a long time to 
first division could lead to Ery differentiation whereas a shorter one to Ly differentiation. To test this 
hypothesis, I took advantage of a specific CDK6 inhibitor, Palbociclib (PD033299 or PD in short) to 
elongate the time to first division of the faster dividing CD49f+ Subset2 cells and then monitored their 
differentiation behaviour in-vitro. If cell cycle properties are linked to cell fate decisions in HSCs, this 
assay should reveal an in-vitro differentiation behaviour of CD49f+ Subset2 CDK6 inhibited cells 
similar to the slower dividing CD49f+ Subset1 cells. 
Untreated and PD treated (200 nM) CD49f+ Subset2 single cells were sorted and cultured in liquid media 
as described in Figure 10 A. PD treated cells were washed out after 3 days of culture to reverse CDK6 
inhibition and assess their differentiation potential in-vitro. CD49f+ Subset1 cells were cultured in 
parallel and used as a control. The time to first division was monitored and the colony output measured 
by high-throughput flow cytometry after 3 weeks in culture. After CDK6 inhibition CD49f+ Subset2 
cells show a similar time to first division as CD49f+ Subset1 cells confirming that CDK6 plays a central 
role in the division kinetics of these two subsets (Figure 16 A). Moreover, PD treated CD49f+ Subset2 
cells clonogenic efficiency was similar to the untreated counterpart indicating that CDK6 inhibition 
doesn’t affect the in-vitro capacity of producing colonies (Figure 16 B). When looking at the type of 
colonies produced, significant differences were identified in the percentage of colonies containing Ery 
or NK cells between untreated CD49f+ Subset2 cells and cells treated with PD (Figure 16 C). In addition, 
as a result of the transient CDK6 inhibition, CD49f+ Subset2 cells produced a significantly higher 
number of My/Ery and My/Ery/Meg cells compared to untreated cells and a reduced number of My/NK 
colonies (Figure 16 D). However, this was still vastly different from the distribution of colonies 
produced by CD49f+ Subset1 cells (Figure 16 D). In summary, even though lengthening the time to first 
division of CD49f+ Subset2 cells by CDK6 inhibition does slightly impact on their differentiation, it is 
not sufficient to enforce differentiation properties similar to those of CD49f+ Subset1. As most CD49f+ 
Subset2 can’t produce Ery cells in-vitro, and this occurs also independently of their division kinetics, 
these results suggest that other intrinsic mechanisms may be at the base of their inability to differentiate 
towards Ery fate.  
 68 
Figure 16: In-vitro effects of CDK6 inhibition in CD49f+ Subset2 cells. 
A) Mean time of first division of single CD49f+ Subset1, CD49f+ Subset2 and CD49f+ subset2 PD (EC50 of non-linear fit of cumulative first 
division kinetics); n=2 experiments with independent CB samples. Statistical significance is calculated by two-sided paired t-test (CD49f+ 
Subset2 UNTR vs PD treated not significant). B) In-vitro single cell differentiation assay clonogenic efficiency of single CD49f+ Subset1, 
CD49f+ Subset2 cells and PD treated CD49f+ Subset2 cells (n= 2 experiments with independent CB samples, 144 total cells plated for CD49f+ 
Subset1, 336 for CD49f+ Subset2, 192 for CD49f+ Subset2 PD). Statistical significance was calculated by two-sided paired t-test. C) Percentage 
of colonies generated by CD49f+ Subset1 (red), CD49f+ Subset2 (blue) or CD49f+ Subset2 PD (light blue) single cells containing differentiated 
cells of the indicated lineages. Mean ± SEM is shown. Statistical significance was calculated by two-sided paired t-test (*p<0.05, **p<0.01). 
D) Percentage of colonies of the indicated type obtained from in-vitro differentiation of single CD49f+ Subset1, CD49f+ Subset2 cells and PD 
treated CD49f+ Subset2 cells (n =2 experiments with independent CB samples, n = 128 colonies from CD49f+ Subset1, n = 105 colonies from 
CD49f+ Subset2, n=161 colonies from CD49f+ Subset2 PD). Statistical significance was calculated by two-sided paired t-test (*p<0.05).  
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4.4 CD49f+ Subset1 cells are hierarchically placed above CD49f+ Subset2 cells  
Single cell transcriptomic analyses of CD49f+ Subset1 single cells showed a strong enrichment within 
this population of HSC specific genes signature. I thus hypothesised that CD49f+ Subset1 cells are 
positioned above CD49f+ Subset2 cells in the hierarchy and may give rise to CD49f+ Subset2 cells. To 
identify the hierarchical relationship between these two subsets, both populations were sorted in bulk 
(Figure 17 A) and cultured in differentiation medium. After 5 days cells derived from the two subsets 
were then analysed by flow-cytometry and sorted as single cells to perform a secondary differentiation 
assay. In total, 1152 single cells derived from either CD49f+ Subset1 or CD49f+ Subset2 were index-
sorted and placed in liquid culture in the same conditions as in Figure 10 to perform a secondary 
differentiation assay. Because CD38 and CD90 surface expression is known to vary after culture, these 
parameters were not included in the analysis. Sorted cells were cultured for 3 weeks and the in-vitro 
lineage output was assessed. Interestingly, when looking at the type of cells originated from CD49f+ 
subsets at day 5, cells with a phenotype equivalent to that of day 0 CD49f+ Subset2 (CLEC9Alo CD34hi) 
emerged from cultured CD49f+ Subset1 cells, whereas the parental CD49f+ Subset2 population resulted 
to be unable to produce cells with the same phenotype as day 0 CD49f+ Subset1(CLEC9Ahi CD34lo) 
(Figure 17 B). Results from the secondary differentiation assay showed that all the populations derived 
from CD49f+ Subset1 cells (S1_1, S2_1 and Diff1) have a significantly higher clonogenic efficiency 
than the populations derived from CD49f+ Subset2 cells (S2_2 and Diff2, Figure 17 D) which indicates 
a more stem-like state of these cells. Of note, levels of CD45RA surface expression were different 
between Diff1 and Diff2 populations confirming that, despite these populations have similar expression 
of CD34 and CLEC9A, they are indeed different for the expression of other markers (Figure 17 E). 
Interestingly, within 5 days in culture CD49f+ Subset1 cells maintained cells with similar differentiation 
properties as day 0 referred to as S1_1 (Figure 10 E and 17 C, p>0.1). This population other than 
producing the largest colonies (Figure 17 G, p<0.001) was also the only population to give rise to 
multilineage colonies, a property that was suggestive of a more stem-like state similarly to what seen in 
CD49f+ Subset1 cells (Figure 17 C, top panel). Moreover, CD49f+ Subset1 cells also generated: (i) 
phenotypically and functionally undistinguishable cells from CD49f+ Subset2, referred to as S2_1, that 
exclusively produced colonies with My and/or NK cells; (ii) cells with predominant Ery but no Ly output 
referred to as Diff1 (Figure 17 C-D). On the contrary, at 5 days after culture the progeny derived from 
CD49f+ Subset2 cells included: (i) cells which produced colonies of small size but qualitatively similar 
to those of day 0 CD49f+ Subset2 cells although with a higher proportion of NK-cell containing colonies, 
referred to as S2_2 (Figure 17 C-D); (ii) a smaller population of cells, referred to as Diff2, that originated 
very few and mostly unilineage colonies (clonogenic efficiency <20%, Figure 17 C-D). My only 
colonies were further characterised for each of the CD49f+ Subset1 and CD49f+ Subset2 derived 
population. The results showed that the capacity to produce a MonoGran colonies compared to Mono 
only or Gran only is higher in S1_1 and it then decreases from to S2_1 and Diff1 while this was not the 
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case for CD49f+ Subset2 derived populations (Figure 17 F), again suggesting a more stem-like 
phenotype of CD49f+ Subset1 cells. 
In summary, these data are supportive of a model where CD49f+ Subset1 cells are hierarchically placed 
above CD49f+ Subset2 cells. CD49f+ Subset1 can in fact maintain themselves but also move forward in 
their differentiation journey and gradually lose their Ery potential generating CD49f+ Subset2 cells. 
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Figure 17: Hierarchical organisation of CD49f+ Subset1 and CD49f+ Subset2 cells in-vitro. 
A) Sorting strategy used to isolate CD49f+ Subset1 and CD49f+ Subset2 populations at day 0 (top) and FACS plot of the derived population 
after 5 days in culture (bottom). B) Single cells from each of the derived populations at day 5 were sorted. Colours indicate the type of colony 
produced by each cell after 3 weeks of culture (n = 576 cells were plated from 3 independent CB samples for CD49f+ Subset1 derived 
populations, n = 576 cells were plated from 3 independent CB samples for CD49f+ Subset2 derived populations) C) Percentage of colonies of 
the indicated type obtained from in-vitro differentiation of single cells from the indicated day 5 populations. (n= 3 experiments from 
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independent CB samples (except for Diff2 where n =1). Mean ± SEM is shown. The total number of colonies analysed for each population is 
shown on the top of the bars. D) Clonogenic efficiency (calculated as number of colo 
nies/number of seeded cells) of the indicated day 5 populations (n=576 cells plated from 3 independent CB samples for CD49f+ Subset1 derived 
populations, n=576 cells plated from 3 independent CB samples for CD49f+ Subset2 derived populations). Mean ± SEM is shown. Statistical 
significance was calculated by one way-ANOVA with Tukey’s multiple comparison (*p<0.05, **p<0.01). E) Representative example of 
CD45RA cell surface intensity for single cells from Diff1 and Diff2 populations. F) Percentage of MonoGran, Mono, Gran and undetermined 
types myeloid colonies derived from S1_1 (n=159), S2_1 (n=103) and Diff1(n=72); S2_2 (n=62) and Diff2 (n=22) single cells from 3 
independent CB samples. Mean ± SEM is shown. G) Size of the different types of colonies generated by single cells from the indicated CD49f+ 
Subset1 and C49f+ Subset2 derived populations. Size is shown as number of cells per colony. Median, interquartile and 5-95 percentiles are 
shown. Statistical significance is calculated by Kruskal- Wallis test with multiple comparison (***p<0.001). 
4.5 Subset2 cells support durable My/Ly but not Ery engraftment in-vivo 
As per definition, HSCs can regenerate the entire blood system and thus produce long-term 
multipotential engraftment after transplantation in the recipient. In the human system, the CD49f+ HSC 
compartment is the purest compartment isolated to date and can produce robust grafts which last for 
over 20 weeks after transplantation into NSG mice. While the production of My and Ly lineages is quite 
efficient in the NSG model, the production of Ery cells after CD49f+ HSC transplantation is poor and 
not reliable because of the lack of cross-reactivity between the human EPO-receptor and the mouse one. 
Given their different capacity to generate Ery cells in-vitro, to thoroughly assess the repopulating 
capacity and in-vivo lineage potential of CD49f+ Subset1 and CD49f+ Subset2, an improved protocol 
for in-vivo Ery production is needed. A new protocol in which xenotransplanted mice are injected 
intraperitoneally with human EPO (hEPO) for more than 2 weeks before analysis was established in our 
lab (experiments performed by Emily Calderbank). The protocol was tested in engrafted mice that were 
intrafemorally injected with saturating doses of HSCs (CD34+ cells). A 2 weeks treatment with hEPO 
consistently produced robust Ery grafts in treated mice but not in control mice that were injected with 
PBS only (Figure 18 B). Ery grafts were measured as percentage of GlyA+ cells in engrafted mice that 
had total engraftment levels above 0.01%. To ensure that such small grafts in Ery, My and Ly lineage 
could be reliably detected, specific flow cytometry standards were used (as in methods and Notta et al. 
2011). To measure the frequency of repopulating cells within CD49f+ Subset1 and CD49f+ Subset2 
while also assessing their lineage potential in-vivo, limiting dilution analysis (LDA) experiments 20 
weeks post-transplantation were performed and hEPO was administered for 4 weeks before bone 
marrow analysis (Figure 18 A). The repopulating frequency was calculated using the extreme limiting 
dilution analysis (ELDA) statistical method (Hu and Smyth 2009). The frequency of repopulation was 
significantly different between the two subsets (p=1.06x10-10): approximately 1:13 cells from CD49f+ 
Subset1 displayed long-term engraftment capacity at 20 weeks post-transplantation (a similar frequency 
to that of the unfractionated CD49f+ HSC compartment) (Notta et al. 2011). In contrast, only 1:685 
CD49f+ Subset2 cells could produce grafts up to 20 weeks after transplantation (Figure 18 D, E). The 
lineage composition of the grafts was also analysed and strikingly, Ery cells were detected in the injected 
bone of 14 out of 19 mice engrafted with CD49f+ Subset1 cells, but in none of the 3 mice engrafted with 
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CD49f+ Subset2 cells (Figure 18 F). This result supported results obtained in-vitro from single cell 
differentiation assays showing that CD49f+ Subset1 cells mainly produce colonies containing Ery cells 
(Figure 13C). 
It is worth noting that in the NSG model the production of mature lineages is highly skewed towards the 
B cell lineage as compared to other lineages. However, at 20 weeks post-transplantation 3 mice 
transplanted with CD49f+ Subset1 displayed unusually low levels of Ly engraftment (marked by arrows 
in Figure 18 F). These data suggest the presence of a My-bias within CD49f+ Subset1 in-vivo. 
Altogether, these results show that rare cells with long-term in-vivo repopulating capacity are present in 
both CD49f+ Subset1 and CD49f+ Subset2 populations. However, these long-term repopulating cells are 
present at different frequencies and display distinct lineage differentiation capacities: CD49f+ Subset1 
contains a higher frequency of multipotent (Ly/My/Ery) HSCs whereas CD49f+ Subset2 contains rare 
long-term repopulating cells, which cannot make erythroid cells but only myelo-lymphoid lineages. 
Figure 18: CD49f+ Subset1 and CD49f+ Subset2 show distinct long-term repopulation and differentiation capacities in-vivo. 
A) Experimental design of the xentransplants of CD49f+ Subset1 and CD49f+ Subset2 cells in NSG mice. Cells are injected intrafemorally (IF) 
24 h after sublethal irradiation and hEPO is administered intraperitoneally for 4 weeks before BM analysis. B) Representative FACS plot of 
the engraftment of CB CD34+ cells in the injected femur of control mice injected with PBS only (left) or hEPO (20 units/injection). C) 
Percentage of total human engrafted Ery (GlyA+) cells in control (PBS, n=4 mice) and treated mice (hEPO, n=11 mice). Mean ± SEM is shown. 
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Statistical significance is calculated by unpaired Mann–Whitney test (*p < 0.05). D) ELDA estimation of the frequency of long-term 
repopulating cells within CD49f+ Subset1 and CD49f+ Subset2 cells at 20 weeks after transplantation. E) Percentage of human engraftment (% 
CD45++ + % GlyA+) in the injected femur of mice transplanted with CD49f+ Subset1 (red, n= 24 injected mice) or CD49f+ Subset2 cells (blue, 
n= 21 injected mice) at 20 weeks after transplantation. F) Graft lineage composition analysis. The relative lineage engraftment percentage (for 
the injected femur) is shown for each engrafted mouse and for each indicated lineage (My, Ly and Ery) 20 weeks after transplantation of 
CD49f+ Subset1 (n=19 engrafted mice) or CD49f+ Subset2 (n=3 engrafted mice) cells. Bars represent single mice. Arrows indicate mice with 
unusually low levels of Ly engraftment. 
4.6 CD49f+ Subset2 cells are molecularly and functionally distinct from LMPPs 
Transplantation assays into NSG mice confirmed that CD49f+ Subset1 cells are multipotent cells with 
long-term repopulations capacity. On the contrary CD49f+ Subset2 cells with long-term repopulation 
capacity are rare and unable to produce Ery cells, similarly to My-Ly restricted progenitors such as 
LMPPs and MLPs (Goardon et al. 2011; Doulatov et al. 2010; Karamitros et al. 2018). However it is 
important to note that CD49f+ Subset2 cells behaviour in-vivo extends well beyond (20 weeks) that of 
LMPPs and MLPs and, which have only been reported to engraft for up to 2 to 8 weeks after 
transplantation (Goardon et al. 2011; Doulatov et al. 2010; Karamitros et al. 2018). This suggests that 
CD49f+ Subset2 cells may contain cells that are placed upstream of LMPPs and MLPs in the 
haematopoietic hierarchy. To test this hypothesis, I conducted scRNA-seq on 4 different populations 
including CD49f+ Subset2 cells, Subset2 cells, LMPPs and MLPs. The transcriptional profiles of these 
populations were compared and visualised using dimensionality reduction tools. By tSNE analysis the 
transcriptional space was again continuous, with CD49f+ Subset2 and Subset2 cells overlapping but 
significantly shifted from LMPPs and MLPs (Figure 18 A). Differential expression analysis was 
conducted. LMPP cells were transcriptionally well distinct from both CD49f+ Subset2 and Subset2 cells 
(912 genes differentially expressed between LMPPs and CD49f+ Subset2, 437 between LMPP and 
Subset 2 (Figure 19 B). In contrast, only 50 genes were found to be differentially expressed between 
LMPPs and MLPs which thus resulted to be transcriptionally very similar. When looking at specific Ly 
priming specific genes, including BCL11A and SOX4 TFs, which are required for MLPs differentiation 
into B cells (Laurenti et al. 2013), I found that upregulation of these factors occurred gradually during 
the progression from CD49f+ Subset2 to Subset2 to LMPP to MLP (Figure 18 C). In parallel, genes that 
included ID2, involved in the maintenance of HSC self-renewal (Iwasaki and Akashi 2007), or KIT, 
important for engraftment capacity (Cosgun et al. 2014) were significantly and progressively 
downregulated from CD49f+ Subset2 to LMPPs/MLPs (Figure 19 C). Moreover, comparison of the 
expression of cell surface markers like CD34, CLEC9A and CD45RA showed how CD49f+ Subset 2, 
Subset2 and LMPPs differ in the expression of these markers (Figure 19 E,F,G), again proving that these 
cells are different from each other not only at the transcriptional level but also phenotypically.  
In conclusion, these results show that single cells within the CD49f+ Subset2 and Subset2 compartments 
represent a developmental intermediate between a multipotent long-term repopulating HSCs and 
LMPPs. Moreover, loss of Ery potential and Ly lineage priming, although at lower levels than in LMPPs, 
are already initiated in the CD49f+ HSC compartment within the CD49f+ Subset2, which is characterised 
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by being erythroid-null, myelo-lymphoid committed cells with infrequent durable reconstitution and 
faster division kinetics than CD49f+ Subset1. 
 
Figure 19: Molecular differences between CD49f+ Subset2, Subset2 cells, LMPPs and MLPs. 
A) ScRNA-seq was performed on CD49f+ Subset2 cells (n=119), Subset2 cells (n=100), LMPPs (n=140) and MLPs (n=134). On the left a 3D 
tSNE representation of the transcriptional space of the indicated populations, performed on highly variable genes (5831 genes), is shown. The 
density plot of the distribution of indicated populations along the first tSNE component (tSNE C1) is shown on the right. Statistical significance 
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was calculated by Kruskal–Wallis test with multiple comparison (*p < 0.01). B) Number of differentially expressed genes between the indicated 
populations and LMPPs. (FDR <0.05 by DESeq2). C) Normalised expression (Log10) of selected differentially expressed genes both between 
CD49f+ Subset2 and LMPP and Subset2 and LMPP in single cells from the indicated populations. D-F) Comparison of the cell surface marker 
expression of CD34 (D), CLEC9A (E) and CD45RA (F) between CD49f+ HSCs, Subset2 cells and LMPPs. The median Fluorescent Intensity 
(MFI) of each marker for CD49f+ HSCs, Subset2 and LMPPs is shown (n=3 independent CB samples). Mean ± SEM is shown. Statistical 
significance was calculated by one-way ANOVA with Tukey’s multiple comparison (*p<0.05, **p<0.01, ***p<0.001). 
Chapter B: Cellular and molecular characterisation of exit from quiescence in 
human HSCs 
4.7 An in-vitro model system to study quiescence and activation of human LT-
HSCs and ST-HSCs 
In order to study the molecular and cellular changes associated with exit from quiescence in human 
HSCs, and more in detail in the phenotypic LT-HSC (CD49f+ HSCs) and ST-HSC (CD49f- HSCs) sub-
populations, I adopted an in-vitro model system based on Elisa Laurenti’s publication (Laurenti et al. 
2015). In this work the division kinetics of both LT- and ST-HSCs were defined and CDK6 activity was 
found to be important in the regulation of the duration of quiescence exit. Indeed, CDK6 activity could 
be blocked using a specific inhibitor (Palbociclib, PD033299 or PD in short) which leads to the 
lengthening of the time of exit from quiescence in both LT- and ST-HSCs. 
This model allows to distinguish between quiescence/exit from quiescence and cell cycle progression 
during in-vitro activation of human HSCs. In this system quiescent LT- and ST-HSCs (q-HSCs) become 
activated (see definition of activation, section 1.4.1) (a-HSCs) and divide within 72 h in culture in MEM 
media (see methods). Treating these two populations with the highly specific CDK4/CDK6 inhibitor for 
72 h (Palbociclib, PD033299) pushes these cells into a state of pharmacological quiescence (pq-HSCs), 
either preventing their entrance in the late G1 phase and thus blocking (LT-HSCs) or partially blocking 
(ST-HSCs) them in the G0/early G1 phase as shown by cell cycle staining in Figure 20. Two different 
concentration of the CDK6 inhibitor were tested (50 nM and 200 nM): more than 80% LT-HSCs and 
50% ST-HSCs were in the G0/early G1 phase of the cell cycle after 72 h in culture by Ki67/Hoechst 
staining (Figure 20). Because the effect of PD was stronger at 200 nM (Figure 20), all the following 
experiments have been conducted using this concentration. 
Thanks to this model I initially studied the molecular changes associated with exit from quiescence and 
entrance in the cell cycle in human HSCs distinguishing three different conditions: quiescence, 




Figure 20: In-vitro model system for the study of quiescent and activated HSC.  
The top left side of the figure shows representative FACS plots of the cell cycle analysis of freshly isolated (0 hours) LT-HSCs (q-LT-HSCs) 
and ST-HSCs (q-ST-HSCs). The top right side of the graph shows representative FACS plots of the cell cycle analysis of activated LT-HSCs 
(a-LT-HSCs) and ST-HSCs (a-ST-HSCs), while the bottom right graph shows the same analysis for pharmacologically quiescent LT-HSCs 
(pq-LT-HSCs) and ST-HSCs (pq-ST-HSCs). The Ki67/Hoechst staining differentiates the G0 (Ki67
- Hoechst-), G1 (Ki67
+ Hoechst-), and S-G2-
M (Ki67+ Hoechst+) cell cycle phases. The bar plot shows the percentage of cells in the G0 phase of the cell cycle in both activated LT- and 
ST-HSCs (CTRL) and in pharmacologically quiescent LT- and ST-HSCs when treated with two different concentrations of PD033299 (50 nM 
and 200 nM). 
4.8 Characterisation of the division kinetics and proliferation rate of ST and 
LT-HSCs  
With this in-vitro model system, I first focused on replicating and extending the division kinetics 
experiments published in Laurenti et al. 2015 to define HSC division kinetics in cytokine rich media 
(see methods). A good knowledge of the division kinetics is fundamental to study the regulation of 
quiescence exit in these cells and best interpret the findings in this model. To do this I cultured HSCs in 
MEM medium which includes differentiating cytokines and I confirmed that, in these conditions, LT 
and ST-HSCs complete their first division at significantly different times with an average time of first 
division of 58 h and 49 h respectively (Figure 21 A-B). These assays also showed that CDK6 inhibition 
mediated by PD completely stops LT-HSCs but not ST-HSCs from dividing (Figure 21 A). These results 
are in concordance with the results shown in Laurenti et al. 2015 where ST-HSCs can’t be completely 
stopped from dividing due to their intrinsically higher levels of CDK6 compared to LT-HSCs which, on 
the contrary, can be almost completely stopped from dividing. Because CDK6 inhibition stops most LT-
HSCs from dividing and increases the time of first division in ST-HSCs, it will also affect and thus 
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reduce the proliferation rate of these populations in-vitro. A reduction in cell proliferation over 72 h was 
indeed identified in both populations as shown in Figure 21 C and D.  
To determine the time at which HSCs transition from the exit from quiescence phase (Figure 6) into late 
G1 in-vitro, the phosphorylation of the RB protein (ser807/811) was assessed at different time points 
through flow-cytometry (Rubin 2012). This step defines the entrance in late G1 after which a cell 
becomes committed to enter the cell cycle and progresses through it independently from external signals. 
Because the average time of first division in LT and ST-HSCs is much earlier than 72 hours and no cells 
divide before 24 hours in culture, RB phosphorylation was only assessed at early time-points. 
Interestingly, as shown in Figure 21 E, RB phosphorylation doesn’t happen before 6 h of culture. In fact, 
at 6 h, less than 10% LT- and ST-HSCs are pRB+ and most cells phosphorylate RB by 24 h in culture.  
Overall, these results provide a solid understanding of the division kinetics and kinetics of exit from 
quiescence of LT- and ST- HSCs in MEM media and their behavior after inhibition of CDK6, a master 
regulator of quiescence exit. This will be important to study quiescence exit in these cells and to 
understand the results that will be presented in the next sections.  
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Figure 21: Division kinetics of untreated and CDK6 inhibited LT- and ST-HSCs. 
A) Representative example of first division kinetics for single untreated LT- or ST-HSCs and PD treated LT- or ST-HSCs. The graph is a non-
linear fit cumulative curve. Statistical significance is calculated by extra sum-of-square F test. B) Mean time of first division of single LT- and 
ST-HSCs (EC50 of non-linear fit of cumulative first division kinetics); n =5 experiments with independent CB samples. Statistical significance 
is calculated by two-sided paired t-test (**p<0.01). C-D) Two representative examples of the proliferation rate of 100 LT-HSCs (D) and 100 
ST-HSCs (E) over 72 h in culture with and without CDK6 inhibition. The graphs show the number of cells over time. E) Percentages of pRB+ 
cells at different time points are shown. (n=4 experiments with independent CB samples). Statistical significance was calculated by unpaired 
t-test (***p<0.001). pRB staining assays were performed by Michael Drakopoulos. 
4.9 Transcriptomic analysis of bulk RNA-sequencing data for the 
characterisation of the regulation of quiescence, quiescence exit and activation in 
LT-HSCs 
After having characterised the kinetics of quiescence exit in human HSCs I focused on understanding 
the molecular regulation of quiescent exit in both LT- and ST-HSCs. To this purpose I analysed bulk 
RNA-sequencing data obtained from 500 LT- and ST-HSCs at 0h (q), 72 h (a) and 72 h after PD 
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treatment (pq), accordingly to the model shown in Figure 20. Expression files for each of these 
conditions were obtained from a collaboration with John Dick’s group.  
4.9.1 Most transcriptional changes associated with activation occur during 
quiescence exit in a cell cycle independent manner 
Because LT- and ST-HSCs differ in their division kinetics in-vitro I first decided to investigate if, 
transcriptionally, the process of activation occurs in similar ways in these two populations or if there are 
broad differences in the regulation of activation in these two HSC subsets. 
To this purpose, differential expression analysis was conducted by DESeq between q-LT-HSC and a-
LT-HSC or q-ST-HSC and a-ST-HSC (Figure 22 A, top). More than 6000 genes were found 
differentially expressed in both comparisons (6367 and 8372 genes respectively, Figure 22 D and E), 
with a relatively large overlap between the subsets (Figure 22 A, bottom left). Interestingly, the 
proportion of up regulated genes and down regulated genes was similar with a ratio of 1:1. Gene 
expression changes occurring from quiescence to activation were highly correlated between LT- and 
ST-HSCs (Figure 22 A, bottom right). This overall indicates that the process of activation is very similar 
between LT- and ST-HSCs at the molecular level. Moreover, as previously reported in Laurenti et al., 
2015, only a few hundred genes were found to be differentially expressed between quiescent ST and 
LT-HSCs (Figure 22 D and E). 
Secondly, to compare the molecular programmes involved in exit from quiescence from those associated 
with cell cycle progression I compared the gene expression data obtained from q-LT- , pq-LT- and a-
LT-HSCs (Figure 22 B, top). This comparison was not deemed relevant in ST-HSCs because CDK6 
inhibition with PD doesn’t completely block these cells from dividing (Figure 21 A). Data obtained from 
cells treated with PD can only be considered indicative of what happens during exit from quiescence 
knowing that all the cells are blocked in the early G1 phase and before PB phosphorylation. Differential 
expression analysis between quiescent and activated (q vs a), and quiescent and CDK6 inhibited LT-
HSCs (q vs pq) revealed that most of the transcriptional changes occur during exit of quiescence and 
before the RB cell cycle restriction point. Indeed, by DESeq analysis, 3818 genes were found to be 
differentially expressed in q vs pq. Moreover, in both comparisons, the proportion of up regulated genes 
was similar to the proportion of the downregulated ones. (Figure 22 B, bottom). These results indicate 
that gene expression regulation associated with cell culture and in-vitro activation already happen during 
exit from quiescence and it is not dependent on progression of the cell cycle.  
To understand which genes and which biological pathways are involved in the regulation of exit from 
quiescence, a Venn diagram analysis was conducted together with a Gene Ontology (GO) analysis of 
the differentially expressed genes shared between q-LT- vs a-LT-HSCs and q-LT- vs pq-LT-HSCs. This 
analysis identified 3142 differentially expressed genes to be regulated during both quiescence exit and 
activation. GO terms analysis revealed that these genes mainly belong to ribosomal biogenesis and 
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mitochondria metabolism signatures, other than transcriptional control, protein biogenesis and histone 
core signatures. As expected, cell cycle signatures were mainly enriched in q vs a and not in q vs pq 
supporting the idea that expression of cell cycle genes only comes late during the activation process, 
specifically after exit from quiescence and the G1 phase restriction point (Figure 22, C). 
Altogether, these results show that most transcriptional changes associated with activation occur during 
quiescence exit and are independent of progression beyond early G1 and that increased metabolic 
functions and activation of cell growth pathways are the first responses associated with exit from 
quiescence. 
Figure 22: Bulk RNA-seq analysis of the transcriptional changes associated with activation and exit from quiescence. 
A) A scheme illustrating the DESeq analysis comparisons investigated is shown at the top (q vs a). A Venn diagram and a linear fit graph 
comparing differentially expressed genes between LT- and ST-HSCs quiescent (q) and activated (a) state are shown at the bottom. The number 
of biological replicates is n=2 for q-LT-HSC, n=3 for a-LT-HSC, n=3 for q-ST-HSC, n=3 for a-ST-HSC.  B) A scheme illustrating the DESeq 
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analysis comparisons investigated is shown at the top (q vs a, q vs pq). The bar graph shows the number of differentially expressed genes and 
the proportions of upregulated and downregulated genes. C) A Venn diagram comparing differentially expressed genes between quiescent (q) 
and activated (a) state  and quiescent (q) and CDK6 inhibited LT-HSC is shown. On the right the most significant (p-value shown) GO groups 
identified in the intersection and in the symmetric difference are shown. D-E) The number of differentially expressed genes obtained by DESeq 
in all the indicated comparisons is shown in the table. Cell colour intensity increases with the number of differentially expressed genes. The 
total number of differentially expressed genes in shown together with the numbers of upregulated and downregulated genes (D). The number 
of differentially expressed genes between quiescent and activated LT or ST-HSCs and the number of differentially expressed genes between 
LT and ST-HSCs in their quiescent or activated state are represented in the graph. Up regulated genes are shown in red and down regulated 
genes are shown in blue (E). 
4.9.2 Patterns of gene expression change during the transition from quiescence 
to exit from quiescence and activation 
To understand how gene expression changes over time from quiescence through exit from quiescence 
and activation and to identify the biological processes involved in this transition, I used the Short Time-
series Expression Miner (STEM) software (Jason Ernst and Bar-Joseph 2006). This software 
implements the STEM clustering method (J. Ernst, Nau, and Bar-Joseph 2005) which allows to define 
patterns of gene expression over a short period of time while discriminating for significant (real) and 
non-significant (random) patterns. Moreover, the biological significance of these patterns can be 
assessed with Gene Ontology (GO) enrichment analysis for a better interpretation of the results.  
In this case, we assumed that the 0 h (q), 72 h PD (pq) and 72 h UNTR (a) could be placed in this 
temporal order. STEM analysis of this short time-series clustered genes into 16 different model 
expression profiles of which 8 were statistically significant (coloured profiles, p<0.05 before Bonferroni 
correction). Significant profiles could be grouped into three major profile groups displaying similar 
trends and identified by the same colour (Figure 23). 
Interestingly, association of the profiles with the GO terms revealed that activation of mitochondria 
metabolism and ribosome biogenesis, and in general pathways related to cell growth are the first 
response during the process of activation and quiescence exit (profiles 14, 11, 15 and 12, Figure 23 and 
Table 11). Cellular processes related to cell cycle, chromatin reassembly and cell division are only 
enriched later in the process of activation (profiles 15 and 12, Figure 23 and Table 11) again suggesting 
that the transcriptional changes associated with activation are not dependent on cell cycle progression. 
On the other hand, cellular processes that were down regulated during exit from quiescence included 
chromatin silencing, positive regulation of transcription and processes related to hematopoiesis and cell 
differentiation (profiles 4, 0, 2 and 3, Figure 23 and Table 11). Despite some of these were more generic 
and of more difficult interpretation they suggested the idea that HSC quiescence probably involves the 
action of many TFs to maintain this apparently “inactive” state of HSCs. Moreover, these results also 
suggested that the activation process is characterised by a down regulation of genes important in HSC 
maintenance. Additionally, the fact that genes belonging to the “cell differentiation” GO term are down 
regulated may suggest that activation of cell differentiation signatures could be important already during 
 83 
early activation and exit from quiescence rather than later, when HSCs are progressing into the cell 
cycle.  
Despite the oversimplification of the STEM analysis, this allowed to obtain initial important information 
about the biological changes occurring in HSC from the quiescent state to the active state. Although, a 
more detailed analysis of the canonical pathways and TFs involved in this regulation is needed and it 
will be performed by GSEA and presented in the next sections. 
Figure 23: STEM analysis on the 0 h (q), 72 h PD (pq) and 72 h UNTR (a) time series in LT-HSCs.  
Each box represents a model expression profile. Profiles are ordered by the number of genes in each profile. Colored profiles have a statistically 
significant number of genes assigned (p<0.05). In each box the profile ID is shown in the top left corner. The lines represent the model profile 
log of expression change over time. The number of genes assigned to each profile is shown in the bottom left corner. STEM software standard 
parameters were used for the analysis (see methods). 
Profile GO terms 
0 
protein modification processes 
positive regulation of gene expression 
regulation of cellular metabolic process 
positive regulation of transcription 
positive regulation of RNA biosynthetic process 
4 
regulation of metabolic process 
positive regulation of gene expression 
hematopoietic or lymphoid organ development 















ribonucleoprotein complex biogenesis 






protein localization to nucleoplasm 
mitochondrial membrane 
cell cycle 
Table 11: GO terms significantly enriched in the indicated STEM profiles. 
For each of the indicated model profiles, a selection of significant (corrected p-value <0.05) representative GO terms is shown.  
 
4.9.3 Quiescence exit is accompanied by remodelling of transcription factors 
activity  
To have a more detailed picture of which pathways are enriched during exit from quiescence (q vs pq) 
and activation (q vs a) I ran GSEA against the C2 curated gene sets sub-collection of canonical pathways 
(CP) and the C3 collection of Transcription Factor Targets (TFT) from the MSigDB (Subramanian et 
al. 2005). Results obtained from the q vs a comparison showed that cell cycle and mitochondria 
metabolism related gene sets are enriched in a-LT-HSCs. Moreover, other pathways like AURORA B, 
ATR and PLK1 pathways, involved in post-mitotic surveillance and G2/M transition, were also enriched 
in a-LT-HSCs. On the other hand, inflammation related gene sets including interferon (IFN), NFAT, 
AP1 and CD40 pathways resulted to be the prevalent signatures enriched in q-LT-HSCs. GATA3 and 
RHOA regulation pathways were also among other interesting pathways enriched in q-LT-HSCs (Figure 
24 A).  
A heatmap of the top 50 genes expressed within each phenotype (q and a) is shown in Figure 24. Among 
the highly expressed genes in the quiescent state there are NR4A1 and NR4A3 genes that were recently 
confirmed to have an important role in restricting HSC proliferation (Freire and Conneely 2018). Other 
genes included FOSB and JUND, that together form the TF complex AP1 and MAFF and EGR3, two 
genes with opposing effects on cell cycle, that have been reported to be highly expressed in HSCs where 
they cooperate to regulate cell cycle (Li et al. 2017). Cell cycle related genes including E2F, CDK1 and 
CCNA2 and genes of the cytochrome P450 family such as CYP1A1 and CYP2S1 were instead included 
in the top 50 features of the activated phenotype (Figure 24 B).  
According to the results already presented in Figure 22, most of the transcriptional changes associated 
with activation already occur during exit from quiescence. Here, I have investigated the pathways 
enriched in q vs pq to understand which ones are activated first during quiescence exit. Results from 
GSEA analysis showed enrichment of several metabolic pathways (Figure 24 C) including nucleotide 
metabolism and mitochondria metabolism but, as expected, no cell cycle related signatures. However in 
pq, I found genes involved in metabolism like genes from the Cytocrome P450 family, and the growth 
promoting TF MYC which is known to regulate the balance between self-renewal and differentiation in 
HSCs (A. Wilson et al. 2004; Laurenti et al. 2008). This analysis supports the results from STEM 
analysis, overall indicating that metabolic activation of HSCs is the first response associated with 
quiescence exit, followed by cell cycle activation.  
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The STEM analysis reported in section 4.9.2 supports a model in which a series of TFs have an active 
role of TFs in the maintenance of quiescence. To assess more in details the activity of the TFs involved 
in the regulation of quiescence and quiescence exit, I ran GSEA against the transcription factor targets 
(TFT) signature database. After combining all the results obtained from the comparison of q vs a and q 
vs pq I generated the graph shown in Figure 25. Three TF activity patterns can be identified: 
Figure 24: GSEA analysis for common pathways (CP) signatures on q vs a and q vs pq comparisons in LT-HSCs. A, C) GSEA analysis 
results showing significantly enriched (FDR<25%) common pathways (CP) signatures in the q vs a LT-HSC comparison (A) and q vs pq LT-
HSC comparison. Similar colours indicate gene sets of similar biological processes. Gene sets indicated in grey and they haven’t been assigned 
to a specific macro group.  B, D) Heat Map of the top 50 features for each phenotype in q vs a comparison (B) and q vs pq (D) LT-HSC 
comparison. Columns represent different samples.  
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I) TFs whose activity is rapidly downregulated already during exit from quiescence, hence postulated to 
play an active role in quiescence maintenance (Figure 25, bottom left, blue); II) TFs whose activity is 
maintained during quiescence exit but is not required for transition to late G1-S-G2-M (Figure 25, top 
left, orange);  III) TFs whose activity is upregulated only after exit from quiescence from late G1 onwards 
(Figure 25, top right, red). 
Interestingly, these results show that quiescence maintenance is possible thanks to the activity of many 
TFs while activation appears more as a default cellular state driven by the activity of TFs such as MYC, 
E2F and PPARG. This again highlights how quiescence is not, as it was previously thought, an inactive 
state of HSCs but is rather a phase that needs to be carefully regulated in order to be maintained. Among 
the TF active in quiescence, I identified LMO2, AHR, P53, MYB and HLF, which have previously been 
reported to be involved in quiescence maintenance in HSCs (Cleveland et al. 2013; Bennett et al. 2015; 
Liu et al. 2009; Baker et al. 2014; Komorowska et al. 2017). TF targets for ATF and CREB, important 
TFs for the maintenance of normal haematopoiesis (Cheng et al. 2008) were also enriched in the 
quiescent state. While the activity of most TF involved in HSC maintenance and quiescence is rapidly 
downregulated during exit from quiescence, for some of these factors, including HOXA, TAL1 and 
MAF, this only occurs after entrance in late G1 (Figure 25). 
Taken together, these results show that TF activity is predominantly changed during G0 exit rather than 
later in the activation process, demonstrating how, to maintain the quiescence state in HSCs, a high 
regulated molecular network is required. 
Figure 25: GSEA analysis for transcription factor target (TFT) signatures on q vs a and q vs pq comparisons in LT-HSCs. 
The graph shows the results of a combined comparison of the GSEA analysis results obtained from enrichment analysis of transcription factor 
targets signatures (TFT) in the q vs and q vs pq LT-HSC comparison. TF activity trends are shown for each cell state. The most significant 
TFT signature are highlighted.  
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4.10 A single cell time-course analysis of the transcriptional landscape of LT-
HSCs from quiescence to activation 
The transcriptional analysis just presented in bulk LT-HSCs showed that most transcriptional changes 
related to activation already occur during exit from quiescence. However, in this analysis, the events 
occurring during quiescence exit were inferred from cells pharmacologically stopped at the end of early 
G1 for a significant period in culture. As a result, it is difficult to establish if the changes observed are 
related to the time spent in culture or the block in the G0 exit state (G0/early G1 phase). Analysis of 
earlier time points in presence or absence of CDK6 inhibition is thus required. Moreover, transcriptomic 
analysis of bulk samples only gives an averaged information of the gene expression which may not be 
representative of what occurs in each of the cells in the population analysed. For these reasons, I 
performed a time-course scRNA-sequencing on LT-HSCs to investigate the transcriptional changes 
associated with exit from quiescence and initiation of the activation process at the single cell level. I 
thus cultured LT-HSCs in low cytokine media (see methods) for 6, 24 and 72 h and 24 h and 72 h with 
PD and index-sorted single cells at each of these time points to perform scRNA-seq. The results shown 
here are obtained from the analysis of a total number of 835 single LT- HSCs (539 of which passed QC; 
64% efficiency) derived from two independent experiments which, for the purpose of this analysis were 
combined bioinformatically (with appropriate batch correction – see methods).  
To identify the transcriptional changes associated with quiescence exit and activation in correlation to 
the time spent in culture, a first analysis was conducted on the time-course data obtained at 6, 24 and 72 
hours without CDK6 inhibition. Dimensionality reduction on HVGs through 3D UMAP analysis 
showed that changes at the transcriptional level mostly occur gradually over time (Figure 26 A). 
However, whereas a trajectory of transcriptional changes was evident from 0 h to 24 h to 72 h, the 6 h 
time point emerged outside of this trajectory, potentially indicating a specific different state of LT-HSCs 
at this time point. Because previously presented functional data showed that RB phosphorylation occurs 
between 6 and 24 h in culture in these conditions (Figure 21 E), I expected the 6 h timepoint to be 
representative of the exit from quiescence phase. Cell cycle phase assignment for all single cells 
analysed confirmed that almost 100% and more than 50% of the cells are in the G0/G1 phase at 6 h and 
24 h respectively as expected, while most cells at 72 h were assigned to any other phase of the cell cycle 
(Figure 26 C and D). Differential expression analysis with DESeq2 showed that a large number of 
transcriptional changes already occur within 6 h, and thus during exit from quiescence, with most genes 
being up regulated rather than down regulated. Interestingly, 38% of the genes differentially expressed 
at 72 h are already differentially expressed after 6 h in culture (Figure 26 B) and the number of 
differentially expressed genes increases with the time spent in culture and cell cycle progression (Figure 
26 B and D). Overall this indicates that exit from quiescence is associated with gradual changes in 
expression of genes associated with HSC activation. But many genes are only differentially expressed 
at 6 h and not later on (2175 genes differentially expressed from 0 to 6 h but at no other time point), 
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suggesting that this time-point during quiescence exit may represent a specific state of HSCs required 
before further progressing into the cell cycle. 
Figure 26: Time course scRNA-seq on single LT-HSCs. 
A-D) ScRNA-seq analysis of LT-HSCs cultured for 0, 6, 24 and 72 h (0 h n=85; 6 h n=134; 24 h n=86; 72 h n=124 cells). A) 3D UMAP 
representation of indicated populations performed on highly variable genes (16276 HVGs). Different colours indicate cells analysed at different 
time points. B) Number of genes differentially expressed from 0 h to the indicated timepoints are shown (positive axis: upregulated from 0 h, 
negative axis: down regulated from 0 h). Red bars indicate differentially expressed genes also differentially expressed from 0 h to 72 h. C) 3D 
UMAP representation as in (A) indicating the cell cycle phases assigned to each single cell. D) The bars indicate the percentage of cells in each 
of the indicated cell cycle phases for each timepoint analysed. 
4.10.1 Gene expression patterns clustering analysis of LT-HSCs time-course 
scRNA-seq data 
To assess how gene expression changes over time and what are the main biological processes and genes 
involved, a gene expression pattern clustering analysis was performed on the 0, 6 ,24 and 72 h dataset. 
A total number of 10010 differentially expressed genes between any two time points was identified and 
these clustered into 11 different patterns (only patterns with a minimum number of 15 genes were 
considered) (Figure 27). Figure 27 shows all patterns lined by similarity. Clusters type can be mainly 
subclassified in patterns of up regulation (clusters 1, 2) and patterns of down regulation (clusters 7, 8) 
over time or a mix of both (clusters 3, 4, 5, 6, 9, 10, 11), where some genes are first either up or down 
regulated at 6 h and then vice-versa. 
ClueGO analysis was performed for each cluster (cluster 6 was excluded due to the low number of genes 
in the cluster) or for combined clusters, if very similar between each other’s, to visualize biological 
terms (GO terms) genes in a functionally grouped network. Priority of analysis was given to those 
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patterns of gene expression where genes are down or up regulated right after 0 or 6 h and where this 
regulation would persist over time (clusters 1, 2, 7, 8). This, because these patterns are more 
representative of important changes related to exit from quiescence and activation.  
Interestingly, some of the ClueGO analysis results for these clusters were similar to what identified with 
STEM analysis or GSEA analysis of bulk RNA-seq data. In particular, ribosome, mitochondria and 
oxidative phosphorylation related processes were found to be gradually up regulated during exit from 
quiescence and activation in cluster 2 (Figure 27). Ribosome and HSF1 related processes were also up 
regulated during exit from quiescence in cluster 1. These included several ribosomal protein coding 
genes of the RPL and RPS (S and L ribosomal proteins) families (RPS13, RPS16, RPS23, RPL27, 
RPL30, RPL35 among others), and heat shock proteins of the HSPA family (HSPA1A, HSPA1B, 
HSPA2, HSPA8). Interestingly, activation of the p38MAPK cascade was identified at later time points 
during HSC activation. This could indeed be linked to stress response due to the presence of cytokines 
in the culturing media but also, it is in accordance with other studies showing that ex-vivo expansion of 
human CB CD133+ cells activates the p38MAPK cascade. Oxidative stress has also been liked with 
activation of this signalling pathway and overall, this is in accordance with the data shown in Figure 27 
where activation of p38 MAPK correlates with the time spent in culture and oxidative stress that occurs 
during metabolic activation (J. Zou et al. 2012) 
On the contrary, when looking at which processes were down regulated through exit from quiescence 
and activation, I identified MHC class II gene sets (including HLA-DRA, HLA-DRB1 and HLA-DRB5) 
(cluster 8), ribosome processes (cluster 7), although including different RPL and RPS genes from the 
ones identified previously in cluster 1 and 2. Hematopoiesis and IFN signaling related pathways, which 
I previously found to be enriched in the 0 h time point in the GSEA analysis results presented earlier 
(Figure 27, Figure 24 for GSEA analysis), were here enriched in clusters 5 and 7. Among the genes 
rapidly down regulated during quiescence exit and associated with haematopoiesis FOS, JUN, JUNB, 
CD74, GATA3, FOXP, HLX and HIF1A were identified. Some of these were previously mentioned as 
they were also found up regulated at 0 h in bulk RNA-seq data. Other genes that were gradually down 
regulated included many HLA molecules such as HLA-A, -B, -C and -F and EGR1 and several IRF 
molecules including IRF4 and IRF7. 
Taken together, these results show that genes are regulated in a different number of ways during exit 
from quiescence to progression in the cell cycle, although an important part of these genes is already up 
or down regulated during exit from quiescence. Once again, exit from quiescence is associated with 
rapid downregulation of genes important for HSC and quiescence maintenance and upregulation of 
metabolism and cell growth related genes. Overall, transcriptomic analysis of single cells provides very 
similar results to data obtained in bulk, confirming that these responses are specific for all LT-HSCs and 
no differences can be seen at the single cell level. However, from these data, the 6 h timepoint resulted 
to be a particular state of HSCs where the cells probably prepare to exit quiescence and thus activates 
immune response pathways in response to external cytokine stimuli that are present in the culturing 
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media. A general metabolic and cell growth response is instead what characterises quiescence exit and 
progression in the cell cycle, even before activation of cell cycle related genes. 
 
Figure 27: Patterns of gene expression identified during time course of LT-HSC activation.  
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Identified clustering patterns are shown together with pattern number and number of genes in the cluster. For each time-point the gene 
expression trend is shown by the black lines. Red lines indicate expression of single genes within the cluster. Selected significantly enriched 
(Bonferroni adjusted p <0.1) GO terms identified with ClueGO are shown for each expression pattern. 
4.10.2 LT-HSC exit from quiescence and activation occurs independently from 
cell cycle progression 
A second analysis was performed combining the previous dataset with data from untreated (UNTR) 
single cells cultured for 24 h and 72 h in presence of PD (24 h PD and 72 h PD). The aim was to 
investigate if the transcriptional changes occurring over 72 h in culture are dependent on cell cycle 
progression and to assess potential transcriptional differences between LT-HSCs stopped at the end of 
early G1 and those progressing into the cell cycle at different time points. Once again, dimensionality 
reduction analysis identified the 6 h as a clearly separate group that doesn’t follow the transcriptional 
trajectory identified for the other time points (Figure 28 A). Moreover, PD treated LT-HSCs from both 
24 and 72 h were similarly positioned in the transcriptional space and most of the cells within these 
groups resulted, as expected, to be in the G0/G1 phase of the cell cycle (Figure 28 B) (90% of 24 h PD 
cells and 74% of 72 h PD cells, data not shown)  
Pseudotime analysis was conducted to build temporal trajectories based on the transcriptional states of 
the cells identified. As expected, 0 h, 6 h, 24 h UNTR and 72 h UNTR single cells were placed in 
succession along the pseudotime trajectory. Similar to what observed with the dimensionality reduction 
techniques, 24 h PD and 72 h PD substantially overlapped with 24 h UNTR cells along this pseudotime, 
indicating a high degree of similarity in the transcriptional changes of these cells (Figure 28 C). 
Importantly, when pseudotime analysis was repeated removing cell cycle genes (see methods), it yielded 
almost identical results, suggesting that most transcriptional changes are cell cycle independent. 
I then compared genes differentially expressed between 24 h PD and 24 h UNTR cells as well as 72 h 
and 72 h PD. Compared to their respective UNTR cells, 238 genes were significantly downregulated in 
24 h PD and 659 in 72 h PD (p.adj<0.05). Pathway analysis identified, as expected, cell cycle genes to 
be enriched in both gene sets (predominantly related to G1/S transition at 24 h, and to all phases of the 
cell cycle at 72 h, data not shown). 286 genes were significantly upregulated in 24 h PD compared to 24 
h UNTR and 105 genes in 72 h PD vs 72 h UNTR (p.adj<0.05). Of note, ribosomal proteins were highly 
enriched in the latter.  
Altogether, the single cell analysis of LT-HSC treated with PD supports the results obtained from bulk 
RNA-seq. I conclude that most of the transcriptional changes occurring during in-vitro culture of LT-
HSC are independent of cell cycle progression and are rather due to exposure to activation signals. 
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Figure 28: Analysis of time course scRNA-seq on single LT-HSCs including CDK6 inhibited LT-HSCs. 
A-C) ScRNA-seq analysis of LT-HSCs cultured for 0, 6, 24 UNTR, 24 PD, 72 UNTR and 72 h PD (cells passing QC: 0 h n=85; 6 h n=134; 
24 h UNTR n=86; 24 h PD n=80; 72 h UNTR n=124 cells; 72 h PD n=92). A) 3D UMAP representation of indicated populations performed 
on highly variable genes (14759 HVGs). Different colours indicate cells analysed at different time points. B) 3D UMAP representation as in 
(A) indicating the cell cycle phases assigned to each single cell. C) Left: DPT pseudotime analysis on HVGs identified between all the indicated 
timepoints. Cell cycle genes were included for the analysis. Right: DPT pseudotime analysis on HVGs identified between all the indicated 
timepoints. Cell cycle genes were excluded for the analysis. 
4.11 Functional changes associated with exit from quiescence and activation are 
not dependent on cell cycle progression  
Because previously shown transcriptomic data suggested that activation of cell growth and metabolic 
pathways are the first responses during exit from quiescence in LT-HSCs (Figure 29) and that the 
activation processes are overall similar between LT- and ST-HSCs, I decided to functionally validate 
these results at the cellular level in both LT-HSCs and ST-HSCs. As previously demonstrated human 
LT-HSCs and ST-HSCs are equally quiescent and equally small in terms of cell size and they are 
characterised by a low cytoplasm content, a common feature of cells residing in the G0 quiescent state 
(Laurenti et al. 2015). Moreover, at the metabolic level they are characterised by low mitochondrial 
mass together with low mitochondrial activity, underlying the preference for a glycolytic metabolism 
instead of a mitochondrial oxidative metabolism (Warr and Passegué 2013; Kohli and Passegué 2014). 
Using the previously described in-vitro system (Figure 29) as the basis of these experiments I 
investigated the cellular effects of CDK6 inhibition after PD treatment on either LT- and ST-HSCs and 
I compared these to their quiescent or activated counterparts. I analysed different cellular parameters 
associated with stem cell quiescence and activation including cell size, mitochondrial mass and 
mitochondrial activity, measured as mitochondrial membrane potential before and after CDK6 
inhibition (Figure 29). CB derived LT- and ST-HSCs were cultured in rich cytokine media over 72 h 
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with or without CDK6 inhibitor and monitored over time with live-microscopy. I could confirm that 
these cells are small when quiescent (0 h, ~8 µm average diameter, Figure 29 A-C), but increase 
significantly in size upon exit from quiescence and after 48 h in culture, with a further increase in cell 
size at 72 h (~15 µm average diameter, Figure 29 A-C). Moreover, this phenomenon is common to both 
untreated and PD treated LT-HSCs and ST-HSCs, as no significant differences between the two 
conditions arose from these data. In summary, because cell size increase is not affected by PD treatment 
in both LT- and ST-HSCs, I conclude that cell growth is independent from cell cycle entry (as defined 
by the phosphorylation of RB that separates early G1 from late G1) and the increase in HSC cell size 
upon activation is in agreement with what reported in the literature showing that stem cell activation is 
accompanied by increased cell size (van Velthoven et al. 2019). 
To examine how mitochondria function changes during exit from quiescence and activation in live cells, 
I used two mitochondria specific dyes: the mitochondrial mass dye MitoTracker Green and 
TetraMethylRhodamine Methyl ester (TMRM), a cell-permeant dye that accumulates in active 
mitochondria with intact membrane potential. This should give a reliable idea of how mitochondria 
function changes during exit from quiescence and activation.  
As expected, quiescent LT-HSCs and ST-HSCs showed a lower mitochondrial mass than their activated 
counterparts. After 24 h in culture, activated LT- and ST-HSCs had an increased mitochondrial mass, 
but no significant differences were detected between 24 and 48 h in culture (Figure 29 D). Similar results 
were obtained when measuring the mitochondrial activity with TMRM which also resulted to be 
increased after 24 h in culture. This increase was even higher at 48 h in both LT- and ST-HSCs, 
indicating that HSCs activation is accompanied by a gradual switch to mitochondria metabolism. A 
possible interpretation of these results is that mitochondrial mass increases upon exit from quiescence 
while mitochondrial function is gradually up regulated through progression into the cell cycle. Other 
dye-independent quantifications methods may be useful to better identify mitochondrial mass changes. 
Moreover, the increase in mitochondrial mass and activity was not altered by CDK6 inhibition in both 
LT- and ST-HSCs, suggesting that despite blocking LT-HSCs from progressing beyond the restriction 
point, their metabolic switch is not linked to cell cycle progression but is instead driven by the presence 
of external signals.  
Importantly, a recent publication reported that using dyes such as MitoTracker Green has led to 
inaccurate interpretations of HSCs having higher mitochondrial content than committed progenitors due 
to the highest capacity of HSCs to efflux these dyes (de Almeida et al. 2017). The authors however did 
not look at how this high mitochondrial activity of quiescent HSC changes upon activation. My data 
indicates alteration of mitochondrial function upon activation. Moreover, CDK6 specific inhibition had 
no effect on the mitochondrial function in all the analysed populations (Figure 29 E) demonstrating once 
again that CDK6 inhibition stops the cells in the G0/early G1 but leaves unaltered the upregulation of 
metabolic functions which is connected to the process of activation. 
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Figure 29: Changes in cell size and mitochondria metabolism accompanying HSC activation are not affected by cell cycle progression. 
A-B) Cell size was measured as cell diameter (μm) in LT- and ST-HSCs over time before and after PD treatment. n=2 experiments with 
independent CB samples. Graphs represent the cell size of n=25 cells per condition. Median, interquartile and 5-95 percentiles are shown. 
Statistical significance was calculated by Two-way ANOVA for multiple comparisons (***p<0.0001). No significant differences were found 
between untreated and PD treated conditions. C) Live-microscopy images of single LT- and ST-HSCs at 0, 48 and 72 hours in culture. 
Representative examples are shown. D) For each shown population MitoTracker Green Median Fluorescence Intensity (MFI) is shown on a 
logarithmic scale after measurement at 0, 24 and 48 h in culture with or without PD treatment (n=6 experiments with independent CB samples). 
Mean ± SD is shown. Statistical significance was calculated by Two-way ANOVA for multiple comparisons (ns). E) For each shown population 
TMRM Median Fluorescence Intensity (MFI) is shown on a logarithmic scale after measurement at 0, 24 and 48 h in culture with or without 
PD treatment (n=5 experiments with independent CB samples). Mean ± SD is shown. Statistical significance was calculated by Two-way 
ANOVA for multiple comparisons (**p<0.01). No significant differences were found between untreated and PD treated conditions. 
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4.12 In-vitro activation affects the frequency of long-term repopulating HSCs 
independently of cell cycle progression 
Previously presented data have shown how exit of quiescence and cell cycle progression affect LT-
HSCs transcriptionally and functionally. However, if these changes also affect the long-term 
repopulating capacity of LT-HSCs has not been investigated yet. 
Based on literature and given the important changes observed in the transcriptome of LT-HSCs in 
correlation with their time spent in culture (Ema et al. 2000; Kent et al. 2009), differences in the 
repopulation capacity are expected for HSC cultured for different lengths of time, but no quantification 
has been reported to date at this level of resolution in the human system. Moreover, to discriminate if, 
in addition to time spent in culture, progression into cell cycle also affects in-vivo engraftment capacity 
or self-renewal, I investigated this using LT-HSC cultured over 24 h and 72 h with or without CDK6 
inhibitor. 
To test the above, I performed limiting dilutions transplantation assays (LDA) to compare the 
frequencies of long-term-repopulating LT-HSCs between these conditions. LT-HSCs were cultured in 
MEM cytokine media and three different doses of cells (700, 300 and 50 for 72 h; 300, 50 and 10 for 24 
h) were transplanted intrafemorally into NSG mice. The size and composition of the grafts was measured 
at 18 weeks post-transplantation. Injected (IB) and non-injected (BM) bones from transplanted mice 
were collected, processed and analysed separately.  
To assess the effects of the time spent in culture on the frequency of repopulating HSCs, I first compared 
the engraftment capacity (human engraftment was identified as percentage of CD45+ and GlyA+ cells) 
of untreated LT-HSCs cultured for 24 h and 72 h. Using the extreme limiting dilution analysis (ELDA) 
statistical method, a significant reduction in the frequency of repopulating cells (p<0.05)  was identified 
between LT-HSCs cultured for 72 h compared to those cultured for 24 h. This indicates that the time 
spent in liquid culture in the presence of cytokines decreases the number of HSCs that can reconstitute 
the recipient mouse over a long time. ELDA results estimated a frequency of 1/86 and 1/217 (2.5 fold 
difference) long-term repopulating cells respectively within 24 h and 72 h cultured LT-HSCs (Figure 30 
A-C).  
Engraftment levels in 24 h and 72 h untreated LT-HSCs were also compared to their CDK6 inhibited 
counterparts to investigate if the differences seen in the frequency of long-term repopulating LT-HSCs 
could be due the fact that these cells progress in the cell cycle while cultured in-vitro. As expected, 
engraftment levels varied based on the dose of cells injected. However, no significant differences in the 
percentage of human engraftment were identified between mice transplanted with untreated or PD 
treated LT-HSCs at 24 h at any transplanted dose (Figure 30 A). ELDA results showed no significant 
differences in the frequency of long-term repopulating cells between 24 h UNTR and PD treated LT-
HSCs (Figure 30 D). Similarly, no differences were identified in the size of human engraftment between 
mice transplanted with untreated or PD treated LT-HSCs cultured for 72 h (Figure 30 B). In this case 
 96 
700 and 300 doses had similar graft size distribution, indicating that 300 cells dose is probably a 
saturation dose for 72 h cultured LT-HSCs. LT-HSCs repopulating frequencies were also not 
significantly different after ELDA analysis when comparing untreated and treated conditions at 72 h 
(Figure 30 E). Of note, no differences in lineage composition of the grants were found in any of the 
conditions (data not shown). Overall, because no differences could be found in the in-vivo engraftment 
capacities of LT-HSCs that progressed into the cell cycle (untreated) and cells that were stopped by 
CDK6 inhibition in G0/early G1 in-vitro, these results suggest that the time spent in culture rather than 
cell cycle progression, affects the in-vivo repopulation capacity of LT-HSCs.  
Moreover, while progression in the cell cycle did not affect the number of engrafting LT-HSCs, 
differences could still be present in the long-term self-renewal capacity of these cells.  
To assess this, I performed serial transplantation assays from primary engrafted mice injected with 24 
and 72 h cultured LT-HSCs. Two out of five 24 h UNTR and two out of five 24 h PD LT-HSCs 
secondary recipient were successfully engrafted at 12 weeks post transplantation (Figure 31 A), 
indicating that CDK6 inhibition over 24 h in-vitro doesn’t confer better self-renewal properties to LT-
HSCs. When looking instead at secondary recipients of 72 h untreated and 72 h PD LT-HSCs, three out 
of eight and one out of ten mice were respectively engrafted (Figure 31 B, not significant). Because of 
the small number of secondary mice engrafted, more secondary transplantation experiments will be 
needed to conclusively determine if blocking cell cycle progression in-vitro increases LT-HSC self-
renewal capacity. 
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Overall, these results confirm that the time spent in culture, in cytokine rich media,is the major factor in 
determining the engraftment capacity of LT-HSCs, and not their cell cycle progression.  
Figure 30: Long-term repopulation capacity of LT-HSCs cultured for 24 h or 72 h in-vitro with or without CDK6 inhibition. 
A) Percentage of human engraftment (% CD45++ + % GlyA+) by dose at 18 weeks after transplantation in the injected bone (IB) or bone marrow 
(BM) of mice injected with LT-HSCs cultured in-vitro for 24 h with (dark grey, n=31 mice transplanted) or without PD (white, n=31 mice 
transplanted). Only engrafted mice are shown. Dashed line indicated the threshold for engraftment. Mean  SEM is shown. B) Percentage of 
human engraftment (%CD45++ + % GlyA+) by dose at 18 weeks after transplantation in the injected bone (IB) or bone marrow (BM) of mice 
injected with LT-HSCs cultured in-vitro for 72 h with (dark grey, n=42 mice transplanted) or without PD (white, n=39 mice transplanted). 
Only engrafted mice are shown. Dashed line indicated the threshold for engraftment. Mean  SEM is shown. C) ELDA results table for the 24 
h UNTR vs 72 h UNTR comparison. D) Top: ELDA results table for the 24 h PD vs UNTR comparison. Bottom: Doses, number of injected 
mice (tested), number of engrafted mice (response) and treatment groups used for ELDA analysis are shown. E) Top: ELDA results table for 
the 72 h PD vs UNTR comparison. Bottom: Doses, number of injected mice (tested), number of engrafted mice (response) and treatment groups 
used for ELDA analysis are shown. 
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Figure 31: Long-term repopulation and self-renewal capacity of LT-HSCs cultured for 72 h in-vitro with or without CDK6 inhibition. 
A) Percentage of human engraftment (%CD45++ + GlyA+) in the injected bone of secondary transplantation recipients injected with CD34+ 
CD38- cells isolated from primary mice engrafted with 24 h UNTR (white, n=5 mice transplanted) and 24 h PD treated (dark grey, n=5 mice 
transplanted) (A) or with 72 h UNTR (white, n=8 mice transplanted) and 72 h PD treated (dark grey, n=10 mice transplanted) (B). Only 




The first myelo-lymphoid lineage restriction already occurs within the human 
haematopoietic stem cell compartment 
 
Decades of studies on HSCs have made these cells the most characterised adult stem cells. Extensive 
studies in mouse (Muller-Sieburg et al. 2004; Dykstra et al. 2007; Sanjuan-Pla et al. 2013; Yamamoto 
et al. 2013), and more recently in human (Doulatov et al. 2010; Notta et al. 2016; Velten et al. 2017) 
contributed to redefine the structure of the haematopoietic hierarchy thanks to discovery of more refined 
and diverse HSC and progenitor populations. Heterogeneity in self-renewal properties, cycling 
properties and differentiation potential have been identified in both mouse and human HSCs. Indeed, 
more and more studies focused on investigating HSC properties at the single cell level rather than at the 
population level, in order to obtain a more comprehensive picture of HSC molecular and functional 
properties. Although there are similarities between mouse and human HSCs, species-specific differences 
have also been identified, highlighting the need to study human HSC directly. The purest HSCs isolated 
in human, to date, have been identified as CD49f+ HSCs and they are characterised by the expression of 
Lin- CD34+ CD38- CD45RA- CD90+ CD49f+. However, not all these cells are capable of long-term 
repopulation, indicating that heterogeneity is also present within this compartment (Notta et al. 2011). 
In recent years, more studies are focusing on identifying new cell surface markers that would allow for 
better purification of purer populations of true long-term HSCs or specific HSC subsets (Knapp et al. 
2018). Although the use of surface markers for HSC purification has sometimes been defines as 
“limiting” for the study of heterogeneous populations, it remains a very useful tool to enrich for cells 
with a particular behaviour. Integrating, scRNA-seq with index FACS sorting and functional assays has 
been proven to be the best approach for the study of the transcriptional and differentiation properties of 
haematopoietic cells (Paul et al. 2015; Velten et al. 2017; Karamitros et al. 2018). These approaches, in 
mouse, led to the identification of lineage biased HSCs, however, evidence of such populations in human 
has not been reported to date.  
Here, I combined scRNA-seq with index FACS sorting and functional assays to comprehensively 
characterise the differentiation potential and transcriptome of single CD49f+ HSCs. I thus combined 
scRNA-seq and in-vitro differentiation assays and I analysed more than 3000 single cells from this 
compartment. My findings reveal that the first lineage restriction event separates multipotent long-term 
repopulating cells from single cells with My/Ly but no Ery potential (Figure 18). This demonstrates that 
lineage restriction events already occur within the phenotypic CD49f+ HSC compartment and not 
downstream of it as classically thought. Indirect evidence that lineage specification must occur to some 
degree either in the HSC or MPP compartment was already suggested by numerous recent studies that 
analysed progenitor cells at single cell resolution (Paul et al. 2015; Notta et al. 2016; Velten et al. 2017; 
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Karamitros et al. 2018). More specifically, I confirmed that a high degree of functional and molecular 
polarisation exists within the most immature CD49f+ HSC compartment along an axis of anti-correlated 
cell surface expression of CLEC9A and CD34 surface markers (Figure 14 and 32). 
 
Figure 32: Graphical representation showing the proposed single-cell structure of the CD49f+ HSC compartment based on findings 
shown in this report. The figure shows a schematic representation of the continuum of differentiation and transcriptional states within the 
CD49f+ HSC compartment. The main differences identified between CD49f+ Subset1 and CD49f+ Subset2 are shown. Circles represent single 
cells and colours are indicative of their lineage potential. Expression intensity of CD34 and CLEC9A is shown by the arrows (blue: higher 
expression of CD34, red: higher expression of CLEC9A) in correlation with the single cell structure of the CD49f+ HSC compartment. Black 
arrows indicate restriction of lineage potential towards My/Ery and My/Ly lineages. 
I provided evidence for a gradual developmental transition from true multipotentiality to bipotentiality 
occurring already within the purest HSC compartment identified to date. Thanks to the correlation of 
functional properties with the cell surface expression of CLEC9A and CD34, I could identify 
prospective purification strategies that could highly enrich for the earliest fully erythroid-deficient 
myelo-lymphoid restricted (Ery-null My/Ly committed) cell type reported to date (CD49f+ Subset2, 
CLEC9Alo CD34hi) and for the more multipotent CD49f+ Subset1 (CLEC9Ahi CD34lo) population (Figure 
13). Transcriptional analysis confirmed differences between the CD49f+ Subset2 population and LMPPs 
showing that the former is placed upstream of LMPPs and it thus retain properties of HSCs rather than 
progenitor cells (Figure 19). Additionally, the repopulation capacity of CD49f+ Subset2 cells extends 
well beyond the one of LMPPs (Goardon et al. 2011; Kohn et al. 2012; Karamitros et al. 2018). For this 
reason, if a name has to be given to this population, I would choose lymphoid-primed short-term 
repopulating HSCs. 
As previously mentioned, similar data were gathered from the parallel study of the less pure HSC/MPP 
pool. These experiments were mainly performed by Emily Calderbank and they are not shown in this 
report. However, these findings were published in a co-authored manuscript (Belluschi et al. 2018) and, 
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together, they considerably expand the current knowledge of the molecular and cellular structure of the 
CD49f+ HSC compartment and HSC/MPP pool in humans at single cell resolution. 
More in detail, the results presented in Chapter A show a comprehensive molecular and functional 
characterisation of the CD49f+ HSC compartment. Pre-existing functional and molecular heterogeneity 
identified in this compartment is found to be correlated with CLEC9A and CD34 cell surface expression. 
Anti-correlating expression of these two markers identifies a polarised but continuous structure in the 
differentiation output of single CD49f+ HSCs (Figure 11). Specifically, I identified a progression from 
the CLEC9Ahi CD34lo extreme, which contains both rare cells with in-vivo long-term repopulating 
multipotent capacity and cells with in-vitro bilineage My/Ery potential, to the CLEC9Alo CD34hi extreme 
where single cells with in-vitro and in-vivo restricted My/Ly potential reside. Because differences in cell 
fate decisions were not found to be associated with the higher expression of each single surface marker, 
CD34hi or CLEC9Ahi (data not shown) and because major differences in cell fate were identified only 
by anticorrelating expression of CLEC9A and CD34 surface markers (Figure 11), cells displaying 
intermediate cell surface phenotypes, such as CLEC9Alo CD34lo and CLEC9Ahi CD34hi, are predicted to 
show heterogeneous behaviours between CD49f+ Subset1 and CD49f+ Subset2. Although, this will need 
to be explored further through prospective purification and in-vitro and in-vivo functional assays to 
confirm this hypothesis. 
It is not uncommon to forget that cell surface markers used for the prospective isolation of specific cell 
population may also have an important function in those cells. Whereas CD34 has been used for long 
time as an important HSC cell surface marker, CLEC9A has been predominantly used as a dendritic cell 
marker (Schreibelt et al. 2012). However, little is known about the function of these two markers in 
HSCs. While this was beyond the scope of this study, it would still be interesting to investigate more in 
detail their role in CD49f+ HSCs ideally through specific inhibition of the expression of these two 
markers and subsequent in-vitro functional or in-vivo assays to assess their specific roles in HSCs. The 
results presented here were obtained from the study of CB derived HSCs, however, it is not to exclude 
that differences in the cell surface expression of these markers may be present in BM or PB derived 
HSCs. Preliminary data obtained by Emily Calderbank and Carys Johnson show that expression of 
CLECL9A is present in the BM HSC pool and CD49f+ HSC compartment but not in PB (data not 
shown). Because downregulation of cell surface markers is not unusual for circulating cells, as 
previously demonstrated for EPCR expressions (Cohen et al. 2015) this could also be happening for 
CLEC9A. Further studies are needed to investigate if CLEC9Ahi CD34lo CD49f+ Subset1 and CLEC9Alo 
CD34hi CD49f+ Subset2 HSCs have the same functional properties as in CB, or if populations with 
similar properties exist are characterised by expression of different markers. 
When interpreting the results obtained from single cell in-vitro differentiation assays presented here 
(Figure 10, 13, 16 and 17), it is to note that these assays may not have fully read-out the differentiation 
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potential of the cells analysed. These limitations need to be considered. For example, many of the single 
cells analysed here appeared to produce exclusively myeloid cells. A first possibility is that these cells 
would also differentiate into other fates (for example dendritic cells or mast cells) in other conditions or 
could acquire different fates under stress conditions. Evidence of direct dendritic cell specification from 
human HSC/MPP was recently demonstrated in a study by Lee et al. (J. Lee et al. 2017). Our laboratory 
has now developed single cells assays for simultaneous differentiation of single HSCs towards the 
myeloid and dendritic lineages or myeloid and mast cells (Emily Calderbank, unpublished). It will be 
of interest to determine the differentiation potential of CD49f+ Subset1 and CD49f+ Subset2 cells with 
these novel methods. Another possibility is that myeloid differentiation may simply represent a default 
programme when Ly- or Ery-priming is missing, as previously postulated by another publication 
(Iwasaki and Akashi 2007). 
From the results presented here, it stands out that phenotypic HSC show many different behaviours in-
vitro. However, this is in sharp contrast with the transcriptional similarities identified between these 
cells. The data presented here prove that distinct functional behaviours and restriction to bilineage 
differentiation potential are coordinated by an underlying transcriptional structure (Figure 15). Despite 
the continuity observed after dimensionality reduction analysis, differences in this structure were 
identified using the ICGS algorithm (Olsson et al. 2016). Three different transcriptional states could be 
identified within the CD49f+ HSC compartment: one cluster (I) enriched in CD49f+ Subset1 cells and 
two clusters with similar gene expression patterns, enriched in CD49f+ Subset2 cells (Clusters IIa and 
IIb). One hypothesis is that quiescent and metabolic signatures shared by phenotypic HSC subsets (Notta 
et al. 2011; Laurenti et al. 2013; Chen et al. 2014) and not present in progenitor populations (Laurenti 
et al. 2013; Cabezas-Wallscheid et al. 2014), could be responsible of the continuous appearance of the 
CD49f+ HSC transcriptional landscape. Data presented here demonstrate that this continuum is polarised 
at its extremes and changes in the transcriptional programmes of single CD49f+ HSCs are associated 
with distinct differentiation behaviours (Figure 12 and 15). This finding highlights the importance of 
developing robust algorithms to identify such discrete states and has important implications for the 
interpretation of large single-cell transcriptomics studies. 
Transcriptional differences and in-vitro differentiation output of CD49f+ Subset1 and CD49f+ Subset2 
are accompanied by differences in cell cycle properties. These populations show consistently different 
time of first division (Figure 13). This is of interest because evidence in other stem cell types has 
emerged showing a correlation between the length of G0 to G1 transition and cell fate decisions (Pauklin 
and Vallier 2013; Dalton et al. 2015). Some evidence can be found in the literature (Mende et al. 2015; 
Grinenko et al. 2018) demonstrating such correlations in HSCs. Here, the time of first division is used 
as an indicative measure of the time spent in G0/early G1. The lengthening of the time of first division, 
mediated by CDK6 inhibition of CD49f+ Subset2 cells has a slight but significant impact on their 
differentiation, showing an increase in the number of colonies including Ery and Meg cells (Figure 16). 
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However, this can’t totally recapitulate the CD49f+ Subset1 phenotype. While this may suggest that 
lengthening of the time spent in G0/early G1 increases the propensity to produce colonies of the My/Ery 
and My/Ery/Meg type, it is not enough to revert CD49f+ Subset2 properties. Overall, these results put 
forward the idea that the time spent in these phases can affect, at least to some extent, HSC 
differentiation decisions. To confirm this, novel tools to accurately measure the duration of the G0 to 
early G1 transition will be needed. Because transcriptional data suggest that a level of lineage priming 
is already present within CD49f+ Subset1 and CD49f+ Subset2 cells it is hard to believe that the sole 
modulation of the cell cycle could significantly affect HSC differentiation and it is rather more plausible 
that, in HSCs, cell fate decisions are only slightly affected by cell cycle modulation.  
To overcome the limitation in erythroid differentiation seen in the xenograft model human EPO was 
administered to NSG mice, unlike other recent studies on human HSC populations (Notta et al. 2011; 
Majeti, Park, and Weissman 2007; Knapp et al. 2018). Extending the in-vivo lineage read out 
significantly improved the understanding of the diversity of phenotypic HSC differentiation behaviours 
and helped with the identification of rare multipotent (Ery/My/Ly) long-term repopulating HSC within 
the CLEC9Ahi CD34lo fraction of the CD49f+ HSC compartment.  
Similarly to all Ly-restricted or Ly-biased HSC/MPP populations previously described in mice (Dykstra 
et al. 2007; Cabezas-Wallscheid et al. 2014; Pietras et al. 2015; Carrelha et al. 2018) CD49f+ Subset2 
cells exhibit infrequent and limited repopulation capacity (Figure 18). This is in line with other studies 
which demonstrate that networks of TFs involved in promoting Ly-priming also inhibit HSC long term 
repopulation in human HSCs (Laurenti et al. 2013; Beer et al. 2014; van Galen et al. 2014). Even though 
the cells with long-term repopulation capacity from the CD49f+ Subset2 population may not share the 
exact same molecular properties of all the cells within the subset, it is clear that acquisition of Ly-
priming in these cells is accompanied by faster quiescence exit. In addition, the level of Ly-priming at 
the molecular level is lower than LMPPs (Figure 19), indicating that CD49f+ Subset2 cells represent the 
very first step at which Ery potential is permanently lost and Ly potential specified. 
In conclusion, data presented here support a model of haematopoiesis in which lymphoid lineage 
commitment is specified very early in quiescent and durably engrafting HSCs, as opposed to shorter 
lived and/or higher cycling progenitors. Lymphoid lineage is also accompanied by acquisition of a more 
“activated” phenotype, with shorter quiescence exit times, suggesting a transition towards a shallower 
or more primed quiescent state. Moreover, as differences in the niche microenvironment have been 
recently associated with differences in HSC bias towards My or Ly lineages in mouse (Pinho and 
Frenette 2019; Y. H. Ho et al. 2019), future experiment will be needed to assess if differences in the 
niche microenvironment and age-related niche remodelling are also responsible of the differences 
identified between CD49f+ Subset1 and CD49f+ Subset2 cells. This will have important implications in 
the understanding of the impact of ageing and pre-leukaemic mutations on blood formation in humans. 
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Cellular and molecular characterisation of exit from quiescence in human HSCs 
 
The balance between quiescence and cell cycle entry in HSCs is finely regulated to prevent exhaustion 
of the HSC pool and development of haematological malignancies (Orford and Scadden 2008). 
Quiescence is an intrinsic property of HSCs and its regulation has been extensively studied in the mouse 
model (Rossi et al. 2012). However, a precise definition of HSC activation and exit from quiescence is 
still lacking in the field and the molecular regulation of quiescence exit has not yet been investigated in 
human HSCs. In the context of this study, I define exit from quiescence from the moment in which HSC 
are stimulated to when they phosphorylate RB (pRB) and I present a comprehensive characterisation of 
the molecular and cellular events occurring during activation in human HSCs, distinguishing those 
occurring during exit from quiescence and those requiring cell cycle progression. 
In-vitro culture of HSCs results in their division. Thus, to study quiescence exit in-vitro, I used a model 
system to stop the cells in G0/early G1 through specific inhibition of CDK6. Division kinetics analysis 
of LT- and ST-HSCs recapitulated results shown in (Laurenti et al. 2015) confirming that most cells 
divide by 72 h in culture (Figure 21). Moreover, pRB staining assays show that exit from quiescence in 
these culture conditions occurs between 6 and 24 h after culture initiation in both LT- and ST-HSCs. 
Because CDK6 expression is higher in ST-HSCs than LT-HSCs (Laurenti et al. 2015), ST-HSC are not 
stopped from dividing after CDK6 inhibition and for this reason, regulation of exit from quiescence was 
studied mainly in LT-HSCs. 
Overall, data presented here show that the transcriptional regulation of activation is very similar between 
LT- and ST-HSCs but more interestingly, most of the gene expression changes associated with in-vitro 
activation already occur independently of cell cycle progression (Figure 22), during exit of quiescence 
(before RB phosphorylation). It is known from the literature that quiescent HSCs are small in size, rely 
on glycolytic metabolism and have low mRNA content and activated HSCs are characterised by a switch 
to oxidative metabolism and active protein synthesis (Passegué et al. 2005; Simsek et al. 2010; van 
Velthoven et al. 2019). However, how these properties change during exit from quiescence and later cell 
cycle phases in-vitro is not known. From the data presented here, the first functions to be activated 
during exit from G0 in LT-HSC are increased metabolic functions and ribosome biogenesis, together 
with activation of cell growth and protein synthesis, while activation of cell cycle genes is only a later 
response (Figure 23, 24 and 27). These results are consistent with results from studies in neural stem 
cells (NSCs) showing that exit from quiescence is accompanied by a remodelling of the cell metabolism 
(Llorens-Bobadilla et al. 2015; van Velthoven et al. 2019). Altogether, they provide first evidence that 
this also occurs in human HSCs independently of cell cycle progression. 
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Although quiescence has long been viewed as a dormant and inactive state of the cell, increasing 
evidence has suggested that quiescence is more like a poised state of the cell which anticipates 
activation, proliferation, and differentiation. This has been demonstrated in model organisms and in 
other stem cells to be regulated mainly at the epigenetic and post-transcriptional level (Cheung and 
Rando 2013; van Velthoven et al. 2019). However, experimental evidence proving that this is also valid 
in human HSCs is still lacking. GSEA analysis presented here, performed on bulk RNA-seq data, shows 
that HSC quiescence is actively maintained by the action of many TFs, most of which have been 
described as specific for HSC maintenance (LMO2, AHR, P53, MYB and HLF) (Cleveland et al. 2013; 
Bennett et al. 2015; Liu et al. 2009; Baker et al. 2014). Exit from quiescence and activation are 
characterised by a rapid remodelling of the activity of these TFs. This is indicative that, also in HSCs, 
quiescence is a poised state that allows for rapid activation. In contrast cell cycle progression in HSCs 
results to be driven by TF like MYC and E2F, the default TF circuity for growth in many cell types 
(Leone et al. 2001). Moreover, pathways involved in post-mitotic surveillance, cell cycle and 
mitochondria metabolism are highly enriched in activated HSCs. Metabolism related pathways only are 
instead enriched in LT-HSCs stopped in G0/Early G1 while inflammation related genes signatures (IFN, 
NFAT and AP1) are highly enriched in quiescent HSCs (Figure 24). These results are consistent with 
accumulating evidence supporting the fact that HSCs are direct targets of inflammatory signalling and 
that inflammatory signals may also contribute to HSC regulation in homeostatic conditions (Schuettpelz 
and Link 2013; Pietras 2017). Specifically, recent publications showed how the expression of IFN 
stimulated genes is a shared property of many stem cells, including HSCs (X. Wu et al. 2018). This was 
demonstrated to provide a defence mechanism for stem cells against infective agents. In accordance to 
data shown here, the expression of IFN stimulated genes is downregulated upon progression into the 
cell cycle and differentiation (Figure 27). 
Bulk-RNAseq analysis provided a first characterisation of the molecular processes involved in exit from 
quiescence and activation in HSCs. These results were complemented with time-course transcriptomic 
analysis at the single cell level of LT-HSCs cultured at different time point. This is important to study 
exit from quiescence at the cellular level rather than at the population level, but also to discriminate if 
the transcriptional changes observed are related to the time spent in culture or to the fact that HSCs are 
blocked in the G0 exit state (G0/early G1 phase). This analysis confirmed that transcriptional remodeling 
during quiescence exit is fairly synchronous between single cells, occurs gradually between 0 and 72 h 
and is mainly characterised by the up regulation of many genes, most of which are already up regulated 
at early time points (Figure 26). Interestingly, LT-HSCs appear to transit through a particular state, 
identified at 6 h in culture, before progressing into late G1. This time point may coincide with a stress 
response phase where HSCs sense external signals likely associated to stress and potentially adapt to 
these stresses while they prepare to progress into cell cycle. 50% of the genes differentially expressed 
at 6 h are not differentially expressed at later time points. One hypothesis is that HSCs, after sensing 
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mitogenic stimuli, first enter a state similar to the Galert phase, which has been described for muscle stem 
cells and HSCs as a priming mechanism, marked by mTORC activation, to mount a proliferative 
response faster in conditions of injury (Rodgers et al. 2014). It is possible that the 6 h time point 
corresponds to a phase where HSC prepare to exit quiescence modulating the expression of most of the 
genes required for G0 exit and cell cycle progression but without actually progressing. Further 
experiments will be needed to assess if most cells are still in G0 at 6 h to confirm that this time point is 
indicative of a different quiescence depth in LT-HSCs. In addition, analysis of mTORC activity should 
be carried out to formally compare the 6 h state to Galert. 
Gene expression pattern analysis on scRNA-seq data also shows similar findings to what has been 
previously identified by transcriptomic analysis performed in bulk. Genes like FOS, JUN, JUNB, CD74, 
GATA3, FOXP, HLX and HIF1A are among the genes identified as those rapidly down regulated during 
quiescence exit. As expected, metabolic, cell cycle and cell growth related pathways are gradually up 
regulated during activation in HSC in a cell cycle independent manner (van Velthoven et al. 2019). 
These findings were also confirmed functionally by mitochondrial staining and cell size measurement. 
Cell size, mitochondrial mass and mitochondrial function are all up regulated during exit from 
quiescence and progression in the cell cycle (Figure 29). Importantly, I confirmed that all these processes 
occur independently of cell cycle progression. Altogether, these results indicate that the metabolism 
response triggered by external signals and not by cell cycle progression, is an intrinsic property that 
drives exit from quiescence in HSCs. This is very interesting especially in the context of the role of 
mitochondria in HSCs and it comes in support of recent evidence demonstrating that mitochondria have 
an active role in regulating HSC functions and cell fate decisions independently of cell cycle progression 
(Vannini et al. 2016; T. T. Ho et al. 2017).  
In-vitro characterisation of quiescence exit in HSCs has shown consistent remodeling of the metabolic 
functions of these cells. To assess if these changes affect the in-vivo repopulation capacity of HSCs, 
limiting dilution analysis was performed with LT-HSCs cultured for 24 and 72 h in NSG mice. It is still 
largely accepted that transition from G0 to cell cycle leads to loss of HSC transplantation capacity 
(Gothot et al. 1998). My work revealed that it is the time LT-HSC spent in culture rather than their cell 
cycle progression that affects the frequency of long-term repopulating HSCs measured at 18 weeks from 
transplantation (Figure 30). This indicates that longer exposure to mitogenic signals is the main driver 
of the reduction of the repopulation capacity of LT-HSCs observed in-vitro. Because this was only 
demonstrated in cytokine rich media, where HSCs are forced to divide and differentiate, it is not to be 
excluded that HSCs cultured in different conditions may behave differently in terms of kinetics of 
division in-vitro and repopulation capacity in-vivo. Other culturing conditions aimed at preserving the 
HSC phenotype for longer times are routinely used and tested (Tajer et al. 2019) however, no ex-vivo 
culturing conditions have still been able to significantly maintain and expand human HSCs over long 
periods of time. Overall, because data presented here suggest that cell cycle progression is not the main 
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driver of differences in repopulating capacity of cultured HSCs, it can be speculated that in other 
culturing conditions, the repopulating capacity of HSC would still be affected depending on the time 
spent in culture and the type of factors present in the media, although probably to a lower extent if a 
reduced number of growth factors and oxygen levels are used for culturing. This could change the 
kinetics of activation of HSCs and reduce the pace of the metabolic activation, thus preserving better 
repopulation capacity in-vivo when compared to culture in differentiating conditions.  
Moreover, in-vivo transplantation assays aimed at investigating the role of cell cycle progression at the 
base of the differences in repopulation capacity identified between LT-HSCs cultured for different times 
in-vitro, showed a slight but non-statistically significant increase in the frequency of long-term 
repopulating cells from untreated and CDK6 inhibited cells at both time points examined (24 h or 72 h 
in-vitro). If these results were confirmed to be significant after the analysis of a higher number of mice, 
CDK6 inhibition and thus a longer permanence of the cell in the early G1 phase in-vitro could reduce 
the loss of engraftment capacity due to the time spent in culture. Useful applications could derive from 
the transplant of HSCs cultured in-vitro in the presence of CDK6 inhibitor. This would particularly 
benefit transplantation protocols that require prior in-vitro manipulation of HSCs.  
In conclusion, here I provide a comprehensive characterisation of the molecular and functional changes 
associated with HSC activation, distinguishing events occurring during exit from quiescence from those 
driven by cell cycle progression. Understanding how HSC coordinate quiescence exit and cell division 
is of fundamental importance, as it will help to develop protocols of ex-vivo HSCs expansion that could 
be used for HSC transplants. Moreover, it may shed light on the causes of the dysregulation of the 
quiescence and activation balance that characterises most of the haematological malignancies. Here, 
results obtained from different assays all point in the same direction, indicating that metabolic regulation 
plays a central role in exit from quiescence and activation of HSCs. Because HSC activation occurs 
independently of cell cycle progression it could be hypothesised that cell cycle independent HSC 
activation may allow HSCs to return to quiescence or differentiate without division. However, to 
confirm this, further experiments will be needed. It would thus be interesting to test if this is also the 
case when cell cycle is inhibited through other CDK6 independent mechanisms, this could indeed be 
done utilising specific inhibitors of other cell cycle phases. Moreover, as CDK6 kinase independent 
roles have been reported (Tigan et al. 2016), it would be interesting to see if these CDK6 functions are 
also responsible of driving quiescence exit and are thus not detected through inhibition of CDK6 kinase 
activity with PD. Other inhibitors, targeting for example the TF activity of CDK6 may be used in the 
future to better understand the role of CDK6 in quiescence exit.  
In conclusion, future studies should also focus on studying HSC metabolism more in detail as 
modulation of the metabolic response associated with exit from quiescence could contribute to the 




Adolfsson, Jörgen, Robert Månsson, Natalija Buza-Vidas, Anne Hultquist, Karina Liuba, Christina T. 
Jensen, David Bryder, et al. 2005. “Identification of Flt3 + Lympho-Myeloid Stem Cells Lacking 
Erythro-Megakaryocytic Potential: A Revised Road Map for Adult Blood Lineage Commitment.” 
Cell 121 (2): 295–306. https://doi.org/10.1016/j.cell.2005.02.013. 
Ahlqvist, Kati J., Anu Suomalainen, and Riikka H. Hämäläinen. 2015. “Stem Cells, Mitochondria and 
Aging.” Biochimica et Biophysica Acta - Bioenergetics. Elsevier. 
https://doi.org/10.1016/j.bbabio.2015.05.014. 
Akashi, Koichi, David Traver, Toshihiro Miyamoto, and Irving L. Weissman. 2000. “A Clonogenic 
Common Myeloid Progenitor That Gives Rise to All Myeloid Lineages.” Nature 404 (6774): 193–
97. https://doi.org/10.1038/35004599. 
Almeida, Mariana Justino de, Larry L. Luchsinger, David J. Corrigan, Linda J. Williams, and Hans 
Willem Snoeck. 2017. “Dye-Independent Methods Reveal Elevated Mitochondrial Mass in 
Hematopoietic Stem Cells.” Cell Stem Cell 21 (6): 725-729.e4. 
https://doi.org/10.1016/j.stem.2017.11.002. 
Anders, S., P. T. Pyl, and W. Huber. 2015. “HTSeq--a Python Framework to Work with High-
Throughput Sequencing Data.” Bioinformatics 31 (2): 166–69. 
https://doi.org/10.1093/bioinformatics/btu638. 
Anders, Simon, and Wolfgang Huber. 2010. “Differential Expression Analysis for Sequence Count 
Data.” Genome Biology 11 (10): R106. https://doi.org/10.1186/gb-2010-11-10-r106. 
Anjos-Afonso, Fernando, Erin Currie, Hector G Palmer, Katie E Foster, David C Taussig, and 
Dominique Bonnet. 2013. “CD34 - Cells at the Apex of the Human Hematopoietic Stem Cell 
Hierarchy Have Distinctive Cellular and Molecular Signatures.” Cell Stem Cell 13 (2): 161–74. 
https://doi.org/10.1016/j.stem.2013.05.025. 
Baker, Stacey J., Avi Ma’ayan, Yen K. Lieu, Premila John, M. V.Ramana Reddy, Edward Y. Chen, 
Qiaonan Duan, Hans Willem Snoeck, and E. Premkumar Reddy. 2014. “B-Myb Is an Essential 
Regulator of Hematopoietic Stem Cell and Myeloid Progenitor Cell Development.” Proceedings 
of the National Academy of Sciences of the United States of America 111 (8): 3122–27. 
https://doi.org/10.1073/pnas.1315464111. 
Becker, A.J., E.A. McCulloch, and J.E. Till. 1963. “Cytological Demonstration of the Clonal Nature of 
Spleen Colonies Derived from Transplanted Mouse Marrow Cells.” Nature 197 (4866): 452–54. 
https://doi.org/10.1038/197452a0. 
Becker, Klaus A., Prachi N. Ghule, Jaclyn A. Therrien, Jane B. Lian, Janet L. Stein, Andre J. van Wijnen, 
and Gary S. Stein. 2006. “Self-Renewal of Human Embryonic Stem Cells Is Supported by a 
Shortened G1 Cell Cycle Phase.” Journal of Cellular Physiology 209 (3): 883–93. 
https://doi.org/10.1002/jcp.20776. 
Beer, Philip A., David J.H.F. Knapp, Nagarajan Kannan, Paul H. Miller, Sonja Babovic, Elizabeth 
Bulaeva, Nima Aghaeepour, et al. 2014. “A Dominant-Negative Isoform of IKAROS Expands 
Primitive Normal Human Hematopoietic Cells.” Stem Cell Reports 3 (5): 841–57. 
https://doi.org/10.1016/j.stemcr.2014.09.006. 
Beerman, Isabel, Deepta Bhattacharya, Sasan Zandi, Mikael Sigvardsson, Irving L Weissman, David 
Bryder, and Derrick J Rossi. 2010. “Functionally Distinct Hematopoietic Stem Cells Modulate 
Hematopoietic Lineage Potential during Aging by a Mechanism of Clonal Expansion.” 
 109 
Proceedings of the National Academy of Sciences of the United States of America 107 (12): 5465–
70. https://doi.org/10.1073/pnas.1000834107. 
Belluschi, Serena, Emily F. Calderbank, Valerio Ciaurro, Blanca Pijuan-Sala, Antonella Santoro, Nicole 
Mende, Evangelia Diamanti, et al. 2018. “Myelo-Lymphoid Lineage Restriction Occurs in the 
Human Haematopoietic Stem Cell Compartment before Lymphoid-Primed Multipotent 
Progenitors.” Nature Communications 9 (1): 4100. https://doi.org/10.1038/s41467-018-06442-4. 
Bennett, John A., Kameshwar P. Singh, Zeenath Unnisa, Stephen L. Welle, and Thomas A. Gasiewicz. 
2015. “Deficiency in Aryl Hydrocarbon Receptor (AHR) Expression throughout Aging Alters 
Gene Expression Profiles in Murine Long-Term Hematopoietic Stem Cells.” Edited by Kevin D 
Bunting. PLOS ONE 10 (7): e0133791. https://doi.org/10.1371/journal.pone.0133791. 
Benveniste, Patricia, Catherine Frelin, Salima Janmohamed, Mary Barbara, Robert Herrington, Deborah 
Hyam, and Norman N. Iscove. 2010. “Intermediate-Term Hematopoietic Stem Cells with Extended 
but Time-Limited Reconstitution Potential.” Cell Stem Cell 6 (1): 48–58. 
https://doi.org/10.1016/J.STEM.2009.11.014. 
Bhatia, M., J. C. Y. Wang, U. Kapp, D. Bonnet, and J. E. Dick. 1997. “Purification of Primitive Human 
Hematopoietic Cells Capable of Repopulating Immune-Deficient Mice.” Proceedings of the 
National Academy of Sciences 94 (10): 5320–25. https://doi.org/10.1073/pnas.94.10.5320. 
Bindea, Gabriela, Bernhard Mlecnik, Hubert Hackl, Pornpimol Charoentong, Marie Tosolini, Amos 
Kirilovsky, Wolf-Herman Fridman, Franck Pagès, Zlatko Trajanoski, and Jérôme Galon. 2009. 
“ClueGO: A Cytoscape Plug-in to Decipher Functionally Grouped Gene Ontology and Pathway 
Annotation Networks.” Bioinformatics 25 (8): 1091–93. 
https://doi.org/10.1093/bioinformatics/btp101. 
Birbrair, Alexander, and Paul S Frenette. 2016. “Niche Heterogeneity in the Bone Marrow.” Annals of 
the New York Academy of Sciences. https://doi.org/10.1111/nyas.13016. 
Blomen, V. A., and J. Boonstra. 2007. “Cell Fate Determination during G1 Phase Progression.” Cellular 
and Molecular Life Sciences 64 (23): 3084–3104. https://doi.org/10.1007/s00018-007-7271-z. 
Boward, Ben, Tianming Wu, and Stephen Dalton. 2016. “Concise Review: Control of Cell Fate Through 
Cell Cycle and Pluripotency Networks.” Stem Cells 34 (6): 1427–36. 
https://doi.org/10.1002/stem.2345. 
Brennecke, Philip, Simon Anders, Jong Kyoung Kim, Aleksandra A. Kołodziejczyk, Xiuwei Zhang, 
Valentina Proserpio, Bianka Baying, et al. 2013. “Accounting for Technical Noise in Single-Cell 
RNA-Seq Experiments.” Nature Methods 10 (11): 1093–98. https://doi.org/10.1038/nmeth.2645. 
Bruns, Ingmar, Daniel Lucas, Sandra Pinho, Jalal Ahmed, Michele P Lambert, Yuya Kunisaki, 
Christoph Scheiermann, et al. 2014. “Megakaryocytes Regulate Hematopoietic Stem Cell 
Quiescence through CXCL4 Secretion.” Nature Medicine 20 (11): 1315–20. 
https://doi.org/10.1038/nm.3707. 
Busch, Katrin, Kay Klapproth, Melania Barile, Michael Flossdorf, Tim Holland-Letz, Susan M. 
Schlenner, Michael Reth, Thomas Höfer, and Hans-Reimer Reimer Rodewald. 2015. 
“Fundamental Properties of Unperturbed Haematopoiesis from Stem Cells in Vivo.” Nature 518 
(7540): 542–46. https://doi.org/10.1038/nature14242. 
Cabezas-Wallscheid, Nina, Florian Buettner, Pia Sommerkamp, Daniel Klimmeck, Luisa Ladel, 
Frederic B. Thalheimer, Daniel Pastor-Flores, et al. 2017. “Vitamin A-Retinoic Acid Signaling 
 110 
Regulates Hematopoietic Stem Cell Dormancy.” Cell 169 (5): 807-823.e19. 
https://doi.org/10.1016/J.CELL.2017.04.018. 
Cabezas-Wallscheid, Nina, Daniel Klimmeck, Jenny Hansson, Daniel B. B Lipka, Alejandro Reyes, Q. 
Qi Wang, Dieter Weichenhan, et al. 2014. “Identification of Regulatory Networks in HSCs and 
Their Immediate Progeny via Integrated Proteome, Transcriptome, and DNA Methylome 
Analysis.” Cell Stem Cell 15 (4): 507–22. https://doi.org/10.1016/J.STEM.2014.07.005. 
Calder, Ashley, Ivana Roth-Albin, Sonam Bhatia, Carlos Pilquil, Jong Hee Lee, Mick Bhatia, Marilyne 
Levadoux-Martin, et al. 2013. “Lengthened G1 Phase Indicates Differentiation Status in Human 
Embryonic Stem Cells.” Stem Cells and Development 22 (2): 279–95. 
https://doi.org/10.1089/scd.2012.0168. 
Calvi, L. M., G. B. Adams, K. W. Weibrecht, J. M. Weber, D. P. Olson, M. C. Knight, R. P. Martin, et 
al. 2003. “Osteoblastic Cells Regulate the Haematopoietic Stem Cell Niche.” Nature 425 (6960): 
841–46. https://doi.org/10.1038/nature02040. 
Carrelha, Joana, Yiran Meng, Laura M. Kettyle, Tiago C. Luis, Ruggiero Norfo, Verónica Alcolea, 
Hanane Boukarabila, et al. 2018. “Hierarchically Related Lineage-Restricted Fates of Multipotent 
Haematopoietic Stem Cells.” Nature 554 (7690): 106–11. https://doi.org/10.1038/nature25455. 
Catlin, Sandra N, Lambert Busque, Rosemary E Gale, Peter Guttorp, Janis L Abkowitz, SH. Orkin, LI. 
Zon, et al. 2011. “The Replication Rate of Human Hematopoietic Stem Cells in Vivo.” Blood 117 
(17): 4460–66. https://doi.org/10.1182/blood-2010-08-303537. 
Challen, Grant A., Nathan C. Boles, Stuart M. Chambers, and Margaret A. Goodell. 2010. “Distinct 
Hematopoietic Stem Cell Subtypes Are Differentially Regulated by TGF-Β1.” Cell Stem Cell 6 
(3): 265–78. https://doi.org/10.1016/J.STEM.2010.02.002. 
Challen, Grant A, Nathan Boles, Karen Kuan-Yin Yin Lin, and Margaret A Goodell. 2009. Mouse 
Hematopoietic Stem Cell Identification and Analysis. Cytometry Part A. Vol. 75. NIH Public 
Access. https://doi.org/10.1002/cyto.a.20674. 
Chen, Lu, M. Kostadima, Joost H.A. A. Martens, Giovanni Canu, Sara P. Garcia, E. Turro, Kate 
Downes, et al. 2014. “Transcriptional Diversity during Lineage Commitment of Human Blood 
Progenitors.” Science 345 (6204): 1251033–1251033. https://doi.org/10.1126/science.1251033. 
Cheng, Jerry C., Kentaro Kinjo, Dejah R. Judelson, Jenny Chang, Winston S. Wu, Ingrid Schmid, Deepa 
B. Shankar, et al. 2008. “CREB Is a Critical Regulator of Normal Hematopoiesis and 
Leukemogenesis.” Blood 111 (3): 1182–92. https://doi.org/10.1182/blood-2007-04-083600. 
Cheung, Tom H., and Thomas A. Rando. 2013. Molecular Regulation of Stem Cell Quiescence. Nature 
Reviews Molecular Cell Biology. Vol. 14. Nature Publishing Group. 
https://doi.org/10.1038/nrm3591. 
Cho, Inchul J, Prudence Pok Wai Lui, Jana Obajdin, Federica Riccio, Wladislaw Stroukov, Thea Louise 
Willis, Francesca Spagnoli, and Fiona M Watt. 2019. “Mechanisms, Hallmarks, and Implications 
of Stem Cell Quiescence.” Stem Cell Reports. Elsevier. 
https://doi.org/10.1016/j.stemcr.2019.05.012. 
Choe, Kevin S., Olga Ujhelly, Sandeep N. Wontakal, and Arthur I. Skoultchi. 2010. “PU.1 Directly 
Regulates Cdk6 Gene Expression, Linking the Cell Proliferation and Differentiation Programs in 
Erythroid Cells.” Journal of Biological Chemistry 285 (5): 3044–52. 
https://doi.org/10.1074/jbc.M109.077727. 
 111 
Civin, C I, L C Strauss, C Brovall, M J Fackler, J F Schwartz, and J H Shaper. 1984. “Antigenic Analysis 
of Hematopoiesis. III. A Hematopoietic Progenitor Cell Surface Antigen Defined by a Monoclonal 
Antibody Raised against KG-1a Cells.” Journal of Immunology (Baltimore, Md. : 1950) 133 (1): 
157–65. http://www.ncbi.nlm.nih.gov/pubmed/6586833. 
Cleveland, Susan M., Stephen Smith, Rati Tripathi, Elizabeth M. Mathias, Charnise Goodings, Natalina 
Elliott, Dunfa Peng, et al. 2013. “Lmo2 Induces Hematopoietic Stem Cell‐Like Features in T‐Cell 
Progenitor Cells Prior to Leukemia.” STEM CELLS 31 (5): 882–94. 
https://doi.org/10.1002/stem.1345. 
Cohen, Shiri Gur, Tomer Itkin, Sagarika Chakrabarty, Claudine Graf, Orit Kollet, Aya Ludin, Karin 
Golan, et al. 2015. “PAR1 Signaling Regulates the Retention and Recruitment of EPCR-Expressing 
Bone Marrow Hematopoietic Stem Cells.” Nature Medicine advance on (October). 
https://doi.org/10.1038/nm.3960. 
Copley, Michael R., Philip A. Beer, and Connie J. Eaves. 2012. “Hematopoietic Stem Cell 
Heterogeneity Takes Center Stage.” Cell Stem Cell 10 (6): 690–97. 
https://doi.org/10.1016/J.STEM.2012.05.006. 
Copley, Michael R, and Connie J Eaves. 2013. “Developmental Changes in Hematopoietic Stem Cell 
Properties.” Experimental & Molecular Medicine 45 (11): e55–e55. 
https://doi.org/10.1038/emm.2013.98. 
Coronado, Diana, Murielle Godet, Pierre-Yves Bourillot, Yann Tapponnier, Agnieszka Bernat, Maxime 
Petit, Marielle Afanassieff, et al. 2013. “A Short G1 Phase Is an Intrinsic Determinant of Naïve 
Embryonic Stem Cell Pluripotency.” Stem Cell Research 10 (1): 118–31. 
https://doi.org/10.1016/j.scr.2012.10.004. 
Cosgun, Kadriye Nehir, Susann Rahmig, Nicole Mende, Sören Reinke, Ilona Hauber, Carola Schäfer, 
Anke Petzold, et al. 2014. “Kit Regulates HSC Engraftment across the Human-Mouse Species 
Barrier.” Cell Stem Cell 15 (2): 227–38. https://doi.org/10.1016/j.stem.2014.06.001. 
Crisan, Mihaela, and Elaine Dzierzak. 2016. The Many Faces of Hematopoietic Stem Cell 
Heterogeneity. Development (Cambridge). Vol. 143. Oxford University Press for The Company of 
Biologists Limited. https://doi.org/10.1242/dev.114231. 
Dalton, Stephen, Y. Sela, et al., S. Pauklin, L. Vallier, Stephen Dalton, M.V. Blagosklonny, et al. 2015. 
“Linking the Cell Cycle to Cell Fate Decisions.” Trends in Cell Biology 25 (10): 592–600. 
https://doi.org/10.1016/j.tcb.2015.07.007. 
Danet, Guénahel H., Yi Pan, Jennifer L. Luongo, Dominique A. Bonnet, and M. Celeste Simon. 2003. 
“Expansion of Human SCID-Repopulating Cells under Hypoxic Conditions.” Journal of Clinical 
Investigation 112 (1): 126–35. 
Ding, Lei, and Sean J. Morrison. 2013. “Haematopoietic Stem Cells and Early Lymphoid Progenitors 
Occupy Distinct Bone Marrow Niches.” Nature 495 (7440): 231–35. 
https://doi.org/10.1038/nature11885. 
Ding, Lei, Thomas L. Saunders, Grigori Enikolopov, and Sean J. Morrison. 2012. “Endothelial and 
Perivascular Cells Maintain Haematopoietic Stem Cells.” Nature 481 (7382): 457–62. 
https://doi.org/10.1038/nature10783. 
Doulatov, Sergei, Faiyaz Notta, Kolja Eppert, Linh T Nguyen, Pamela S Ohashi, and John E Dick. 2010. 
“Revised Map of the Human Progenitor Hierarchy Shows the Origin of Macrophages and Dendritic 
 112 
Cells in Early Lymphoid Development.” Nature Immunology 11 (7): 585–93. 
https://doi.org/10.1038/ni.1889. 
Doulatov, Sergei, Faiyaz Notta, Elisa Laurenti, and John E Dick. 2012. “Hematopoiesis: A Human 
Perspective.” Cell Stem Cell. Elsevier Inc. https://doi.org/10.1016/j.stem.2012.01.006. 
Dykstra, Brad, David Kent, Michelle Bowie, Lindsay McCaffrey, Melisa Hamilton, Kristin Lyons, 
Shang-Jung Lee, Ryan Brinkman, and Connie Eaves. 2007. “Long-Term Propagation of Distinct 
Hematopoietic Differentiation Programs In Vivo.” Cell Stem Cell 1 (2): 218–29. 
https://www.sciencedirect.com/science/article/pii/S1934590907000215?via%3Dihub. 
Eaves, Connie J. 2015. “Hematopoietic Stem Cells: Concepts, Definitions, and the New Reality.” Blood 
125 (17): 2605–13. https://doi.org/10.1182/blood-2014-12-570200. 
Ema, Hideo, Yohei Morita, and Toshio Suda. 2014. “Heterogeneity and Hierarchy of Hematopoietic 
Stem Cells.” Experimental Hematology 42 (2): 74-82.e2. 
https://doi.org/10.1016/j.exphem.2013.11.004. 
Ema, Hideo, Hina Takano, Kazuhiro Sudo, and Hiromitsu Nakauchi. 2000. “In Vitro Self-Renewal 
Division of Hematopoietic Stem Cells.” Journal of Experimental Medicine 192 (9): 1281–88. 
https://doi.org/10.1084/jem.192.9.1281. 
Ernst, J., G. J. Nau, and Z. Bar-Joseph. 2005. “Clustering Short Time Series Gene Expression Data.” 
Bioinformatics 21 (Suppl 1): i159–68. https://doi.org/10.1093/bioinformatics/bti1022. 
Ernst, Jason, and Ziv Bar-Joseph. 2006. “STEM: A Tool for the Analysis of Short Time Series Gene 
Expression Data.” BMC Bioinformatics 7 (1): 191. https://doi.org/10.1186/1471-2105-7-191. 
Farlik, Matthias, Florian Halbritter, Fabian Müller, Fizzah A Choudry, Peter Ebert, Johanna 
Klughammer, Samantha Farrow, et al. 2016. “DNA Methylation Dynamics of Human 
Hematopoietic Stem Cell Differentiation.” Cell Stem Cell 19 (6): 808–22. 
https://doi.org/10.1016/j.stem.2016.10.019. 
Filippi, Marie-Dominique, and Saghi Ghaffari. 2019. “Mitochondria in the Maintenance of 
Hematopoietic Stem Cells: New Perspectives and Opportunities.” Blood 133 (18): 1943–52. 
https://doi.org/10.1182/blood-2018-10-808873. 
Folmes, C.D. Clifford D L C.D.L., P.P. Petras P Dzeja, T.J. Timothy J Nelson, Andre Terzic, M. 
Agathocleous, N.K. Love, O. Randlett, et al. 2012. “Metabolic Plasticity in Stem Cell Homeostasis 
and Differentiation.” Cell Stem Cell 11 (5): 596–606. https://doi.org/10.1016/j.stem.2012.10.002. 
Ford, C. E., J. L. Hamerton, D. W.H. Barnes, and J. F. Loutit. 1956. “Cytological Identification of 
Radiation-Chimæras.” Nature 177 (4506): 452–54. https://doi.org/10.1038/177452a0. 
Forsberg, E. Camilla, Emmanuelle Passegué, Susan S. Prohaska, Amy J. Wagers, Martina Koeva, 
Joshua M. Stuart, and Irving L. Weissman. 2010. “Molecular Signatures of Quiescent, Mobilized 
and Leukemia-Initiating Hematopoietic Stem Cells.” Edited by Catherine M. Verfaillie. PLoS ONE 
5 (1): e8785. https://doi.org/10.1371/journal.pone.0008785. 
Foudi, Adlen, Konrad Hochedlinger, Denille Van Buren, Jeffrey W Schindler, Rudolf Jaenisch, Vincent 
Carey, and Hanno Hock. 2009. “Analysis of Histone 2B-GFP Retention Reveals Slowly Cycling 
Hematopoietic Stem Cells.” Nature Biotechnology 27 (1): 84–90. https://doi.org/10.1038/nbt.1517. 
 113 
Freire, Pablo R, and Orla M Conneely. 2018. “NR4A1 and NR4A3 Restrict HSC Proliferation via 
Reciprocal Regulation of C/EBPα and Inflammatory Signaling.” Blood 131 (10): 1081–93. 
https://doi.org/10.1182/blood-2017-07-795757. 
Fujimoto, T., K. Anderson, S. E.W. Jacobsen, S. I. Nishikawa, and C. Nerlov. 2007. “Cdk6 Blocks 
Myeloid Differentiation by Interfering with Runx1 DNA Binding and Runx1-C/EBPα Interaction.” 
EMBO Journal 26 (9): 2361–70. https://doi.org/10.1038/sj.emboj.7601675. 
Gao, Xin, Chunliang Xu, Noboru Asada, and Paul S Frenette. 2018. “The Hematopoietic Stem Cell 
Niche: From Embryo to Adult.” Development 145 (2): dev139691. 
https://doi.org/10.1242/dev.139691. 
García-Prat, Laura, Marta Martínez-Vicente, Eusebio Perdiguero, Laura Ortet, Javier Rodríguez-
Ubreva, Elena Rebollo, Vanessa Ruiz-Bonilla, et al. 2016. “Autophagy Maintains Stemness by 
Preventing Senescence.” Nature 529 (7584): 37–42. https://doi.org/10.1038/nature16187. 
Georgantas, Robert W, Vivek Tanadve, Matthew Malehorn, Shelly Heimfeld, Chen Chen, Laura Carr, 
Francisco Martinez-Murillo, Greg Riggins, Jeanne Kowalski, and Curt I Civin. 2004. “Microarray 
and Serial Analysis of Gene Expression Analyses Identify Known and Novel Transcripts 
Overexpressed in Hematopoietic Stem Cells.” CANCER RESEARCH. Vol. 64. 
http://www.ncbi.nlm.nih.gov/GenBank/. 
Goardon, Nicolas, Emanuele Marchi, Ann Atzberger, Lynn Quek, Anna Schuh, Shamit Soneji, Petter 
Woll, et al. 2011. “Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute 
Myeloid Leukemia.” Cancer Cell 19 (1): 138–52. https://www.cell.com/cancer-
cell/fulltext/S1535-6108(10)00526-X. 
Gonzales, Kevin Andrew Uy, Hongqing Liang, Yee Siang Lim, Yun Shen Chan, Jia Chi Yeo, Cheng 
Peow Tan, Bin Gao, et al. 2015. “Deterministic Restriction on Pluripotent State Dissolution by 
Cell-Cycle Pathways.” Cell 162 (3): 564–79. https://doi.org/10.1016/j.cell.2015.07.001. 
Goodell, M A, K Brose, G Paradis, A S Conner, and R C Mulligan. 1996. “Isolation and Functional 
Properties of Murine Hematopoietic Stem Cells That Are Replicating in Vivo.” The Journal of 
Experimental Medicine 183 (4): 1797–1806. https://doi.org/10.1084/jem.183.4.1797. 
Gothot, André, Johannes C.M. Van der Loo, D. Wade Clapp, and Edward F. Srour. 1998. “Cell Cycle-
Related Changes in Repopulating Capacity of Human Mobilized Peripheral Blood CD34+ Cells in 
Non-Obese Diabetic/Severe Combined Immune- Deficient Mice.” Blood 92 (8): 2641–49. 
https://doi.org/10.1182/blood.v92.8.2641.420k36_2641_2649. 
Grinenko, Tatyana, Anne Eugster, Lars Thielecke, Beáta Ramasz, Anja Krüger, Sevina Dietz, Ingmar 
Glauche, et al. 2018. “Hematopoietic Stem Cells Can Differentiate into Restricted Myeloid 
Progenitors before Cell Division in Mice.” Nature Communications 9 (1): 1898. 
https://doi.org/10.1038/s41467-018-04188-7. 
Grover, Amit, Alejandra Sanjuan-Pla, Supat Thongjuea, Joana Carrelha, Alice Giustacchini, Adriana 
Gambardella, Iain Macaulay, et al. 2016. “Single-Cell RNA Sequencing Reveals Molecular and 
Functional Platelet Bias of Aged Haematopoietic Stem Cells.” Nature Communications 7 (1): 
11075. https://doi.org/10.1038/ncomms11075. 
Guo, Guoji, Sidinh Luc, Eugenio Marco, Ta-Wei Wei Lin, Cong Peng, Marc A. A. Kerenyi, Semir 
Beyaz, et al. 2013. “Mapping Cellular Hierarchy by Single-Cell Analysis of the Cell Surface 
Repertoire.” Cell Stem Cell 13 (4): 492–505. https://doi.org/10.1016/j.stem.2013.07.017. 
 114 
Haas, Simon, Jenny Hansson, Daniel Klimmeck, Dirk Loeffler, Lars Velten, Hannah Uckelmann, 
Stephan Wurzer, et al. 2015. “Inflammation-Induced Emergency Megakaryopoiesis Driven by 
Hematopoietic Stem Cell-like Megakaryocyte Progenitors.” Cell Stem Cell 17 (4): 422–34. 
https://doi.org/10.1016/j.stem.2015.07.007. 
Haas, Simon, Andreas Trumpp, and Michael D Milsom. 2018. “Causes and Consequences of 
Hematopoietic Stem Cell Heterogeneity.” Cell Stem Cell 22 (5): 627–38. 
https://doi.org/10.1016/j.stem.2018.04.003. 
Haghverdi, Laleh, Florian Buettner, and Fabian J. Theis. 2015. “Diffusion Maps for High-Dimensional 
Single-Cell Analysis of Differentiation Data.” Bioinformatics 31 (18): 2989–98. 
https://doi.org/10.1093/bioinformatics/btv325. 
Hamey, Fiona K., and Berthold Göttgens. 2019. “Reconstructing Gene Regulatory Networks That 
Control Hematopoietic Commitment.” In Methods in Molecular Biology, 1975:239–49. Humana, 
New York, NY. https://doi.org/10.1007/978-1-4939-9224-9_11. 
Hamey, Fiona K, Sonia Nestorowa, Sarah J Kinston, David G Kent, Nicola K Wilson, and Berthold 
Göttgens. 2017. “Reconstructing Blood Stem Cell Regulatory Network Models from Single-Cell 
Molecular Profiles.” Proceedings of the National Academy of Sciences of the United States of 
America 114 (23): 5822–29. https://doi.org/10.1073/pnas.1610609114. 
Hao, Sha, Chen Chen, and Tao Cheng. 2016. “Cell Cycle Regulation of Hematopoietic Stem or 
Progenitor Cells.” International Journal of Hematology. Springer Japan. 
https://doi.org/10.1007/s12185-016-1984-4. 
Hay, Stuart B., Kyle Ferchen, Kashish Chetal, H. Leighton Grimes, and Nathan Salomonis. 2018. “The 
Human Cell Atlas Bone Marrow Single-Cell Interactive Web Portal.” Experimental Hematology 
68 (December): 51–61. https://doi.org/10.1016/j.exphem.2018.09.004. 
Hermitte, Francis, Philippe Brunet de la Grange, Francis Belloc, Vincent Praloran, and Zoran Ivanovic. 
2006. “Very Low O 2 Concentration (0.1%) Favors G 0 Return of Dividing CD34 + Cells.” Stem 
Cells 24 (1): 65–73. https://doi.org/10.1634/stemcells.2004-0351. 
Ho, Theodore T., Matthew R. Warr, Emmalee R. Adelman, Olivia M. Lansinger, Johanna Flach, 
Evgenia V. Verovskaya, Maria E. Figueroa, and Emmanuelle Passegué. 2017. “Autophagy 
Maintains the Metabolism and Function of Young and Old Stem Cells.” Nature 543 (7644): 205–
10. https://doi.org/10.1038/nature21388. 
Ho, Ya Hsuan, Raquel del Toro, José Rivera-Torres, Justyna Rak, Claudia Korn, Andrés García-García, 
David Macías, et al. 2019. “Remodeling of Bone Marrow Hematopoietic Stem Cell Niches 
Promotes Myeloid Cell Expansion during Premature or Physiological Aging.” Cell Stem Cell 25 
(3): 407-418.e6. https://doi.org/10.1016/j.stem.2019.06.007. 
Hock, Hanno. 2010. “Some Hematopoietic Stem Cells Are More Equal than Others.” The Journal of 
Experimental Medicine 207 (6): 1127–30. https://doi.org/10.1084/jem.20100950. 
Hordyjewska, Anna, Łukasz Popiołek, and Anna Horecka. 2015. Characteristics of Hematopoietic Stem 
Cells of Umbilical Cord Blood. Cytotechnology. Vol. 67. Springer. https://doi.org/10.1007/s10616-
014-9796-y. 
Hu, Yifang, and Gordon K. Smyth. 2009. “ELDA: Extreme Limiting Dilution Analysis for Comparing 
Depleted and Enriched Populations in Stem Cell and Other Assays.” Journal of Immunological 
Methods 347 (1–2): 70–78. https://doi.org/10.1016/J.JIM.2009.06.008. 
 115 
Ichii, Michiko, Kenji Oritani, Takafumi Yokota, Qingzhao Zhang, Karla P. Garrett, Yuzuru Kanakura, 
and Paul W. Kincade. 2010. “The Density of CD10 Corresponds to Commitment and Progression 
in the Human B Lymphoid Lineage.” Edited by Derya Unutmaz. PLoS ONE 5 (9): e12954. 
https://doi.org/10.1371/journal.pone.0012954. 
Itkin, Tomer, Shiri Gur-Cohen, Joel A. Spencer, Amir Schajnovitz, Saravana K. Ramasamy, Anjali P. 
Kusumbe, Guy Ledergor, et al. 2016. “Distinct Bone Marrow Blood Vessels Differentially 
Regulate Haematopoiesis.” Nature 532 (7599): 323–28. https://doi.org/10.1038/nature17624. 
Ito, Kyoko, Raphaël Turcotte, Jinhua Cui, Samuel E. Zimmerman, Sandra Pinho, Toshihide Mizoguchi, 
Fumio Arai, et al. 2016. “Self-Renewal of a Purified Tie2+ Hematopoietic Stem Cell Population 
Relies on Mitochondrial Clearance.” Science 354 (6316): 1156–60. 
https://doi.org/10.1126/SCIENCE.AAF5530. 
Ito, Mamoru, Hidefumi Hiramatsu, Kimio Kobayashi, Kazutomo Suzue, Mariko Kawahata, Kyoji 
Hioki, Yoshito Ueyama, et al. 2002. “NOD/SCID/Gamma(c)(Null) Mouse: An Excellent Recipient 
Mouse Model for Engraftment of Human Cells.” Blood 100 (9): 3175–82. 
https://doi.org/10.1182/blood-2001-12-0207. 
Ivanova, Natalia B, John T Dimos, Christoph Schaniel, Jason A Hackney, Kateri A Moore, Ihor R 
Lemischka, I. L. Weissman, et al. 2002. “A Stem Cell Molecular Signature.” Science (New York, 
N.Y.) 298 (5593): 601–4. https://doi.org/10.1126/science.1073823. 
Iwasaki, Hiromi, and Koichi Akashi. 2007. “Myeloid Lineage Commitment from the Hematopoietic 
Stem Cell.” Immunity. https://doi.org/10.1016/j.immuni.2007.06.004. 
Jacobson, L. O., E. L. Simmons, E. K. Marks, and J. H. Eldredge. 1951. “Recovery from Radiation 
Injury.” Science 113 (2940): 510–11. https://doi.org/10.1126/science.113.2940.510. 
Kamel-Reid, S, and J. Dick. 1988. “Engraftment of Immune-Deficient Mice with Human Hematopoietic 
Stem Cells.” Science 242 (4886): 1706–9. https://doi.org/10.1126/science.2904703. 
Karamitros, Dimitris, Bilyana Stoilova, Zahra Aboukhalil, Fiona Hamey, Andreas Reinisch, Marina 
Samitsch, Lynn Quek, et al. 2018. “Single-Cell Analysis Reveals the Continuum of Human 
Lympho-Myeloid Progenitor Cells Article.” Nature Immunology 19 (1): 85–97. 
https://doi.org/10.1038/s41590-017-0001-2. 
Katajisto, Pekka, Julia Döhla, Christine L Chaffer, Nalle Pentinmikko, Nemanja Marjanovic, Sharif 
Iqbal, Roberto Zoncu, Walter Chen, Robert A Weinberg, and David M Sabatini. 2015. 
“Asymmetric Apportioning of Aged Mitochondria between Daughter Cells Is Required for 
Stemness.” Science 348 (6232): 340–43. https://doi.org/10.1126/science.1260384. 
Kataoka, Keisuke, Tomohiko Sato, Akihide Yoshimi, Susumu Goyama, Takako Tsuruta, Hiroshi 
Kobayashi, Munetake Shimabe, et al. 2011. “Evi1 Is Essential for Hematopoietic Stem Cell Self-
Renewal, and Its Expression Marks Hematopoietic Cells with Long-Term Multilineage 
Repopulating Activity.” The Journal of Experimental Medicine 208 (12): 2403–16. 
https://doi.org/10.1084/jem.20110447. 
Kawamoto, H, K Ohmura, S Fujimoto, and Y Katsura. 1999. “Emergence of T Cell Progenitors without 
B Cell or Myeloid Differentiation Potential at the Earliest Stage of Hematopoiesis in the Murine 
Fetal Liver.” Journal of Immunology (Baltimore, Md. : 1950) 162 (5): 2725–31. 
http://www.ncbi.nlm.nih.gov/pubmed/10072517. 
Kawamoto, Hiroshi, Tomokatsu Ikawa, Kyoko Masuda, Haruka Wada, and Yoshimoto Katsura. 2010. 
“A Map for Lineage Restriction of Progenitors during Hematopoiesis: The Essence of the Myeloid-
 116 
Based Model.” Immunological Reviews 238 (1): 23–36. https://doi.org/10.1111/j.1600-
065X.2010.00959.x. 
Kent, David G, Michael R Copley, Claudia Benz, Stefan Wöhrer, Brad J Dykstra, Elaine Ma, John 
Cheyne, et al. 2009. “Prospective Isolation and Molecular Characterization of Hematopoietic Stem 
Cells with Durable Self-Renewal Potential.” Blood 113 (25): 6342–50. 
https://doi.org/10.1182/blood-2008-12-192054. 
Kheir, Tony Bou, and Anders H. Lund. 2010. “Epigenetic Dynamics across the Cell Cycle.” Essays in 
Biochemistry 48 (September): 107–20. https://doi.org/10.1042/BSE0480107. 
Knapp, David J.H.F. H. F., Colin A. Hammond, Tony Hui, Marijn T.J. J. van Loenhout, Fangwu Wang, 
Nima Aghaeepour, Paul H. Miller, et al. 2018. “Single-Cell Analysis Identifies a CD33 + Subset 
of Human Cord Blood Cells with High Regenerative Potential.” Nature Cell Biology 20 (6): 710–
20. https://doi.org/10.1038/s41556-018-0104-5. 
Kobayashi, Chiharu I., and Toshio Suda. 2012. “Regulation of Reactive Oxygen Species in Stem Cells 
and Cancer Stem Cells.” Journal of Cellular Physiology 227 (2): 421–30. 
https://doi.org/10.1002/jcp.22764. 
Kohli, Latika, and Emmanuelle Passegué. 2014. “Surviving Change: The Metabolic Journey of 
Hematopoietic Stem Cells.” Trends in Cell Biology 24 (8): 479–87. 
https://doi.org/10.1016/j.tcb.2014.04.001. 
Kohn, Lisa A, Qian-Lin Hao, Rajkumar Sasidharan, Chintan Parekh, Shundi Ge, Yuhua Zhu, Hanna K 
A Mikkola, and Gay M Crooks. 2012. “Lymphoid Priming in Human Bone Marrow Begins before 
Expression of CD10 with Upregulation of L-Selectin.” Nature Immunology 13 (10): 963–71. 
https://doi.org/10.1038/ni.2405. 
Kollmann, Karoline, Gerwin Heller, Christine Schneckenleithner, Wolfgang Warsch, Ruth Scheicher, 
Rene G. Ott, Markus Schäfer, et al. 2013. “A Kinase-Independent Function of CDK6 Links the 
Cell Cycle to Tumor Angiogenesis.” Cancer Cell 24 (2): 167–81. 
https://doi.org/10.1016/j.ccr.2013.07.012. 
Komorowska, Karolina, Alexander Doyle, Martin Wahlestedt, Agatheeswaran Subramaniam, 
Shubhranshu Debnath, Jun Chen, Shamit Soneji, et al. 2017. “Hepatic Leukemia Factor Maintains 
Quiescence of Hematopoietic Stem Cells and Protects the Stem Cell Pool during Regeneration.” 
Cell Reports 21 (12): 3514–23. https://doi.org/10.1016/j.celrep.2017.11.084. 
Kondo, Motonari, Irving L. Weissman, and Koichi Akashi. 1997. “Identification of Clonogenic 
Common Lymphoid Progenitors in Mouse Bone Marrow.” Cell 91 (5): 661–72. 
https://doi.org/10.1016/S0092-8674(00)80453-5. 
Kozar, Katarzyna, and Piotr Sicinski. 2005. “Cell Cycle Progression without Cyclin D-CDK4 and 
Cyclin D-CDK6 Complexes.” Cell Cycle. Taylor and Francis Inc. 
https://doi.org/10.4161/cc.4.3.1551. 
Lange, Christian, and Federico Calegari. 2010. “Cdks and Cyclins Link G1 Length and Differentiation 
of Embryonic, Neural and Hematopoietic Stem Cells.” Cell Cycle. Taylor & Francis. 
https://doi.org/10.4161/cc.9.10.11598. 
Lansdorp, P M, H J Sutherland, and C J Eaves. 1990. “Selective Expression of CD45 Isoforms on 
Functional Subpopulations of CD34+ Hemopoietic Cells from Human Bone Marrow.” The Journal 
of Experimental Medicine 172 (1): 363–66. https://doi.org/10.1084/jem.172.1.363. 
 117 
Larochelle, A., M. Savona, M. Wiggins, S. Anderson, B. Ichwan, K. Keyvanfar, S. J. Morrison, and C. 
E. Dunbar. 2011. “Human and Rhesus Macaque Hematopoietic Stem Cells Cannot Be Purified 
Based Only on SLAM Family Markers.” Blood 117 (5): 1550–54. https://doi.org/10.1182/blood-
2009-03-212803. 
Laurenti, Elisa, and John E Dick. 2012. “Molecular and Functional Characterization of Early Human 
Hematopoiesis.” Annals of the New York Academy of Sciences 1266 (1): 68–71. 
https://doi.org/10.1111/j.1749-6632.2012.06577.x. 
Laurenti, Elisa, Sergei Doulatov, Sasan Zandi, Ian Plumb, Jing Chen, Craig April, Jian-Bing Fan, and 
John E. Dick. 2013. “The Transcriptional Architecture of Early Human Hematopoiesis Identifies 
Multilevel Control of Lymphoid Commitment.” Nature Immunology 14 (7): 756–63. 
https://doi.org/10.1038/ni.2615. 
Laurenti, Elisa, Catherine Frelin, Stephanie Xie, Robin Ferrari, Cyrille F. F. Dunant, Sasan Zandi, 
Andrea Neumann, et al. 2015. “CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic 
Stem Cells.” Cell Stem Cell 16 (3): 302–13. https://doi.org/10.1016/j.stem.2015.01.017. 
Laurenti, Elisa, and Berthold Göttgens. 2018. “From Haematopoietic Stem Cells to Complex 
Differentiation Landscapes.” Nature. Nature Publishing Group. 
https://doi.org/10.1038/nature25022. 
Laurenti, Elisa, Barbara Varnum-Finney, Anne Wilson, Isabel Ferrero, William E. Blanco-Bose, Armin 
Ehninger, Paul S. Knoepfler, et al. 2008. “Hematopoietic Stem Cell Function and Survival Depend 
on C-Myc and N-Myc Activity.” Cell Stem Cell 3 (6): 611–24. 
https://doi.org/10.1016/j.stem.2008.09.005. 
Lee, Jaeyop, Yu Jerry Zhou, Wenji Ma, Wanwei Zhang, Arafat Aljoufi, Thomas Luh, Kimberly Lucero, 
et al. 2017. “Lineage Specification of Human Dendritic Cells Is Marked by IRF8 Expression in 
Hematopoietic Stem Cells and Multipotent Progenitors.” Nature Immunology 18 (8): 877–88. 
https://doi.org/10.1038/ni.3789. 
Lee, Sung-Young, Jaeho Yoon, Mee-Hyun Lee, Sung Keun Jung, Dong Joon Kim, Ann M Bode, 
Jaebong Kim, and Zigang Dong. 2012. “The Role of Heterodimeric AP-1 Protein Comprised of 
JunD and c-Fos Proteins in Hematopoiesis.” The Journal of Biological Chemistry 287 (37): 31342–
48. https://doi.org/10.1074/jbc.M112.387266. 
Leone, Gustavo, Rosalie Sears, Erich Huang, Rachel Rempel, Faison Nuckolls, Chi Hyun Park, Paloma 
Giangrande, et al. 2001. “Myc Requires Distinct E2F Activities to Induce S Phase and Apoptosis.” 
Molecular Cell 8 (1): 105–13. https://doi.org/10.1016/S1097-2765(01)00275-1. 
Li, Rudong, Yin Wang, Hui Cheng, Gang Liu, Tao Cheng, Yunlong Liu, and Lei Liu. 2017. “System 
Modeling Reveals the Molecular Mechanisms of HSC Cell Cycle Alteration Mediated by Maff and 
Egr3 under Leukemia.” BMC Systems Biology 11 (S5): 91. https://doi.org/10.1186/s12918-017-
0467-4. 
Lim, Shuhui, and Philipp Kaldis. 2013. “Cdks, Cyclins and CKIs: Roles beyond Cell Cycle Regulation.” 
Development 140 (15): 3079–93. https://doi.org/10.1242/dev.091744. 
Liu, Yan, Shannon E. Elf, Yasuhiko Miyata, Goro Sashida, Yuhui Liu, Gang Huang, Silvana Di 
Giandomenico, et al. 2009a. “P53 Regulates Hematopoietic Stem Cell Quiescence.” Cell Stem Cell 
4 (1): 37–48. https://doi.org/10.1016/J.STEM.2008.11.006. 
———. 2009b. “P53 Regulates Hematopoietic Stem Cell Quiescence.” Cell Stem Cell 4 (1): 37–48. 
https://doi.org/10.1016/j.stem.2008.11.006. 
 118 
Llorens-Bobadilla, Enric, Sheng Zhao, Avni Baser, Gonzalo Saiz-Castro, Klara Zwadlo, and Ana 
Martin-Villalba. 2015. “Single-Cell Transcriptomics Reveals a Population of Dormant Neural 
Stem Cells That Become Activated upon Brain Injury.” Cell Stem Cell 17 (3): 329–40. 
https://doi.org/10.1016/j.stem.2015.07.002. 
Love, Michael I., Wolfgang Huber, and Simon Anders. 2014. “Moderated Estimation of Fold Change 
and Dispersion for RNA-Seq Data with DESeq2.” Genome Biology 15 (12). 
https://doi.org/10.1186/s13059-014-0550-8. 
Luchsinger, Larry L., Mariana Justino de Almeida, David J. Corrigan, Melanie Mumau, and Hans-
Willem Snoeck. 2016. “Mitofusin 2 Maintains Haematopoietic Stem Cells with Extensive 
Lymphoid Potential.” Nature 529 (7587): 528–31. https://doi.org/10.1038/nature16500. 
Luchsinger, Larry L., Alexandros Strikoudis, Nichole M. Danzl, Erin C. Bush, Michael O. Finlayson, 
Prakash Satwani, Megan Sykes, Masayuki Yazawa, and Hans-Willem Snoeck. 2019. “Harnessing 
Hematopoietic Stem Cell Low Intracellular Calcium Improves Their Maintenance In Vitro.” Cell 
Stem Cell, June. https://doi.org/10.1016/j.stem.2019.05.002. 
Ludin, Aya, Shiri Gur-Cohen, Karin Golan, Kerstin B. Kaufmann, Tomer Itkin, Chiara Medaglia, Xin 
Jiang Lu, Guy Ledergor, Orit Kollet, and Tsvee Lapidot. 2014. “Reactive Oxygen Species Regulate 
Hematopoietic Stem Cell Self-Renewal, Migration and Development, as Well as Their Bone 
Marrow Microenvironment.” Antioxidants and Redox Signaling. Mary Ann Liebert Inc. 
https://doi.org/10.1089/ars.2014.5941. 
Majeti, Ravindra, Christopher Y. Park, and Irving L. Weissman. 2007. “Identification of a Hierarchy of 
Multipotent Hematopoietic Progenitors in Human Cord Blood.” Cell Stem Cell 1 (6): 635–45. 
https://doi.org/10.1016/j.stem.2007.10.001. 
Malumbres, Marcos, and Mariano Barbacid. 2009. “Cell Cycle, CDKs and Cancer: A Changing 
Paradigm.” Nature Reviews Cancer. Nature Publishing Group. https://doi.org/10.1038/nrc2602. 
Malumbres, Marcos, Rocío Sotillo, David Santamaría, Javier Galán, Ana Cerezo, Sagrario Ortega, 
Pierre Dubus, and Mariano Barbacid. 2004. “Mammalian Cells Cycle without the D-Type Cyclin-
Dependent Kinases Cdk4 and Cdk6.” Cell 118 (4): 493–504. 
https://doi.org/10.1016/j.cell.2004.08.002. 
Månsson, Robert, Anne Hultquist, Sidinh Luc, Liping Yang, Kristina Anderson, Shabnam Kharazi, 
Suleiman Al-Hashmi, et al. 2007. “Molecular Evidence for Hierarchical Transcriptional Lineage 
Priming in Fetal and Adult Stem Cells and Multipotent Progenitors.” Immunity 26 (4): 407–19. 
https://doi.org/10.1016/j.immuni.2007.02.013. 
Matsumoto, Akinobu, Shoichiro Takeishi, Tomoharu Kanie, Etsuo Susaki, Ichiro Onoyama, Yuki 
Tateishi, Keiko Keiichi I. Nakayama, and Keiko Keiichi I. Nakayama. 2011. “P57 Is Required for 
Quiescence and Maintenance of Adult Hematopoietic Stem Cells.” Cell Stem Cell 9 (3): 262–71. 
https://www.sciencedirect.com/science/article/pii/S1934590911003298?via%3Dihub. 
Mende, Nicole, Erika E. Kuchen, Mathias Lesche, Tatyana Grinenko, Konstantinos D. Kokkaliaris, 
Helmut Hanenberg, Dirk Lindemann, et al. 2015. “CCND1–CDK4–Mediated Cell Cycle 
Progression Provides a Competitive Advantage for Human Hematopoietic Stem Cells in Vivo.” 
The Journal of Experimental Medicine 212 (8): 1171–83. https://doi.org/10.1084/jem.20150308. 
Méndez-Ferrer, Simón, Tatyana V. Michurina, Francesca Ferraro, Amin R. Mazloom, Ben D. 
MacArthur, Sergio A. Lira, David T. Scadden, Avi Ma’ayan, Grigori N. Enikolopov, and Paul S. 
Frenette. 2010. “Mesenchymal and Haematopoietic Stem Cells Form a Unique Bone Marrow 
Niche.” Nature 466 (7308): 829–34. https://doi.org/10.1038/nature09262. 
 119 
Miller, Cindy L., Brad Dykstra, and Connie J. Eaves. 2008. “Characterization of Mouse Hematopoietic 
Stem and Progenitor Cells.” In Current Protocols in Immunology, 80:22B.2.1-22B.2.31. Hoboken, 
NJ, USA: John Wiley & Sons, Inc. https://doi.org/10.1002/0471142735.im22b02s80. 
Moignard, Victoria, and Berthold Göttgens. 2014. “Transcriptional Mechanisms of Cell Fate Decisions 
Revealed by Single Cell Expression Profiling.” BioEssays 36 (4): 419–26. 
https://doi.org/10.1002/bies.201300102. 
Moignard, Victoria, Iain C. MacAulay, Gemma Swiers, Florian Buettner, Judith Schütte, Fernando J. 
Calero-Nieto, Sarah Kinston, et al. 2013. “Characterization of Transcriptional Networks in Blood 
Stem and Progenitor Cells Using High-Throughput Single-Cell Gene Expression Analysis.” 
Nature Cell Biology 15 (4): 363–72. https://doi.org/10.1038/ncb2709. 
Moore, M. A. S., N. Williams, and D. Metcalf. 1973. “In Vitro Colony Formation by Normal and 
Leukemic Human Hematopoietic Cells: Characterization of the Colony-Forming Cells 2.” JNCI: 
Journal of the National Cancer Institute 50 (3): 603–23. https://doi.org/10.1093/jnci/50.3.603. 
Morita, Yohei, Hideo Ema, and Hiromitsu Nakauchi. 2010. “Heterogeneity and Hierarchy within the 
Most Primitive Hematopoietic Stem Cell Compartment.” The Journal of Experimental Medicine 
207 (6): 1173–82. https://doi.org/10.1084/jem.20091318. 
Mortensen, Monika, Elizabeth J. Soilleux, Gordana Djordjevic, Rebecca Tripp, Michael Lutteropp, 
Elham Sadighi-Akha, Amanda J. Stranks, et al. 2011. “The Autophagy Protein Atg7 Is Essential 
for Hematopoietic Stem Cell Maintenance.” The Journal of Experimental Medicine 208 (3): 455–
67. https://doi.org/10.1084/jem.20101145. 
Muller-Sieburg, Christa E, Rebecca H Cho, Lars Karlsson, Jing-F Huang, and Hans B Sieburg. 2004. 
“Myeloid-Biased Hematopoietic Stem Cells Have Extensive Self-Renewal Capacity but Generate 
Diminished Lymphoid Progeny with Impaired IL-7 Responsiveness.” Blood 103 (11): 4111–18. 
https://doi.org/10.1182/blood-2003-10-3448. 
Müller-Sieburg, Christa E, Rebecca H Cho, Marilyn Thoman, Becky Adkins, and Hans B Sieburg. 2002. 
“Deterministic Regulation of Hematopoietic Stem Cell Self-Renewal and Differentiation.” Blood 
100 (4): 1302–9. http://www.ncbi.nlm.nih.gov/pubmed/12149211. 
Muller-Sieburg, Christa E, Hans B Sieburg, Jeff M Bernitz, and Giulio Cattarossi. 2012. “Stem Cell 
Heterogeneity: Implications for Aging and Regenerative Medicine.” Blood 119 (17): 3900–3907. 
https://doi.org/10.1182/blood-2011-12-376749. 
Nakamura-Ishizu, Ayako, Hitoshi Takizawa, and Toshio Suda. 2014. “The Analysis, Roles and 
Regulation of Quiescence in Hematopoietic Stem Cells.” Development (Cambridge, England) 141 
(24): 4656–66. https://doi.org/10.1242/dev.106575. 
Nakamura-Ishizu, Ayako, Keiyo Takubo, Masato Fujioka, and Toshio Suda. 2014. “Megakaryocytes 
Are Essential for HSC Quiescence through the Production of Thrombopoietin.” Biochemical and 
Biophysical Research Communications 454 (2): 353–57. 
https://doi.org/10.1016/J.BBRC.2014.10.095. 
Neganova, I, X Zhang, S Atkinson, and M Lako. 2009. “Expression and Functional Analysis of G1 to 
S Regulatory Components Reveals an Important Role for CDK2 in Cell Cycle Regulation in 
Human Embryonic Stem Cells.” Oncogene 28 (1): 20–30. https://doi.org/10.1038/onc.2008.358. 
Nestorowa, Sonia, Fiona K Hamey, Blanca Pijuan Sala, Evangelia Diamanti, Mairi Shepherd, Elisa 
Laurenti, Nicola K Wilson, David G Kent, and Berthold Göttgens. 2016. “A Single-Cell Resolution 
 120 
Map of Mouse Hematopoietic Stem and Progenitor Cell Differentiation.” Blood 128 (8): e20–31. 
https://doi.org/10.1182/blood-2016-05-716480. 
Ng, Ashley P, and Warren S Alexander. 2017. “Haematopoietic Stem Cells: Past, Present and Future.” 
Cell Death Discovery. Nature Publishing Group. https://doi.org/10.1038/cddiscovery.2017.2. 
Notta, Faiyaz, Sergei Doulatov, Elisa Laurenti, Armando Poeppl, Igor Jurisica, John E. Dick, M. 
Sauvageau, et al. 2011. “Isolation of Single Human Hematopoietic Stem Cells Capable of Long-
Term Multilineage Engraftment.” Science 333 (6039): 218–21. 
https://doi.org/10.1126/science.1201219. 
Notta, Faiyaz, Sasan Zandi, Naoya Takayama, Stephanie Dobson, Olga I. Gan, Gavin Wilson, Kerstin 
B. Kaufmann, et al. 2016. “Distinct Routes of Lineage Development Reshape the Human Blood 
Hierarchy across Ontogeny.” Science 351 (6269): aab2116. 
https://doi.org/10.1126/science.aab2116. 
Novershtern, Noa, Aravind Subramanian, Lee N. Lawton, Raymond H. Mak, W. Nicholas Haining, 
Marie E. McConkey, Naomi Habib, et al. 2011. “Densely Interconnected Transcriptional Circuits 
Control Cell States in Human Hematopoiesis.” Cell 144 (2): 296–309. 
https://doi.org/10.1016/j.cell.2011.01.004. 
Oguro, Hideyuki, Atsushi Iwama, Yohei Morita, Takehiko Kamijo, Maarten van Lohuizen, and 
Hiromitsu Nakauchi. 2006. “Differential Impact of Ink4a and Arf on Hematopoietic Stem Cells 
and Their Bone Marrow Microenvironment in Bmi1-Deficient Mice.” The Journal of Experimental 
Medicine 203 (10): 2247–53. https://doi.org/10.1084/jem.20052477. 
Olsson, Andre, Meenakshi Venkatasubramanian, Viren K. Chaudhri, Bruce J. Aronow, Nathan 
Salomonis, Harinder Singh, and H. Leighton Grimes. 2016. “Single-Cell Analysis of Mixed-
Lineage States Leading to a Binary Cell Fate Choice.” Nature 537 (7622): 698–702. 
https://doi.org/10.1038/nature19348. 
Omatsu, Yoshiki, Tatsuki Sugiyama, Hiroshi Kohara, Gen Kondoh, Nobutaka Fujii, Kenji Kohno, and 
Takashi Nagasawa. 2010. “The Essential Functions of Adipo-Osteogenic Progenitors as the 
Hematopoietic Stem and Progenitor Cell Niche.” Immunity 33 (3): 387–99. 
https://doi.org/10.1016/J.IMMUNI.2010.08.017. 
Orford, Keith W., and David T. Scadden. 2008. “Deconstructing Stem Cell Self-Renewal: Genetic 
Insights into Cell-Cycle Regulation.” Nat Rev Genet 9 (2): 115–28. 
https://doi.org/10.1038/nrg2269. 
Orkin, Stuart H, and Leonard I Zon. 2008. “Hematopoiesis: An Evolving Paradigm for Stem Cell 
Biology.” Cell. Howard Hughes Medical Institute. https://doi.org/10.1016/j.cell.2008.01.025. 
Pantano, Lorena. 2019. “DEGreport: Report of DEG Analysis. R Package Version 1.20.0. 
Http://Lpantano.Github.Io/DEGreport/.” 
Park, Jong-Eun, Krzysztof Polański, Kerstin Meyer, and Sarah A. Teichmann. 2018. “Fast Batch 
Alignment of Single Cell Transcriptomes Unifies Multiple Mouse Cell Atlases into an Integrated 
Landscape.” BioRxiv, 397042. https://doi.org/10.1101/397042. 
Passegué, Emmanuelle, Amy J. Wagers, Sylvie Giuriato, Wade C. Anderson, and Irving L. Weissman. 
2005. “Global Analysis of Proliferation and Cell Cycle Gene Expression in the Regulation of 
Hematopoietic Stem and Progenitor Cell Fates.” Journal of Experimental Medicine 202 (11): 
1599–1611. https://doi.org/10.1084/jem.20050967. 
 121 
Pauklin, Siim, and Ludovic Vallier. 2013. “The Cell-Cycle State of Stem Cells Determines Cell Fate 
Propensity.” Cell 155 (6): 1338. https://doi.org/10.1016/j.cell.2013.08.031. 
Paul, Franziska, Ya’ara Arkin, Amir Giladi, Diego Adhemar Adhemar Jaitin, Ephraim Kenigsberg, 
Hadas Keren-Shaul, Deborah Winter, et al. 2015. “Transcriptional Heterogeneity and Lineage 
Commitment in Myeloid Progenitors.” Cell 163 (7): 1663–77. 
https://doi.org/10.1016/j.cell.2015.11.013. 
Pellin, Danilo, Mariana Loperfido, Cristina Baricordi, Samuel L. Wolock, Annita Montepeloso, Olga 
K. Weinberg, Alessandra Biffi, Allon M. Klein, and Luca Biasco. 2019. “A Comprehensive Single 
Cell Transcriptional Landscape of Human Hematopoietic Progenitors.” Nature Communications 
10 (1). https://doi.org/10.1038/s41467-019-10291-0. 
Perié, Leïla, Ken R. Duffy, Lianne Kok, Rob J. De Boer, and Ton N. Schumacher. 2015. “The Branching 
Point in Erythro-Myeloid Differentiation.” Cell 163 (7): 1655–62. 
https://doi.org/10.1016/j.cell.2015.11.059. 
Picelli, Simone, Åsa K. Björklund, Omid R. Faridani, Sven Sagasser, Gösta Winberg, and Rickard 
Sandberg. 2013. “Smart-Seq2 for Sensitive Full-Length Transcriptome Profiling in Single Cells.” 
Nature Methods 10 (11): 1096–98. https://doi.org/10.1038/nmeth.2639. 
Pietras, Eric M. 2017. “Inflammation: A Key Regulator of Hematopoietic Stem Cell Fate in Health and 
Disease.” Blood 130 (15): 1693–98. https://doi.org/10.1182/blood-2017-06-780882. 
Pietras, Eric M., Damien Reynaud, Yoon-A A. Kang, Daniel Carlin, Fernando J. Calero-Nieto, Andrew 
D. Leavitt, Joshua A. M Stuart, et al. 2015. “Functionally Distinct Subsets of Lineage-Biased 
Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions.” Cell 
Stem Cell 17 (1): 35–46. https://doi.org/10.1016/j.stem.2015.05.003. 
Pietras, Eric M., Matthew R. Warr, and Emmanuelle Passegué. 2011. “Cell Cycle Regulation in 
Hematopoietic Stem Cells.” The Journal of Cell Biology 195 (5): 709–20. 
https://doi.org/10.1083/jcb.201102131. 
Pina, Cristina, Cristina Fugazza, Alex J. Tipping, John Brown, Shamit Soneji, Jose Teles, Carsten 
Peterson, and Tariq Enver. 2012. “Inferring Rules of Lineage Commitment in Haematopoiesis.” 
Nature Cell Biology 14 (3): 287–94. https://doi.org/10.1038/ncb2442. 
Pina, Cristina, Gillian May, Shamit Soneji, Dengli Hong, and Tariq Enver. 2008. “MLLT3 Regulates 
Early Human Erythroid and Megakaryocytic Cell Fate.” Cell Stem Cell 2 (3): 264–73. 
https://doi.org/10.1016/J.STEM.2008.01.013. 
Pinho, Sandra, and Paul S. Frenette. 2019. “Haematopoietic Stem Cell Activity and Interactions with 
the Niche.” Nature Reviews Molecular Cell Biology 20 (5): 303–20. 
https://doi.org/10.1038/s41580-019-0103-9. 
Pinho, Sandra, Julie Lacombe, Maher Hanoun, Toshihide Mizoguchi, Ingmar Bruns, Yuya Kunisaki, 
and Paul S Frenette. 2013. “PDGFRα and CD51 Mark Human Nestin+ Sphere-Forming 
Mesenchymal Stem Cells Capable of Hematopoietic Progenitor Cell Expansion.” The Journal of 
Experimental Medicine 210 (7): 1351–67. https://doi.org/10.1084/jem.20122252. 
Pinho, Sandra, Tony Marchand, Eva Yang, Qiaozhi Wei, Claus Nerlov, and Paul S Frenette 
Correspondence. 2018. “Lineage-Biased Hematopoietic Stem Cells Are Regulated by Distinct 
Niches.” Developmental Cell 44: 634–41. https://doi.org/10.1016/j.devcel.2018.01.016. 
 122 
Pluznik, Dov H., and Leo Sachs. 2005. “The Cloning of Normal ‘Mast’ Cells in Tissue Culture.” Journal 
of Cellular and Comparative Physiology 66 (3): 319–24. https://doi.org/10.1002/jcp.1030660309. 
Rodgers, Joseph T., Katherine Y. King, Jamie O. Brett, Melinda J. Cromie, Gregory W. Charville, Katie 
K. Maguire, Christopher Brunson, et al. 2014. “MTORC1 Controls the Adaptive Transition of 
Quiescent Stem Cells from G0 to GAlert.” Nature 510 (7505): 393–96. 
https://doi.org/10.1038/nature13255. 
Rodriguez-Fraticelli, Alejo E., Samuel L. Wolock, Caleb S. Weinreb, Riccardo Panero, Sachin H. Patel, 
Maja Jankovic, Jianlong Sun, Raffaele A. Calogero, Allon M. Klein, and Fernando D. Camargo. 
2018. “Clonal Analysis of Lineage Fate in Native Haematopoiesis.” Nature 553 (7687): 212–16. 
https://doi.org/10.1038/nature25168. 
Rossi, Lara, Kuanyin K. K. Lin, Nathan C. C. Boles, Liubin Yang, Katherine Y. Y. King, Mira Jeong, 
Allison Mayle, and Margaret A. A. Goodell. 2012. “Less Is More: Unveiling the Functional Core 
of Hematopoietic Stem Cells through Knockout Mice.” Cell Stem Cell 11 (3): 302–17. 
https://doi.org/10.1016/j.stem.2012.08.006. 
Rubin, Seth M. 2012. “Deciphering the Rb Phosphorylation Code.” 
https://doi.org/10.1016/j.tibs.2012.10.007. 
Ruiz, Sergio, Athanasia D. Panopoulos, Aída Herrerías, Karl-Dimiter Bissig, Margaret Lutz, W. Travis 
Berggren, Inder M. Verma, and Juan Carlos Izpisua Belmonte. 2011. “A High Proliferation Rate 
Is Required for Cell Reprogramming and Maintenance of Human Embryonic Stem Cell Identity.” 
Current Biology 21 (1): 45–52. https://doi.org/10.1016/J.CUB.2010.11.049. 
Sakaue-Sawano, Asako, Hiroshi Kurokawa, Toshifumi Morimura, Aki Hanyu, Hiroshi Hama, Hatsuki 
Osawa, Saori Kashiwagi, et al. 2008. “Visualizing Spatiotemporal Dynamics of Multicellular Cell-
Cycle Progression.” Cell 132 (3): 487–98. https://doi.org/10.1016/j.cell.2007.12.033. 
Sanjuan-Pla, Alejandra, Iain C. Macaulay, Christina T. Jensen, Petter S. Woll, Tiago C. Luis, Adam 
Mead, Susan Moore, et al. 2013. “Platelet-Biased Stem Cells Reside at the Apex of the 
Haematopoietic Stem-Cell Hierarchy.” Nature 502 (7470): 232–36. 
https://doi.org/10.1038/nature12495. 
Satija, Rahul, Jeffrey A. Farrell, David Gennert, Alexander F. Schier, and Aviv Regev. 2015. “Spatial 
Reconstruction of Single-Cell Gene Expression Data.” Nature Biotechnology 33 (5): 495–502. 
https://doi.org/10.1038/nbt.3192. 
Schreibelt, Gerty, Lieke J.J. Klinkenberg, Luis J. Cruz, Paul J. Tacken, Jurjen Tel, Martin Kreutz, Gosse 
J. Adema, Gordon D. Brown, Carl G. Figdor, and I. Jolanda M. De Vries. 2012. “The C-Type 
Lectin Receptor CLEC9A Mediates Antigen Uptake and (Cross-)Presentation by Human Blood 
BDCA3+ Myeloid Dendritic Cells.” Blood 119 (10): 2284–92. https://doi.org/10.1182/blood-
2011-08-373944. 
Schuettpelz, Laura G., and Daniel C. Link. 2013. “Regulation of Hematopoietic Stem Cell Activity by 
Inflammation.” Frontiers in Immunology 4. https://doi.org/10.3389/fimmu.2013.00204. 
Seita, Jun, and Irving L. Weissman. 2010. Hematopoietic Stem Cell: Self-Renewal versus 
Differentiation. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. Vol. 2. 
http://doi.wiley.com/10.1002/wsbm.86. 
Semenza, Gregg L. 2011. “Hypoxia-Inducible Factor 1: Regulator of Mitochondrial Metabolism and 
Mediator of Ischemic Preconditioning.” Biochimica et Biophysica Acta 1813 (7): 1263–68. 
https://doi.org/10.1016/j.bbamcr.2010.08.006. 
 123 
Shima, Haruko, Keiyo Takubo, Naoko Tago, Hiroko Iwasaki, Fumio Arai, Takao Takahashi, and Toshio 
Suda. 2010. “Acquisition of G₀ State by CD34-Positive Cord Blood Cells after Bone Marrow 
Transplantation.” Experimental Hematology 38 (12): 1231–40. 
https://doi.org/10.1016/j.exphem.2010.08.004. 
Simsek, Tugba, Fatih Kocabas, Junke Zheng, Ralph J. R.J. Ralph J DeBerardinis, Ahmed I. Mahmoud, 
Eric N. Olson, Jay W. Schneider, et al. 2010. “The Distinct Metabolic Profile of Hematopoietic 
Stem Cells Reflects Their Location in a Hypoxic Niche.” Cell Stem Cell 7 (3): 380–90. 
https://doi.org/10.1016/j.stem.2010.07.011. 
Singh, Amar M, James Chappell, Robert Trost, Li Lin, Tao Wang, Jie Tang, Brittany K Matlock, et al. 
2013. “Cell-Cycle Control of Developmentally Regulated Transcription Factors Accounts for 
Heterogeneity in Human Pluripotent Cells.” Stem Cell Reports 1 (6): 532–44. 
https://doi.org/10.1016/j.stemcr.2013.10.009. 
Sitnicka, Ewa, Natalija Buza-Vidas, Staffan Larsson, Jens M Nygren, Karina Liuba, and Sten Erik W 
Jacobsen. 2003. “Human CD34+ Hematopoietic Stem Cells Capable of Multilineage Engrafting 
NOD/SCID Mice Express Flt3: Distinct Flt3 and c-Kit Expression and Response Patterns on 
Mouse and Candidate Human Hematopoietic Stem Cells.” Blood 102 (3): 881–86. 
https://doi.org/10.1182/blood-2002-06-1694. 
Snoeck, Hans Willem. 2017. “Mitochondrial Regulation of Hematopoietic Stem Cells.” Current 
Opinion in Cell Biology. Elsevier Current Trends. https://doi.org/10.1016/j.ceb.2017.12.010. 
Spangrude, G J, S Heimfeld, and I L Weissman. 1988. “Purification and Characterization of Mouse 
Hematopoietic Stem Cells.” Science (New York, N.Y.) 241 (4861): 58–62. 
https://doi.org/10.1126/science.2898810. 
Srivastava, Surabhi, Rakesh K. Mishra, and Jyotsna Dhawan. 2010. “Regulation of Cellular Chromatin 
State: Insights from Quiescence and Differentiation.” Organogenesis. Taylor & Francis. 
https://doi.org/10.4161/org.6.1.11337. 
Subramanian, Aravind, Pablo Tamayo, Vamsi K. Mootha, Sayan Mukherjee, Benjamin L. Ebert, 
Michael A. Gillette, Amanda Paulovich, et al. 2005. “Gene Set Enrichment Analysis: A 
Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles.” Proceedings of 
the National Academy of Sciences of the United States of America 102 (43): 15545–50. 
https://doi.org/10.1073/pnas.0506580102. 
Suda, Toshio, Keiyo Takubo, and Gregg L. Semenza. 2011. Metabolic Regulation of Hematopoietic 
Stem Cells in the Hypoxic Niche. Cell Stem Cell. Vol. 9. Cell Press. 
https://doi.org/10.1016/j.stem.2011.09.010. 
Sun, Jianlong, Azucena Ramos, Brad Chapman, Jonathan B. Johnnidis, Linda Le, Yu-Jui Ho, Allon 
Klein, Oliver Hofmann, and Fernando D. Camargo. 2014. “Clonal Dynamics of Native 
Haematopoiesis.” Nature 514 (7522): 322–27. https://doi.org/10.1038/nature13824. 
Sutherland, H J, C J Eaves, P M Lansdorp, J D Thacker, and D E Hogge. 1991. “Differential Regulation 
of Primitive Human Hematopoietic Cells in Long-Term Cultures Maintained on Genetically 
Engineered Murine Stromal Cells.” Blood 78 (3): 666–72. 
http://www.ncbi.nlm.nih.gov/pubmed/1713512. 
Szilvassy, S J, R K Humphries, P M Lansdorp, A C Eaves, and C J Eaves. 1990. “Quantitative Assay 
for Totipotent Reconstituting Hematopoietic Stem Cells by a Competitive Repopulation Strategy.” 
Proceedings of the National Academy of Sciences of the United States of America 87 (22). 
http://www.ncbi.nlm.nih.gov/pubmed/2247442. 
 124 
Tajer, Parisa, Karin Pike-Overzet, Sagrario Arias, Menzo Havenga, and Frank Staal. 2019. “Ex Vivo 
Expansion of Hematopoietic Stem Cells for Therapeutic Purposes: Lessons from Development and 
the Niche.” Cells 8 (2): 169. https://doi.org/10.3390/cells8020169. 
Takubo, Keiyo, Nobuhito Goda, Wakako Yamada, Hirono Iriuchishima, Eiji Ikeda, Yoshiaki Kubota, 
Haruko Shima, et al. 2010. “Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem 
Cells.” Cell Stem Cell 7 (3): 391–402. https://doi.org/10.1016/j.stem.2010.06.020. 
Terzi, Menderes Yusuf, Muzeyyen Izmirli, and Bulent Gogebakan. 2016. “The Cell Fate: Senescence 
or Quiescence.” Molecular Biology Reports. Springer Netherlands. 
https://doi.org/10.1007/s11033-016-4065-0. 
Tigan, A. S., F. Bellutti, K. Kollmann, G. Tebb, and V. Sexl. 2016. “CDK6-a Review of the Past and a 
Glimpse into the Future: From Cell-Cycle Control to Transcriptional Regulation.” Oncogene. 
Nature Publishing Group. https://doi.org/10.1038/onc.2015.407. 
Till, J.E. E, E.A. A McCulloch, and L. Siminovitch. 1964. “A Stochastic Model of Stem Cell 
Proliferation, Based on the Growth of Spleen Colony-Forming Cells.” Proceedings of the National 
Academy of Sciences of the United States of America 2 (1): 683. 
https://doi.org/10.1073/pnas.51.1.29. 
Tirosh, Itay, Benjamin Izar, Sanjay M. Prakadan, Marc H. Wadsworth, Daniel Treacy, John J. 
Trombetta, Asaf Rotem, et al. 2016. “Dissecting the Multicellular Ecosystem of Metastatic 
Melanoma by Single-Cell RNA-Seq.” Science 352 (6282): 189–96. 
https://doi.org/10.1126/science.aad0501. 
Tothova, Zuzana, Ramya Kollipara, Brian J. Huntly, Benjamin H. Lee, Diego H. Castrillon, Dana E. 
Cullen, Elizabeth P. McDowell, et al. 2007. “FoxOs Are Critical Mediators of Hematopoietic Stem 
Cell Resistance to Physiologic Oxidative Stress.” Cell 128 (2): 325–39. 
https://doi.org/10.1016/J.CELL.2007.01.003. 
Uchida, Naoyuki, Brad Dykstra, KJ. Kristin J Lyons, Frank Y.K FY. Leung, and CJ. Connie J Eaves. 
2003. “Different in Vivo Repopulating Activities of Purified Hematopoietic Stem Cells before and 
after Being Stimulated to Divide in Vitro with the Same Kinetics” 31 (12): 1338–47. 
https://doi.org/10.1016/j.exphem.2003.09.001. 
Umemoto, Terumasa, Michihiro Hashimoto, Takayoshi Matsumura, Ayako Nakamura-Ishizu, and 
Toshio Suda. 2018. “Ca 2+-Mitochondria Axis Drives Cell Division in Hematopoietic Stem Cells.” 
J. Exp. Med 215 (8): 2097–2113. https://doi.org/10.1084/jem.20180421. 
Unnisa, Zeenath, Jason P. Clark, Jayeeta Roychoudhury, Elizabeth Thomas, Lino Tessarollo, Neal G. 
Copeland, Nancy A. Jenkins, H. Leighton Grimes, and Ashish R. Kumar. 2012. “Meis1 Preserves 
Hematopoietic Stem Cells in Mice by Limiting Oxidative Stress.” Blood 120 (25): 4973–81. 
https://doi.org/10.1182/blood-2012-06-435800. 
Vallier, Ludovic. 2015. “Cell Cycle Rules Pluripotency.” Cell Stem Cell. 
https://doi.org/10.1016/j.stem.2015.07.019. 
van Galen, Peter, Antonija Kreso, Erno Wienholds, Elisa Laurenti, Kolja Eppert, Eric R. Lechman, 
Nathan Mbong, et al. 2014. “Reduced Lymphoid Lineage Priming Promotes Human 
Hematopoietic Stem Cell Expansion.” Cell Stem Cell 14 (1): 94–106. 
https://doi.org/10.1016/J.STEM.2013.11.021. 
Vannini, Nicola, Vasco Campos, Mukul Girotra, Vincent Trachsel, Shanti Rojas-Sutterlin, Josefine 
Tratwal, Simone Ragusa, et al. 2019. “The NAD-Booster Nicotinamide Riboside Potently 
 125 
Stimulates Hematopoiesis through Increased Mitochondrial Clearance.” Cell Stem Cell 24 (3): 405-
418.e7. https://doi.org/10.1016/J.STEM.2019.02.012. 
Vannini, Nicola, Mukul Girotra, Olaia Naveiras, Gennady Nikitin, Vasco Campos, Sonja Giger, Aline 
Roch, Johan Auwerx, and Matthias P. Lutolf. 2016. “Specification of Haematopoietic Stem Cell 
Fate via Modulation of Mitochondrial Activity.” Nature Communications 7 (1): 13125. 
https://doi.org/10.1038/ncomms13125. 
Velten, Lars, Simon F. Haas, Simon Raffel, Sandra Blaszkiewicz, Saiful Islam, Bianca P. Hennig, 
Christoph Hirche, et al. 2017. “Human Haematopoietic Stem Cell Lineage Commitment Is a 
Continuous Process.” Nature Cell Biology 19 (4): 271–81. https://doi.org/10.1038/ncb3493. 
Velthoven, Cindy T.J. van, Antoine de Morree, Ingrid M. Egner, Jamie O. Brett, and Thomas A. Rando. 
2017. “Transcriptional Profiling of Quiescent Muscle Stem Cells In Vivo.” Cell Reports 21 (7): 
1994–2004. https://doi.org/10.1016/J.CELREP.2017.10.037. 
Velthoven, Cindy T J van, Thomas A. Rando, Cindy T.J. van Velthoven, and Thomas A. Rando. 2019. 
“Stem Cell Quiescence: Dynamism, Restraint, and Cellular Idling Cindy” 24 (2): 213–25. 
https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30001-
3?dgcid=raven_jbs_etoc_email. 
Viatour, Patrick, Tim C. Somervaille, Shivkumar Venkatasubrahmanyam, Scott Kogan, Margaret E. 
McLaughlin, Irving L. Weissman, Atul J. Butte, Emmanuelle Passegué, and Julien Sage. 2008. 
“Hematopoietic Stem Cell Quiescence Is Maintained by Compound Contributions of the 
Retinoblastoma Gene Family.” Cell Stem Cell 3 (4): 416–28. 
https://doi.org/10.1016/j.stem.2008.07.009. 
Wang, J., T. Kimura, R. Asada, S. Harada, S. Yokota, Y. Kawamoto, Y. Fujimura, T. Tsuji, S. Ikehara, 
and Y. Sonoda. 2003. “SCID-Repopulating Cell Activity of Human Cord Blood-Derived CD34- 
Cells Assured by Intra-Bone Marrow Injection.” Blood 101 (8): 2924–31. 
https://doi.org/10.1182/blood-2002-09-2782. 
Wang, J C, M Doedens, and J E Dick. 1997. “Primitive Human Hematopoietic Cells Are Enriched in 
Cord Blood Compared with Adult Bone Marrow or Mobilized Peripheral Blood as Measured by 
the Quantitative in Vivo SCID-Repopulating Cell Assay.” Blood 89 (11): 3919–24. 
http://www.ncbi.nlm.nih.gov/pubmed/9166828. 
Warr, Matthew R., and Emmanuelle Passegué. 2013. “Metabolic Makeover for HSCs.” Cell Stem Cell 
12 (1): 1–3. https://doi.org/10.1016/j.stem.2012.12.005. 
Wilkinson, Adam C., and Berthold Göttgens. 2013. “Transcriptional Regulation of Haematopoietic 
Stem Cells.” In , 187–212. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6621-1_11. 
Wilson, Anne, Elisa Laurenti, Gabriela Oser, Richard C. van der Wath, William Blanco-Bose, Maike 
Jaworski, Sandra Offner, et al. 2008. “Hematopoietic Stem Cells Reversibly Switch from 
Dormancy to Self-Renewal during Homeostasis and Repair.” Cell 135 (6): 1118–29. 
https://doi.org/10.1016/j.cell.2008.10.048. 
Wilson, Anne, Mark J. Murphy, Thordur Oskarsson, Konstantinos Kaloulis, Michael D. Bettess, 
Gabriela M. Oser, Anne Catherine Pasche, Christian Knabenhans, H. Robson MacDonald, and 
Andreas Trumpp. 2004. “C-Myc Controls the Balance between Hematopoietic Stem Cell Self-
Renewal and Differentiation.” Genes and Development 18 (22): 2747–63. 
https://doi.org/10.1101/gad.313104. 
 126 
Wilson, Nicola K., David G. Kent, Florian Buettner, Mona Shehata, Iain C. Macaulay, Fernando J. 
Calero-Nieto, Manuel S??nchez Castillo, et al. 2015. “Combined Single-Cell Functional and Gene 
Expression Analysis Resolves Heterogeneity within Stem Cell Populations.” Cell Stem Cell 16 (6): 
712–24. https://doi.org/10.1016/j.stem.2015.04.004. 
Wolf, F. Alexander, Philipp Angerer, and Fabian J. Theis. 2018. “SCANPY: Large-Scale Single-Cell 
Gene Expression Data Analysis.” Genome Biology 19 (1): 15. https://doi.org/10.1186/s13059-017-
1382-0. 
Wu, T. D., and S. Nacu. 2010. “Fast and SNP-Tolerant Detection of Complex Variants and Splicing in 
Short Reads.” Bioinformatics 26 (7): 873–81. https://doi.org/10.1093/bioinformatics/btq057. 
Wu, Xianfang, Viet Loan Dao Thi, Yumin Huang, Eva Billerbeck, Debjani Saha, Hans Heinrich 
Hoffmann, Yaomei Wang, et al. 2018. “Intrinsic Immunity Shapes Viral Resistance of Stem Cells.” 
Cell 172 (3): 423-438.e25. https://doi.org/10.1016/j.cell.2017.11.018. 
Yamamoto, Ryo, Yohei Morita, Jun Ooehara, Sanae Hamanaka, Masafumi Onodera, Karl Lenhard 
Rudolph, Hideo Ema, and Hiromitsu Nakauchi. 2013. “Clonal Analysis Unveils Self-Renewing 
Lineage-Restricted Progenitors Generated Directly from Hematopoietic Stem Cells.” Cell 154 (5): 
1112–26. https://doi.org/10.1016/J.CELL.2013.08.007. 
Yu, Wen Mei, Xia Liu, Jinhua Shen, Olga Jovanovic, Elena E. Pohl, Stanton L. Gerson, Toren Finkel, 
Hal E. Broxmeyer, and Cheng Kui Qu. 2013. “Metabolic Regulation by the Mitochondrial 
Phosphatase PTPMT1 Is Required for Hematopoietic Stem Cell Differentiation.” Cell Stem Cell 
12 (1): 62–74. https://doi.org/10.1016/j.stem.2012.11.022. 
Yuan, Youzhong, Hongmei Shen, David S. Franklin, David T. Scadden, and Tao Cheng. 2004. “In Vivo 
Self-Renewing Divisions of Haematopoietic Stem Cells Are Increased in the Absence of the Early 
G1-Phase Inhibitor, P18INK4C.” Nature Cell Biology 6 (5): 436–42. 
https://doi.org/10.1038/ncb1126. 
Zerbino, Daniel R., Premanand Achuthan, Wasiu Akanni, M. Ridwan Amode, Daniel Barrell, Jyothish 
Bhai, Konstantinos Billis, et al. 2018. “Ensembl 2018.” Nucleic Acids Research 46 (D1): D754–
61. https://doi.org/10.1093/nar/gkx1098. 
Zhang, Hongbo, Keir J. Menzies, and Johan Auwerx. 2018. “The Role of Mitochondria in Stem Cell 
Fate and Aging.” Development 145 (8): dev143420. https://doi.org/10.1242/dev.143420. 
Zhang, Jiwang, Chao Niu, Ling Ye, Haiyang Huang, Xi He, Wei-Gang Tong, Jason Ross, et al. 2003. 
“Identification of the Haematopoietic Stem Cell Niche and Control of the Niche Size.” Nature 425 
(6960): 836–41. https://doi.org/10.1038/nature02041. 
Zhao, Meng, and Linheng Li. 2016. “Dissecting the Bone Marrow HSC Niches.” Cell Research 26 (9): 
975–76. https://doi.org/10.1038/cr.2016.71. 
Zhao, Meng, John M Perry, Heather Marshall, Aparna Venkatraman, Pengxu Qian, Xi C He, Jasimuddin 
Ahamed, and Linheng Li. 2014. “Megakaryocytes Maintain Homeostatic Quiescence and Promote 
Post-Injury Regeneration of Hematopoietic Stem Cells.” Nature Medicine 20 (11): 1321–26. 
https://doi.org/10.1038/nm.3706. 
Zheng, Shiwei, Efthymia Papalexi, Andrew Butler, William Stephenson, and Rahul Satija. 2018. 
“Molecular Transitions in Early Progenitors during Human Cord Blood Hematopoiesis.” 
Molecular Systems Biology 14 (3). https://doi.org/10.15252/msb.20178041. 
 127 
Zou, Jing, Ping Zou, Jie Wang, Lei Li, Yong Wang, Daohong Zhou, and Lingbo Liu. 2012. “Inhibition 
of P38 MAPK Activity Promotes Ex Vivo Expansion of Human Cord Blood Hematopoietic Stem 
Cells.” Annals of Hematology 91 (6): 813–23. https://doi.org/10.1007/s00277-011-1397-7. 
Zou, Peng, Hiroki Yoshihara, Kentaro Hosokawa, Ikue Tai, Kaori Shinmyozu, Fujiko Tsukahara, 
Yoshiro Maru, Keiko Keiichi I. Nakayama, Keiko Keiichi I. Nakayama, and Toshio Suda. 2011. 
“P57Kip2 and P27Kip1 Cooperate to Maintain Hematopoietic Stem Cell Quiescence through 
Interactions with Hsc70.” Cell Stem Cell 9 (3): 247–61. 
https://www.sciencedirect.com/science/article/pii/S193459091100333X?via%3Dihub. 
 
